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Stenosis of the aortic valve causes increased left ventricular pressure leading to adverse clinical 
outcomes. The selection and timing of intervention (surgical replacement or transcatheter 
implantation) is often unclear and is based upon limited data.  
 
Hypothesis 
A comprehensive and integrated personalised approach, including recognition of cardiac energetics 
parameters extracted from a personalised mathematical model, mapped to patient activity, has the 
potential to improve diagnosis and the planning and timing of interventions. 
 
Aims 
This project seeks to implement a simple, personalised, mathematical model of patients with aortic 
stenosis (AS), which can ‘measure’ cardiac work and power parameters that provide an effective 
characterisation of the demand on the heart in both rest and exercise conditions and can predict the 
changes of these parameters following an intervention. The specific aims of this project are: 
• to critically review current diagnostic methods 
• to evaluate the potential role of pre- and post-procedural measured patient activity 
• to implement a simple, personalised, mathematical model of patients with AS 
• to evaluate the potential role of a clinical decision support system 
 
Methods 
Twenty-two patients with severe AS according to ESC criteria were recruited. Relevant clinical, 
imaging, activity monitoring, six-minute walk test, and patient reported data were collected, before 
and early and after treatment. Novel imaging techniques were developed to help in the diagnosis of 




AS. A computational model was developed and executed using the data collected to create non-
invasive pressure volume loops and study the global haemodynamic burden on the left ventricle. 
Simulations were run to predict the haemodynamic parameters both during exercise and following 
intervention. Modelled parameters were validated against clinically measured values. This 
information was then correlated with symptoms and activity data. A clinical decision support tool 
was created and populated with data obtained and its clinical utility evaluated. 
 
Outcomes 
The results of this project suggest that the combination of imaging and activity data with 
computational modelling provides a novel, patient-specific insight into patients’ haemodynamics and 
may help guide clinical decision making in patients with AS. 
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Aortic stenosis (AS) is a narrowing of the orifice of the aortic valve that causes an increased 
resistance to blood flow from the ventricle into the systemic circulation. The heart maintains flow, at 
the cost of increased pressure, triggering a series of pathophysiological processes leading to adverse 
clinical outcomes. In this introduction the current knowledge of AS, its importance, and how and 
why it is currently treated, will be reviewed, highlighting areas where computational modelling may 
provide additional information in the decision-making process. This will be followed by an overview 
of what computational modelling is, how it is already employed in healthcare and, in particular, how 
it may be useful in the management of patients with aortic stenosis. 
 
1.1.  Anatomy 
 
The aortic valve is sited between the left ventricle and the aorta. It usually has three leaflets and its 
size varies significantly from person to person [1]. Its function is to maintain the flow of blood in a 
single direction. When the ventricle contracts and the pressure in the left ventricle exceeds that in 
the aorta, the valve opens, and oxygenated blood is pumped to the systemic circulation.  





Figure 1.1 Diagram of the left side of the heart illustrating the aortic valve and related anatomy 
adapted with from Wikimedia commons [2] 
 
The arrangement of the cusps results in an even distribution of mechanical stress to the valve 
annulus and the aorta[3]. The cusps are less than one millimetre thick, smooth and opalescent, with 
very few cells. They are composed of 3 clearly defined tissue layers covered by endothelium, these 
are; the fibrosa, spongiosa, and ventricularis. At their base, the valve leaflets are attached to the 
aortic valve annulus. The aortic valve annulus is a dense collagenous structure that lies at the level of 
the junction of the aortic valve and the ventricular septum. This serves to provide structural support 
to the aortic valve complex[4], [5].The valvular leaflets are attached throughout the length of the 
root and take the form of a three-pronged coronet which results in complex haemodynamic effects 
when the valve opens or becomes diseased. As will be discussed later, changes due to disease can be 
assessed using medical imaging (section 1.4.2) or modelled (section 1.11.5 ). 
 




The aortic root is a continuation of the left ventricular outflow tract. Its components include the 
sinuses of Valsalva, the fibrous inter-leaflet triangles, and the valvar leaflets themselves. Problems 
resulting in thickening and calcification of these structures leads to AS. AS describes the condition 
where the valve orifice is narrowed. This increases the resistance and thus a greater force of 
contraction is required to eject the same volume of blood. Since the blood is ejected through a 
smaller orifice, the velocity of the blood leaving the heart increases, and this is often measured 




Although rheumatic heart disease is uncommon in developed countries such as the UK, it remains an 
important cause of AS worldwide. In 2015, 33.4 million people were estimated to be living with 
rheumatic heart disease around the world, with sub-Saharan Africa, South Asia, and Oceania having 
the highest prevalence[6].  
 
Calcific-degenerative AS (see section 1.3) is the most common valvular disease in the developed 
world and associated with significant morbidity and mortality; this is the focus of this thesis. Two 
percent of adults over 65 years old and four percent over 85 have clinically significant disease [7]. 
With the ageing population, this already important pathology will become increasingly prevalent and 
its diagnosis and management will have an even greater impact upon healthcare.  
 
The UK Hospital Episode Statistics (HES) database suggests that at least 200,000 people were 
admitted to hospital in England between 2002 and 2012 due to AS[8]. Considering that 0.87% of all 
heart failure admissions are due to AS[9], the cost of managing these patients in terms of financial 
cost, hospital bed capacity and clinicians time is huge. Even without specific treatment, the average 
cost of a patient with severe AS is estimated at £31,096 per year[12]. The problem may be greater 




than appreciated; many patients with clinically significant (moderate or severe) valve disease being 
undiagnosed (6.4% in the Ox-valve study)[10]. Patients were twice as likely to have significant 
undiagnosed disease if they were of low socioeconomic status and three times as likely if they had 
atrial fibrillation[10]. These groups may present with complications of the disease or late in the 
disease process so may potentially be of higher risk. In 2017 there were approximately 103,000 
deaths worldwide attributed to non-rheumatic aortic valve disease, which is approximately 1% of 
global cardiovascular deaths - an increase of 40% over the previous 10 years[11].  
 
1.3.  Pathophysiology 
 
Aortic valve stenosis was described first by Lazare Riviere in 1663[12]. Mönckeberg in 1904 went on 
to describe AS as a passive degenerative process associated with rheumatic fever or ageing, where 
serum calcium attaches to the valve surface and forms nodules[13]. The decline in rheumatic fever 
and ageing of the population have led to a demographic transition towards fibrocalcific disease. In 
contrast to the cusp fusion seen with rheumatic heart disease, this process results in increased valve 
stiffness, reduced cusp excursion, and progressive orifice narrowing. Although calcification is still 
viewed by some as a passive process and termed ‘age related’ or ‘degenerative’, it has now been 
shown to be caused by an inflammatory process similar to that of atherosclerosis, with similar risk 
factors [14] (see figure 1.2).  
 
The process starts with endothelial injury, infiltration of lipids, lipid oxidation and a proinflammatory 
response. Following this, osteoblast-like cells promote progressive valvular calcium and bone matrix 
deposition. The osteogenic phenotype involves many molecules involved in bone formation and is 
both self-perpetuating and highly regulated[15]. Advances in imaging now allow for non-invasive 
assessment of both the burden and activity of calcification to be measured (see section 1.4.2.2). 
Endothelial damage is thought to be caused by increased mechanical stress and reduced shear 




stress. Shear stress is highest in the cusps adjacent to the coronary ostia because of the influence of 
coronary artery flow. The non-coronary cusp has lower shear stress and is most frequently involved 
in AS, resulting in a characteristic distribution of lesions in the valve[16]. Mechanical stress is highest 
around the flexion areas of the cusps near their attachment to the aortic root and 50% of lesions can 
also be observed in this region[17]. The position of calcium deposits significantly affects the opening 
orifice area and this varies with changing cardiac output [18]–[20]. For this reason, when 
constructing an image-based computational model to investigate the effects of the disease, it will be 
important to have an accurate assessment of the orifice and its effect on haemodynamics. Since 
valve opening is a dynamic process that changes according to preload and afterload conditions the 
model must also take into account time-varying haemodynamics to reflect different physiological 
states. 
 
Figure 1.2 Illustrating the pathological process in AS that leads to the progression of disease. Adapted 
with permission from Otto et al[21]. 
 




The usual focus of AS assessments has been on the valve. However, the disease process not only 
affects the valve but also reduces arterial compliance and alters the geometry of the left ventricle; 
for this reason it is viewed as a systemic disease [22]. The left ventricular myocardial response to 
pressure overload is important[16]. The response of the left ventricle (LV) to an increased afterload 
is quite complex. It often consists of a combination of wall thickening and a change in cavity size, 
affecting systolic and diastolic function, although remodelling and LV dilatation can occur [23]. There 
are many theories around how pressure overload and the resultant LV hypertrophy (LVH) may 
impair LV systolic function. These include intermittent ischaemia, apoptosis, neurohumoral 
activation and changes to the myocardial cytoskeleton [24]. Interestingly, the correlation between 
echocardiographic measures of AS severity and the degree of LVH is moderate at best[25], 
suggesting that there are other factors which, in combination, increase the load on the ventricle. 
LVH maintains wall stress and cardiac output but pressure-induced LVH also initiates a series of 
events at the molecular level that may eventually lead to cell death and myocardial fibrosis, resulting 
in LV dilatation and decompensation[26]. 
 
Congenital bicuspid aortic valve anatomy is found in 0.5–2.0% of the population although it is 
relatively uncommon compared to calcific AS. However, AS affecting a bicuspid valve is the most 
common indication for surgical aortic valve re placement (SAVR) in patients <70 years of age. 
Bicuspid AS is associated with specific anatomic challenges which impact on treatment choices (see 
section 1.6.3); these include heavy valve calcification, an eccentrically shaped annulus, and a 
horizontal, dilated aorta. The complex haemodynamics of a bicuspid valve may be better understood 








1.3.1. Disease progression and prognosis 
 
The clinical course of AS is usually characterised by a long asymptomatic period that is followed by a 
shorter symptomatic period when patients may physically decline quite rapidly. However, the rate of 
progression of AS is quite variable, which highlights differences in the disease process in individual 
valves and patients [21]. Peak AV velocity can change by 0.24±0.30 m/s/year[28]), but this is subject 
to scan–rescan variation. This presents a challenge to clinicians in terms of when to follow patients 
up and when to intervene by replacing the valve. Currently patients are followed up at varying 
intervals based on clinical opinion using 2D ultrasound. Once symptoms develop, the mortality rate 
is 50% at two years without intervention [27] but when LV dysfunction is primarily caused by the 
increase in afterload as a result of the stenosis, the prognosis after aortic valve replacement appears 
to be good, with improved cardiac function [28]. 
 
Currently there is no easy and accepted method to predict which patients may deteriorate rapidly 
and, apart from a few exceptions (see section 1.8), the general recommendation is not to intervene 
if asymptomatic and LV function is preserved [29]–[31]. In recent years there has been a move to 
operate on asymptomatic patients with very severe AS (see section 1.8). The valve area at which 
patients become symptomatic is variable [32] suggesting, that, the haemodynamics may be complex, 
some hearts are able to cope with a greater degree of obstruction than others, and other factors 
that load the ventricle such as hypertension need to be considered. The whole physiological system 
needs to be considered - not just the valve in isolation; a model representing the patient’s valve and 
systemic circulation could do this. 
 
1.3.2.  Haemodynamics in AS 
 
The pressure gradient across the aortic valve results from both increased resistance due to the 
reduced orifice area and the disturbed nature (including turbulence) of the flow distal to the valve. 




The magnitude of the pressure drop is mainly determined by the degree of stenosis and the flow 
across the valve. However, the aortic valve is coupled to the systemic arterial vasculature and the 
variability in derived stenosis severity is dependent on events occurring downstream i.e. the 
pressure-flow relation in the systemic arterial circulation. Therefore, analysis of stenosis severity 
under various physiological conditions must take into account the dependence of aortic valve 
pressure gradient on systemic arterial haemodynamics. The resistance in the circulation, however, is 
complex to model as a number of factors affect vascular tone and there are many controlling 
mechanisms including those which are local, chemical-mediated and neurohumoral. The aim of 
these mechanisms is to achieve homeostasis, maintaining a constant flow when the metabolic 
demand is stable. 
 
Flow through a linear resistor, representative of elements of the systemic circulation can be 
considered in the following equation, analogous to Ohm’s Law (see section 1.11.4 for further detail):  
 
Flow(Q)= Pressure(P)/Resistance (R) 
 
When blood flows through a stenotic aortic valve, the effective resistance is a nonlinear function of 
the flow. Irrespective of the vessel cross-sectional area the volume of flow passing through must be 
the same, and so the velocity must increase as the blood accelerates into the throat of the stenosis. 
This causes an increase in kinetic energy and a concomitant decrease in potential energy, which is 
proportional to pressure. Thus, the pressure immediately after the stenosis is lower than the 
proximal pressure and the pressure drop can be computed from Bernoulli’s equation (see below). 
When the flow decelerates after the orifice the pressure does not fully recover, due to energy lost 
through flow disturbances and viscous resistances. 





Figure 1.3 Schematic demonstrating a constriction that may represent a stenotic valve. The flow in 
the LVOT (point 1) should equal the flow in the proximal aorta (point 3). At the vena contracta (point 
2) the flow converges into a narrow high velocity jet. 
 
 
Bernoulli's principle is derived from the principle of conservation of energy. In a steady flow, along a 
streamline, the total kinetic and potential energies proximal to the stenosed valve must equal the 
total of the kinetic and potential energies distal to the stenosed valve. There is transition from 
potential to kinetic energy as the flow accelerates into the stenosis, and the reverse as the jet 
expands again after the stenosis, as described above; but, as previously stated, there is some loss of 
energy and therefore the potential energy (pressure per unit volume) does not fully recover in the 
distal vessel.  
 









2 + 𝑔ℎ2                                         Eq. 1.1 
 
Where P= hydrostatic pressure in pascals (pressure in a fluid is a measure of energy per unit volume) 
 = fluid density replacing mass in the energy equations, g = acceleration due to gravity, v=velocity 
and h=height of the fluid. 
 
As there is there is a negligible change in height of the blood and the potential energy is the same 









2                                                           Eq. 1.2 
This can be rearranged to: 

















2 − 𝑣1 
2 )                                                             Eq. 1.3 
 
This equation can be further simplified by substituting the density of blood, neglecting the proximal 
velocity (which is much lower than the velocity in the orifice) and converting from SI units to clinical 
units of pressure and velocity.  
 
Then 
 𝑃 = 4𝑣2 
2                                                                      Eq. 1.4   
 
The inputs to this equation are usually measured clinically using ultrasound imaging. The accuracy of 
the Bernoulli equation and of this simplified formula (Eq. 1.4) in the context of aortic valve disease is 
discussed in section 1.4.2.1. Computational fluid dynamics can be used to solve the Navier-Stokes 
equations which mathematically describe the flow of incompressible fluids. This can improve the 
estimated pressure drop across the valve (see section 1.11.5), but solving the Navier-Stokes 
equations with flexible vessel walls and a flexible aortic valve is complex[33]. There is of course 
energy loss as blood flows through any vessel, as described by Poiseuille’s law but, since this is much 
less significant than the loss across a stenosis, it is not usually calculated in the routine assessment of 
AS.  
 
1.4.  Diagnosis 
 
Currently the diagnosis of AS is based upon clinical history, examination and investigations, including 
limited objective measurements from clinical imaging.  
 
 




1.4.1.  Symptoms 
 
The classical triad of symptoms of AS, which typically occur upon exertion, are angina, shortness of 
breath and syncope, all of which are thought to be a consequence of pressure overload and the 
resulting response of the myocardium. Although the exact mechanism of syncope is uncertain, the 
vasodilatory effect of exercise with a relatively fixed cardiac output is thought to be a contributing 
factor [24]. There is a link between these symptoms and prognosis [27], [34]. Dyspnoea is the most 
common symptom and, as patients progress into heart failure, leg swelling or fatigue may occur [35]. 
Assessment of symptoms can be challenging in elderly patients due to multiple co-morbidities, 
which may have similar symptoms to AS, and inactivity which can conceal exertional symptoms. 
 
AS can be suspected from the patient history and examination; the classic ejection systolic murmur 
radiating to the neck may be heard. With increasing severity, other signs may be present such as a 
diminishing S2 heart sound and a slow rising pulse. When suspicion is raised, the clinician can order a 
number of investigations. An ECG may show evidence of LVH, delayed AV conduction and T wave 
abnormalities. Occasionally calcification is seen on the chest x-ray. Blood tests may reveal a raised 
BNP or troponin. Whilst tests such as these may confirm probable AS, more informative diagnostic 
tests are required.  
 
1.4.2.  Imaging in AS 
 
1.4.2.1.  Echocardiography 
 
The diagnostic test most commonly used to view and confirm AS is transthoracic echocardiography 
using Doppler ultrasound [29], [31]. Continuous Doppler through the aortic valve gives the velocity 
of blood through the narrowed aortic orifice and the pressure gradient across the valve can then be 
calculated. In the simplest form, it is assumed that the velocity is uniform across the area of the 




valve orifice and that the probe can be orientated and positioned to capture this velocity. The 
pressure gradient can then be estimated by the simplified Bernoulli equation. There are two 
important limitations; Doppler measurements are operator-dependent and the Bernoulli equation is 
a gross simplification of valve haemodynamics [36], [37]. It is an idealised formula that holds true for 
cases of steady laminar flow with an assumption that there is only forward flow of blood as the 
result of the kinetic energy. This is obviously not the case in AS where there is turbulence, friction 
and vortex formation. Based on conservation of energy, the Bernoulli equation predicts a recovery in 
hydrostatic pressure (energy) but because of the energy loss there is non-recovery in the distal 
vasculature which is not considered. On average, the Bernoulli formulation overestimates the 
pressure drop across the valve by 54%. This is primarily due to the use of a single peak value of 
velocity, neglecting the variation in velocity across the valve plane. Accuracy could be improved with 
analysis of other components of the pressure drop [38]. However, the author concedes that the 
pressure drop is mainly driven by the spatial (convective) acceleration of blood, which is taken into 
account in the Bernoulli formula.  
 
The effective orifice can be calculated using the continuity equation based on the principles of 
conservation of mass. The flow rate in the LVOT must equal the flow in the proximal aorta (see 
figure 1.4) therefore: 
A1 x V1 =A2 x V2 
A1x VTI1 =A2 x VTI2 
AAv= ALVOT x VTI1/ VTI2                                                                                            Eq. 1.5 
 





Figure 1.4 Illustrating the concepts and components of the continuity equation. A1 is the cross-
sectional area (CSA) of the LVOT. V1 is the velocity in the LVOT. The distance travelled by the column 
of blood per unit time is calculated as the velocity time integral (VTI) and is calculated from pulsed 
wave Doppler in the LVOT (VTI1) and continuous Doppler through the valve (VTI2) . V2 is the velocity in 
the aorta,. A2 is the effective orifice area. 
 
 
Using the continuity equation has several drawbacks since there is variability in acquiring and 
measuring the three components of the equation. The major source of error is the measured LVOT 
diameter used to calculate ALVOT and the assumption made that the LVOT is circular in cross-section 
when it is not; this can underestimate the area. Differences in the sampling point within the LVOT 
for pulsed wave Doppler used to measure VTI1 and factors such as regurgitation, which can alter the 
assumed laminar flow can both cause errors. The continuity equation gives the effective orifice area 
instead of the anatomical orifice area (AOA). This can cause discrepancies when comparing with 
values obtained during catheterisation. However, there is evidence that supports the use of 
continuity equation using the EOA over the AOA, as a primary predictor of clinical outcome. Given 
that continuity equation takes into account flow in the LVOT, it may be more accurate than 
transvalvular gradient in low flow states such as true low flow low gradient AS, but it will still 
underestimate area in pseudo-severe low flow, low gradient AS without the use of stress agents[39]. 
The EOA given by the continuity equation has been found to be a valuable parameter for prediction 
of clinical outcome and may help in decision-making. 
 




Planimetry of the aortic valve area is sometimes performed but, in heavily calcified valves for which 
the image quality is poor, this is often difficult. If transthoracic imaging windows are poor and the 
Doppler signal is suboptimal, transoesophageal echocardiography (TOE) could be performed. Data 
suggest that computed tomography (CT) and cardiovascular magnetic resonance (CMR) imaging 
measurements of the aortic valve orifice area correlate well with planimetric measurements 
obtained at transoesophageal echocardiography. A good correlation also exists between CMR 
estimates and the area obtained with the continuity equation at TTE[40] or the Gorlin equation at 
cardiac catheterisation[41]. However, planimetric measurements, irrespective of the radiologic 
imaging technique used, tend to be larger than measurements derived from velocity and pressure 
relationships. This is probably explained by the complex 3D structure of the aortic valve, with the 



































Figure 1.5 Images of the aortic valve of a patient from the current study showing different ultrasound 
techniques. a) Transthoracic short axis view b) Transoesophageal short axis views c) 3D 
reconstructed valve from Transthoracic image d) showing continuous wave Doppler through the 
aortic valve showing high velocity of 4.85m/s.  
 
 
3D echocardiography systems can be used to assess the severity of AS [43]. Images can be viewed 
from a number of perspectives and no geometric assumptions are needed; when using the 
continuity equation, for instance, the true LVOT area can be used. Also, there is no out-of-plane 
motion of the valve affecting the Doppler measurements. However, some of the limitations 
associated with 2D echocardiography remain, including lower resolution, restricted views in some 
patients, low signal-to-noise ratio, acoustic reflection and ultrasound attenuation (a particular 
problem in calcified structures) and relatively high inter-observer variability. In cases where there is 
poor LV function with resultant low flow and low transvalvular gradient, stress echocardiography 




using either an exercise bike or drugs such as dobutamine to increase myocardial contractility can be 
used to confirm severe AS or unmask pseudo-severe AS[39].  
 
1.4.2.2.  Other imaging techniques 
 
Advances in other non-invasive imaging techniques have led to the availability of a greater number 
of tools to help assess a patient with AS. When compared to echocardiography, cardiac CT and MRI 
can provide clearer images with good spatial resolution, high signal-to-noise ratio and 
comprehensive cross-sectional images of the patient’s heart. This enables more accurate planimetry 
of the orifice, especially with CT [41]. The disadvantages are the difficulty in capturing moving valve 
leaflets in the maximally open position and the high cost.  
 
More recently there has been a drive to use imaging to predict disease progression. Cardiac CT has 
been used in combination with PET using 18F-NaF and 18F-FDG radiotracers and it was found that 
18F-NaF uptake identified active tissue calcification and could predict disease progression in calcific 
AS[44]. CT assessment of AS has shown that measuring the amount of calcium deposition in the 
aortic valve provides incremental prognostic information beyond clinical and Doppler 
echocardiographic assessment with severe valvular calcification independently predicting excess 
mortality. Clavel et al[45] suggest CT should be considered not only for diagnostic purposes but also 
for risk-stratification in patients with AS and this now features in clinical guidelines. 
 
Cardiovascular magnetic resonance (CMR) imaging already offers a reference method for monitoring 
longitudinal changes in LV function in patients with AS[46]. Flow and velocity assessments are also 
undertaken in CMR imaging. However, 2D Q flow analysis is recognised to underestimate 
transvalvular velocities and this is likely to be due to the difficulty in identifying the peak velocity 
during planning and the velocity encoding settings[47]. Four-dimensional (4D) flow CMR is an 




emerging tool which allows cross sectional x/y/z planar components of velocities over the complete 
cardiac cycle to be quantified[48]. Imaging and flow quantification can now produce impressive 
visualisation of blood flow and may give direct insight into patient haemodynamics, in part negating 
the need for modelling [49]. In recent years there has been a focus on using the technique to assess 
wall shear stress and turbulent kinetic energy to evaluate the severity of stenosis[50]–[52] but 4D 
flow analysis also has an advantage in identifying the true peak velocity across the three-dimensional 
aortic sinus and also circumvents many of the issues of echocardiographic measurement such as 
Doppler alignment, flow and geometric assumptions. Being able to identify where maximum velocity 
occurs in a 3D space is a major advantage not only over Doppler TTE but also over the current 
standard two-dimensional (2D) phase contrast methods for AS assessment, which are known to 
underestimate velocities [53], [54]. More accurate velocity fields can be used to calculate pressure 
gradients using the Bernoulli equation. Pressure gradient fields derived from 4D flow using the 
pressure Poisson equation may also be possible[52]. 
 
Moreover, 4D flow MRI enables quantification of the effective orifice area (EOA) using the peak 
velocity plane, which coincides with the vena contracta, identified by an evaluation of the whole 
three-dimensional aortic sinus flow. However, there are many unknowns for wider adoption of these 
methods for AS assessment. Firstly, validation of peak velocity assessment by 4D flow CMR for 
estimating peak pressure drop across the aortic valve against the reference invasive method is 
lacking. Secondly, EOA calculation using the peak velocity plane (vena contracta) from 4D flow CMR 
has not been validated. Thirdly, it remains unclear if 4D flow CMR offers any incremental benefit 
over Doppler TTE. The decision whether or not to intervene on the diseased valve is often based on 
symptoms and upon historical data. Since the severity of disease during clinical assessment is often 
disproportionate to the symptoms exhibited by the patient an assessment which enables clinical 
evaluation of the severity of disease to be correlated with functional capacity may be helpful. 
Independently from computational models, 4D flow MRI can directly assess the severity of the 




disease by modelling the flow through the diseased valve which can then be compared with 
functional capacity along with standard techniques. Furthermore, MRI may also be useful for the 
detection of myocardial fibrosis, thus providing additional prognostic information[29].  
 





Figure 1.6 images of a stenotic valve of a patient from the current study taken with a)CT b) MRI with 
4D flow representation and c) standard MRI with 2D velocity assessment. 
 
 
1.4.3.  Cardiac catheterisation 
 
Cardiac catheterisation, primarily for the purpose of coronary angiography, is still routinely 
performed in patients in whom aortic valve intervention is being considered, because these patients 
are at risk of having CAD and, if obstructive disease is present, this can be treated at the time of 
valve replacement by CABG. Crossing a diseased aortic valve during cardiac catheterisation can be 
challenging and there is evidence that it is unsafe [55]; for this reason it is no longer recommended 
to use this technique to measure pressure gradients to determine the severity of AS. However, 
catheterisation may be performed if the history, examination and other diagnostic tests are 
inconsistent or inconclusive. Simultaneous measurement of pressure with a catheter in the left 




ventricle and another in the proximal aorta is considered to be the ‘gold standard’[56]. In practice a 
pull-back gradient is usually performed, but the results are sometimes erroneous due to catheter 
position within the flow and beat to beat variability.  
 
 
Figure 1.7 Simultaneous aortic (purple) and LV pressures (yellow) obtained during cardiac 
catheterisation in a recruited patient with severe AS undergoing TAVI. Peak to peak gradients (S-s) 
and mean gradients (the integrated gradient between the left ventricular and aortic pressure 
throughout ejection, shaded white) were recorded avoiding ectopic beats. 
 





                                                                               Eq. 1. 6 
Where CO = cardiac output, SEP = systolic ejection period, HR = heart rate and mG = mean pressure 
gradient. 
 
Cardiac catheterisation is the gold standard method for determining the cardiac output is the Fick 
method where oxygen consumption is divided by the difference between arterial and venous 
oxygenation. The thermodilution method (a derivation of the Fick principle) is most often used due 
to its relative ease. The Gorlin equation (Eq. 1.6) also has clear limitations. Significant errors in the 




calculation of cardiac output are common and in deriving their equation , the Gorlins assumed that 
for the aortic valve, the coefficients of  orifice contraction and velocity loss were 1, which is not 
possible.  
 
1.4.4.  Other Biomarkers 
 
Because of reliance upon patient-reported symptoms and imprecise imaging techniques, other 
objective prognostic biomarkers have been pursued, the main ones being BNP and NT-pro BNP. A 
correlation has been shown between the level of serum BNP and NT-Pro BNP and symptoms and it 
has been suggested that these biomarkers could be used to predict the onset of symptoms and 
guide prognosis [24]. However, Ben-Dor et al [57] failed to show a correlation between BNP, severity 
of AS or mortality. Problems may arise because of the wide range of levels of these markers with 
differing significance in terms of symptom onset and prognosis. In addition, the test itself may be 
affected by other disease states such as renal disease and pulmonary hypertension. More recently 
natriuretic peptides have been shown to predict symptom-free survival and outcome in studies of 
normal and low-flow severe AS [58], [59] and therefore BNP is the first cardiac biomarker to be 
included in guidelines[29].  
 
Cardiac troponin is released during myocardial injury and can be detected in the blood steam at very 
low levels. In AS, raised troponins are associated with an increased LV wall thickness, myocardial 
fibrosis and outcomes[60]. However, elevation in cardiac troponin is not specific and is not routinely 
used in clinical practice. In the EVoLVeD study (Early Valve Replacement guided by Biomarkers of 
Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis) that is 
currently underway, investigators are studying patients at risk of LV dysfunction as determined by 
raised troponin, or a strain pattern on ECG, to see if early myocardial fibrosis is present on CMR and 
whether or not early intervention is beneficial to these patients. Novel calculated biomarkers such as 
valvulo-impedance which assesses the load on the left ventricle and has been linked to mortality 




have also been suggested [61]. This has a similar rationale of assessing the system physiology to the 
computational modelling process presented in this thesis. 
 
1.5.  Quantification of AS  
 
As discussed above, there is debate about the best method of quantifying the severity of AS and to 
risk-stratify the patient. The major studies linking symptoms and severity of AS to mortality have 
been catheter-based studies [34], but we now use cardiac ultrasound to help make the same 
judgments with less evidence [62]. However, this difference in approach is unlikely to matter so long 
as whichever method is used is reproducible and correlates with outcome. Cardiac ultrasound and 
Doppler measurements will continue to be used [29] at least until other methods can be shown to 
predict morbidity and mortality more accurately. ESC guidelines recommend the use of ultrasound 
as the main diagnostic tool and for assessing severity of the stenosis using mean and maximum 
transvalvular velocities and a possible diagnostic workflow is shown in figure 1.8. 
 
 





Figure 1.8 Diagnostic algorithm to assess the severity of AS. 
a) High flow may be reversible in settings such as anaemia, hyperthyroidism, arteriovenous shunts.  
b) Pseudo-severe AS is defined by an increase to an AVA 1.0cm2 with flow normalization. 
ΔPm = mean transvalvular pressure gradient; AS = aortic stenosis; AVA = aortic valve area;  
CT = computed tomography; EF = ejection fraction; LVEF = left ventricular ejection fraction;  
SVi = stroke volume index; Vmax = peak transvalvular velocity. Reproduced with permission of the 
ESC, copyright of Oxford University Press.[29] 
 
 
Local gradients across the diseased valve do not inform us about the global burden on the 
whole system’s physiology and it is likely that it is the total load on the left ventricle that 
results in the significant morbidity and mortality associated with AS. If the total load on the 
LV can be measured and predicted reliably, it is anticipated that it will correlate with a 




patient’s symptoms and activity more directly than other measures such as the severity of 
the stenosis. 
 
1.6.  Clinical management and interventions 
 
1.6.1.  Medical therapy 
 
Medical therapy such as statins [63] have been suggested early in the disease to slow progression. 
Other medications to treat any resulting heart failure or to treat hypertension and hence reduce the 
load on the left ventricle are often required. However, despite the clear similarities with 
atherosclerosis, large randomised trials have failed to show significant effect on disease progression 
or clinical outcome[64]. Therefore, currently, there is no medical treatment apart from that used to 
treat the heart failure that may ensue from AS. This has no place in modifying the valve disease 
process or treating the underlying cause. 
 
1.6.2.  Evolution of treatment in AS 
 
Advances in surgical techniques and technology over the last 40 years means that conventional 
surgical aortic valve replacement is safer than it used to be[65]. In addition, there are new, less 
invasive techniques, such as minimally invasive SAVR and TAVI. Advances in cardiopulmonary bypass 
have seen the addition of novel defoaming agents, heparin coated circuitry, ultrafiltration, 
miniaturised circuit design and integrated arterial filters with an oxygenator[66]. 
Figure 1.9 shows the important steps made in the history of aortic valve surgery after the initial 
catastrophic valvotomies undertaken in the 1940s. The invention of the cardiopulmonary bypass 
machine in 1953 dramatically changed the outcome of aortic valve surgery. 













Figure 1.9 Timeline showing the important steps in AV intervention since 1953 
 
1.6.3.  Surgical AVR 
 
All effective ways of treating severe symptomatic AS involve physical relief of the obstruction to the 
LVOT. SAVR remains the currently preferred treatment for patients with symptomatic severe AS and, 
because of the grave prognosis without surgery, there is some urgency in its conduct. Surgery is 
performed under general anaesthetic via traditional open-heart surgery, which involves an incision 
in the chest and fracture of sternum to access the heart and the use of a cardiopulmonary bypass 
machine, or through minimally invasive methods that involve smaller incisions in the chest. 
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Figure 1.10 image showing minimally invasive conventional SAVR. Arterial cannulation of the 
ascending aorta is seen below and venous cannulation of the right atrium on top. The native calcified 
cusps resulting in aortic stenosis are being excised. Reproduced from Walther et al[67] with 
permission from the BMJ Publishing Group Ltd. 
 
The reduction in mortality following SAVR is marked; with survival at three years being 87% in 
operated patients with AS and 21% in unoperated patients (p < 0.001) [34].  
 
Figure 1.11 Illustrating the survival of patients with AS with(upper line) and without (lower line) 
surgical intervention, reproduced from Schwarz et al [34] with permission from Wolters Kluwer 
journals. 




The number of aortic valve operations in the UK has been increasing[68] with the associated costs to 
the healthcare system.  
 
 Number of valve replacements and repairs, United Kingdom 2003 to 2015 
Operation 2003 2005 2007 2009 2011 2013 2015 
Isolated aortic valve 
replacement  3,361 3,545 4,040 4,402 4,787 4,893 5,796 
Aortic valve replacement 
and coronary artery bypass 
graft (CABG) 2,445 2,796 3,122 3,222 3,205 3,240 3,258 
Table 1.1. Showing the trend of the number of aortic valves being replaced in the UK between 2003 
and 2015[68]. 
 




Figure 1.12 Graph showing a downward trend in surgical mortality for aortic valve replacement in 






















An individual’s risk of mortality and complications can be estimated using surgical risk calculators 
such as EUROSCORE II and the Society of Thoracic Surgeons score. Figure 1.13 shows the predictive 
mortality of patients in the UK based on EUROCORE II which suggests that, as well as performing 
more operations, surgeons are taking on higher risk patients with excellent results in terms of 
mortality. An argument in favour of early surgery can be made as operative risk is lower in younger 
patients that are asymptomatic, have less comorbidity and have normal left ventricular function. 
However other complications which need to be considered can include damage to conduction 




Figure 1.13 Graph showing the predicted mortality of patients undergoing isolated AVR in the UK 
between 2006-2015 based on their EUROSCORE II. Data from the Society for Cardiothoracic Surgery 
blue book online [68]. 
 
Early outcomes after SAVR may be further improved using limited access techniques through upper 
sternotomy or right thoracotomy [69], [70] Cardiopulmonary bypass times and cross clamp times 
could be reduced using sutureless aortic valve prostheses[70]. New sutureless valves and stentless 

























Treatment of congenitally bicuspid valves is generally by SAVR. Patients with bicuspid valves have 
been excluded from many TAVI trials because of the geometry of the root and valve. Many of these 
patients also have aortic root dilatation, which is an indication for surgery. Although technically 
feasible, the number of patients that have undergone TAVI is small, and there are reports of 
significant PVL (∼10%) and major vascular complications[72]. These patients are at specific risk of 
aortic root complications due to heavy calcification or associated aortopathy.  
 
1.6.4.  TAVI 
 
The technique of balloon valvotomy has been employed for over 30 years and is still sometimes 
used, often as a bridge to more definitive treatment or to determine whether LV function can 
recover with relief of the obstruction. TAVI is undertaken either under general or local anaesthetic 
and involves inserting a valve usually through the groin (femoral artery) under x-ray guidance. Since 
Alain Cribier performed the first TAVI in an inoperable patient in 2002, transcatheter valve 
intervention has become an established therapy for patients with AS. The number of TAVIs is 
increasing, and in the UK it may overtake SAVR in the future as it has already done in Germany and 
the USA, for example. This procedure is more expensive than surgical SAVR[73] and the benefits 
above and beyond SAVR are not always clear. 
 





Figure 1.14 Fluoroscopic image of a TAVI valve during a procedure in this study. 
 
In the last decade there have been advances in percutaneous approaches and it is now 
commonplace for patients not deemed suitable for conventional AVR to undergo TAVI. The results 
from the PARTNER trials [74], [75] are encouraging, with risks similar to that of traditional AVR in 
high risk groups in terms of mortality (1 year 24% in TAVR vs 27% in surgical AVR) and superior to no 
intervention (1 year mortality of 31% vs 50%). TAVR has the advantages of not always requiring a 
general anaesthetic and potentially a quicker recovery for the patient. 
 
TAVI is starting to change decision making regarding valve intervention. Trials show non-inferiority of 
TAVI compared with surgical intervention in both high, intermediate and low risk patients[74]–[77]. 
Procedural risk has fallen with increased experience and new technology. Major vascular 
complications have decreased from >10% to <5% and stroke rates are now around 2-3%[72]. 




However, the requirement for permanent cardiac pacing post procedure remains consistently higher 
than surgical intervention at >10%[72] and while TAVI allows for rapid patient recovery and 
mobilisation, the long-term durability of these bioprostheses has not been demonstrated[78]. This 
will be key before their widespread use in younger or asymptomatic patient groups can be 
recommended. The TAVR UNLOAD trial[79] will determine whether the increase in afterload caused 
by moderate stenosis has an adverse outcome in patients with impaired LVSF. Looking at the total 
load on the ventricle rather than individual components which can be achieved using computational 
modelling may add insight to questions such as this. 
 
A meta-analysis examined trial results and compared the outcomes of patients with symptomatic AS 
randomised to TAVI or SAVR. This suggested that all-cause mortality was lower after TAVI with a 17% 
relative risk reduction up to two years in patients undergoing a transfemoral procedure, although 
absolute risk reductions were not reported. The risk of stroke was lower after TAVI up to two years, 
and the relative risk reduction was 19%. Although there was lower overall risk of major bleeding, 
new onset atrial fibrillation and AKI, there was an increased risk of permanent pacemaker 
implantation and major vascular complications in patients treated with TAVI.[80] In a study by 
Barbanti et al, at five years post-intervention, the opposite was suggested. At 5 years, the rate of 
death from any cause was 35.8% in the surgical group and 48.3% in the TAVI group (hazard ratio, 
1.38; 95% CI, 1.12–1.69; P=0.002). This is relatively high in both groups and may be due to the fact 
that the patients are elderly and approaching their life average expectancy, when they present with 
symptoms and have an intervention. Similarly, TAVR was associated with an increased risk of major 
adverse cardiac and cerebrovascular events as compared with SAVR (42.5% versus 54.0%; hazard 
ratio, 1.35; 95% CI, 1.11–1.63; P=0.003) [81]. 
 
As discussed above, treatment of bicuspid aortic valve stenosis is primarily with SAVR. However, 
TAVI outcomes may improve with advances in technology and new devices. In a bicuspid TAVR 




registry of 301 patients, moderate or severe PVL was less frequent with newer devices ( (0.0% vs. 
8.5%, P = 0.002)[82]. 
 
1.7.  Prognosis after treatment 
 
It is accepted that valve replacement should only be considered in patients without comorbidities 
which would render the procedure futile due to competing causes of death. Life expectancy 
following AVR should be expected to be at least one year following intervention[29]. As described in 
sections 1.6.3 and 1.6.4, if current guidelines are adhered to, the prognosis following valve 
replacement is better than a conservative approach in the majority of patients, irrespective of which 
technique is used. However, survival after AVR depends on a number of clinical variables, including 
pattern of pre-operative LVH, severity of myocardial dysfunction, and cardiac fibrosis[83] and 
therefore it is difficult to predict which patients will do really well with increased activity levels, 
improved quality of life and longevity. Early LVH regression after AVR seems to be related to gender, 
with more pronounced regression in women than in men[84]. If there is a lack of LV regression, this 
indicates a worse prognosis[85]. Again, this may be due to other factors that load the ventricle which 
were not studied. 
 
Strong correlations have been found between AVR-induced increase in myocardial efficiency and 
changes in exercise work [86], parameters that a computational model can also measure. The effects 
of AS upon myocardial efficiency have been debated [87], [88]. However, work and power may be 
predictors for disease progression and prognosis and therefore it would be useful if this can be 
modelled accurately. In patients with LV dysfunction, the ejection fraction (a measure of cardiac 
function) does not improve in approximately 25% of patients[89]–[91] who are more likely to remain 
symptomatic and have adverse long-term outcomes, they are twice as likely to die over 5 years 
follow-up[92].  





Reductions in ejection fraction are therefore a late, non-specific and often irreversible feature in AS, 
leading to interest in alternative methods for detecting left ventricular decompensation[93], [94] 
and computational modelling may have a role here. 
 
1.8.  Guidelines 
 
Contemporary guidelines are often underpinned by historical observational data and expert opinion 
rather than high-quality randomised controlled trials and there is often debate about the best 
approach for certain patients. Risks scores such as EuroSCORE [95] and the STS scores [96] have 
been used to aid decision making, as have data from randomised control trials. However, these are 
population-based studies which do not consider many of the attributes of the actual person being 
considered for intervention. Recommendations for optimisation of patient care are set out within 
the published clinical guidelines, which are based on expert opinion, clinical consensus and 
systematic review of available published evidence [29], [31]. There is evidence that intervention 
should only be undertaken if a patient develops symptoms and or LV systolic dysfunction. If the 
patient reports symptoms consistent with findings on examination and investigations support this 
then the decision will be quite straightforward, but this is not always the case and problems such as 
low flow low gradient AS are challenging. The indications for intervention that are alluded to in the 
previous sections are set out in an excerpt from the 2017 ESC guidelines below. 
 





Table 1.2 Management of severe AS with class of recommendation (a) and level of evidence (b). 
Reproduced with permission of the ESC, copyright of Oxford University Press [29]. 
 
 




1.8.1.  Timing of intervention 
 
The onset of symptoms is an indication to intervene and replace the aortic valve, because the 
prognosis is poor if the condition is managed conservatively[35]. The evidence that forms the basis 
for management today is over 50 years old and is based upon retrospective data from 12 patients 
with bicuspid and rheumatic aortic valve disease. The mean age of death in the study was 63 years 
and, not truly representative of the demographic we see today. The changing characteristics of our 
much older population who have a different aetiology makes the relevance and interpretation of this 
historical data difficult.  
 
Sometimes patients are operated on before it is necessary, exposing them to surgical risk 
prematurely, including the risk of valve thrombus and it is conceivable that repeat surgery may be 
necessary due to valve degeneration. Occasionally, intervention is too late, and the left ventricle is 
irreparably damaged. If the onset of symptoms occurs late in the disease process, it is associated 
with an ominous prognosis, with increased frequency of sudden death[29].  
 
These risks are also heavily influenced by replacement valve type, with both major bleeding 
associated with anticoagulant use (1.8%–2.6% per year) and thromboembolism (0.7%–1.0% per 
year) more frequent if a mechanical valve is implanted[97]. However structural degeneration is 
exceedingly rare in mechanical valves. Bioprosthetic valves have a limited lifespan with valve 
degeneration usually starting at 10 years following implantation and earlier in younger patients[98]. 
This is an extremely important issue if bioprosthetic valves are to be used in younger asymptomatic 
patients as suggested in some of the recent TAVI trials of patients at low operative risk. The use of a 
transcatheter valve inside a surgical bioprosthetic valve (valve-in-valve TAVI) may reduce the risk of 
future procedures should valve degeneration occur; however, this would again adversely impact 
fluid dynamics with reduced EOA, and long-term outcomes are needed in this patient cohort. There 




is also an increased risk of endocarditis (1%–3% during year one then <0.5% per year[99]), which is 
associated with high morbidity and mortality. 
 
Even when the decision is made to replace the aortic valve, the urgency of such replacement needs 
to be assessed. The risk of death from AS is approximately 1% per year without symptoms but when 
diagnosed and intervention planned 4% would die within the first three months from diagnosis[100]. 
Up to 14% of patients would die on a six month surgical waiting list[101]. There is therefore some 
urgency even when a decision has been made to intervene. However, it is often difficult to decide 
who requires immediate surgery and who is safe to wait on the list. Given that delays from referral 
are common in most healthcare systems, this should also inform decisions. 
 
Rapid progression (>0.3 m/s/year) and significant valve calcification have a rate of symptom 
development or mortality of 79% at 2 years[102]. However, as discussed, due to imaging limitations 
and logistical issues identifying these patients in clinical practice is difficult. The referral for surgical 
intervention in these patients is recommended in the guidelines[29]. This is based on limited 
observational data. Delaying intervention until there is evidence of advanced left ventricular 
dysfunction results in greater perioperative risks. Observational studies have quoted increased 
perioperative mortality (9%–19%)[89], [92], [103] . Risk stratification can be performed by looking 
for contractile reserve using stress echocardiography. If present, there is lower perioperative 
mortality (5% vs 22%–32%)[91], [104] but longer outcome data are needed. The mortality and 
morbidity burden related to delaying valve intervention appears to occur in the months and years 
following AVR. As discussed, patients with an impaired ejection fraction prior to AVR have a poor 
long-term prognosis. However, given the dismal prognosis of untreated AS, improved long-term 
survival can be achieved in patients with poor LV systolic function even without contractile reserve. 
Using fibrosis to predict the probability of LV decompensation, a study found that more than half 




who were deemed high risk were either dead or admitted to hospital with heart failure within 2 
years[25]. Figure 1.15 highlights the risks of early and late intervention as the disease progresses. 
 
 
Figure 1.15 Schematic illustrating the optimal time of intervention in the disease process with the 
competing risks of intervening too early and too late.  
 
Clinical trials such as the Japanese Contemporary outcomes after sURgery and medical tREatmeNT in 
patients with severe AS (CURRENT AS) registry are trying to address the issue about timing of 
surgery. Those who received early AVR had a reduced all-cause mortality at 5 years (15%) compared 
with those who were initially managed conservatively (26%). Frequency of admission to hospital due 
to heart failure was also reduced in the early intervention group (4% vs 20%). A significant 
proportion of the conservatively managed patients who developed symptoms were not referred for 
intervention, contributing to the worse observed survival in this group. Three randomised controlled 
trials currently underway (AVATAR, ESTIMATE and EARLY-TAVR) will examine whether valve 
intervention in unselected asymptomatic patients with severe AS can improve clinical 
outcomes[105]. The RECOVERY trial showed that early surgery in patients with asymptomatic but 
Early Intervention 
Risk of: 
• Early valve 
degeneration and 
need for repeat 
intervention 
• Valve thrombosis 
• Early exposure to 




Progression of disease 
Optimal Timing 
• Before symptoms 
develop 










• Heart failure 





• Sudden death 




very severe AS (transvalvular velocity >4.5m/s) results in improved survival out to 8 years compared 
with watchful waiting, suggesting that we should perhaps intervene on patients earlier than the 
current guideline recommendation of 5.5m/s[106]. 
 
A study examined the total haemodynamic load, quantified by calculating the valvulo-arterial 
impedance (ZVa = (systolic blood pressure + mean AV gradient)/indexed LV stroke volume), seen by 
the left ventricle and its ability to predict outcome[107]. This measure has consistently been shown 
to be an independent marker of adverse outcome in asymptomatic patients[107] and load on the 
ventricle warrants further study for its use in determining the timing of intervention, this can be 
achieved with computational modelling. Another approach is to quantify valvular calcium burden 
using CT calcium scoring. Validated, gender-specific thresholds for severe AS have been proposed 
which provide powerful prediction of clinical events of incremental value to echocardiographic 
assessments[29], [45] . 
 
Most of the guidelines are based on limited observational data and supported by expert consensus 
opinion. There is therefore a need for randomised controlled trials assessing the optimal timing of 
surgery and novel objective methods to guide this major clinical decision that could be produced by 
computational modelling are needed.  
 
1.9.  Assessing symptoms and Outcomes 
 
Over the past decade we have seen a rise in the involvement of patients in decisions about their 
health and care. Measuring ‘what matters to patients’ is crucial in improving patient care. Data can 
also be used to assess health technology, assist in drug development, determine health service 
commission and improve communication between patients and healthcare professionals. Due to the 
variations in presentation and reporting of symptoms as discussed above, exercise testing is already 




performed in certain situations to help guide management decisions [30], [105]. The clinical utility of 
activity monitoring as part of the process of interventional planning and outcome assessment will be 
investigated in this research study. This section reviews potential measures of functional status and 
the technology required. 
 
1.9.1. Assessment of function 
 
Characterisation of functional status in older adults with AS is essential to help guide management 
decisions. Frailty is linked with an increase in morbidity and mortality after cardiac surgery [108], 
[109]. Now, with the advent of TAVI, frailer patients, that would not have previously been offered an 
operation can still be treated effectively [74], [75], so it is becoming more important. Frailty 
measures now feature in the logistic EuroSCORE [95] used to assess the risk of an individual 
undergoing intervention and many clinicians use such scores to inform decisions. The use of gait 
speed is recognised as a marker of frailty and predictor of outcomes in adults undergoing 
cardiovascular intervention.  
  
1.9.2.  Exercise testing in clinical practice 
 
Management of asymptomatic patients with severe AS is controversial [30]. Exercise testing using 
the Bruce protocol is the best-studied risk stratification tool to identify those in whom an 
intervention can be offered before the risk of sudden death and operative morbidity increase, but 
positive predictive value is poor [110]. Negative predictive value for predicting subsequent cardiac 
events is reasonable at 79% [111]. However, data are limited to small observational studies with risk 
of bias and different perceptions of what constitutes an abnormal test. Guidelines state that when 
exercise testing provokes symptoms, patients should be considered symptomatic and there is a 




recommendation for valve replacement [112], but symptoms should be clearly shown to be related 
to AS. This may be difficult, particularly in the elderly and in patients with low physical activity levels.  
There are arguments against stress testing in the clinical environment. Stress testing is 
contraindicated or unreliable in some patient groups and, indeed, patients with AS are often elderly; 
and up to 20%[113] will not be able to perform an exercise test at all due to poor mobility. Also pre-
existing ECG abnormalities are present in up to 50% of patients, confounding test 
interpretation[113]. Exercise testing may also detect abnormalities caused by coexistent coronary 
disease, which is an important determinant of both management and prognosis[114]. 
 
Brala et al have shown that exercise capacity determined by cardio pulmonary exercise testing can 
identify high risk patients with AS who may benefit from valve replacement, independently of echo 
parameters, reported symptoms, age, and sex[115]. Due to the resources required, cardiopulmonary 
exercise testing is rarely used in the day to day assessment of AS. 
 
Measurements made outside the clinical environment might be more representative of the patient’s 
capacity and function. Pervasive or wearable monitors, used in the home environment, may provide 
information that could help guide decision making and prognosis. Following open heart surgery, the 
recovery time can vary from weeks to months [86], but clinical investigation of exercise capacity is 
usually conducted at a single point in time which is inequitable. The assessment of recovery of 
patients from SAVR made at four weekly intervals, over six months, revealed marked improvement 
of most patients within the first six weeks; some patients continued improvement to six months, 
although ADLs were not assessed. Since it is impractical to perform tests at multiple time points 
routinely, wearable monitors might have a role in this situation.  
 
 




1.9.3.  Six-minute walk test 
 
The six-minute walk test (6MWT) can reflect overall hemodynamic function if the patient’s effort is 
good and there is no limitation imposed by mobility issues or other conditions such as respiratory 
disease. Hence the 6MWT could contribute to risk assessment in patients. A study showed, in 
asymptomatic patients with aortic valve stenosis, that the 6MWT is an independent predictor of all-
cause and cardiovascular mortality. It was also shown to be of incremental value to 
echocardiographic evaluation, suggesting it might be useful to guide clinical follow-up intervals and 
treatment strategy[116].  
 
De Arenaza et al investigated the added prognostic value of the six-minute walk test to the 
Euroscore in a study comparing stented and stentless aortic valves[117]. In a Cox regression analysis, 
6MWT distance was the only variable retained as an independent predictor of the composite 
outcome of death, MI or stroke at 12 months, providing potentially important functional and 
prognostic information to clinical and risk assessment. 
 
A study by Altisent et al [118] showed that just less than a quarter of patients undergoing TAVI had 
no improvement of their exercise capacity at six months, as measured by a 6MWT. Poor functional 
recovery was linked to increasing age, female sex, presence of COPD, periprocedural bleeding and 
new onset anaemia at 6 months. The study also found that failure to increase a 6MWT distance by 
20% was independently associated with all-cause mortality, CV death or re-hospitalisation for 
cardiovascular causes. This suggests that exercise capacity assessment pre- and post-TAVR may help 
to improve patient risk stratification. 
 
6MWTs have been used to monitor outcome and assess time to recovery following surgical valve 
replacement. One week post operatively there was a significant decline in function; this was back to 




baseline at four to six weeks with significantly improved walk test distances achieved at three 
months post operatively. Significant improvements were seen in six-minute walk test distances and 
physical quality of life measures[119]. One systematic review showed considerable variation in the 
clinical characteristics of patients undergoing TAVI and in the amount of improvement in functional 
outcomes and quality of life after TAVI across 62 studies with many studies using a 6MWT to assess 
this [118]. 
 
1.10.  Wearable or pervasive activity monitoring 
 
1.10.1. Clinical research using activity monitoring 
 
Several studies have addressed the potential utility of activity monitoring in diagnosis, interventional 
planning and outcome assessment. Mukhopadhyay postulated that emerging technologies could be 
used to predict the future health condition of individuals, affecting both the health decisions and the 
doctor patient relationship [120]. Wearable sensors have supported home care for patient groups 
who would usually spend longer in hospital, but how best to monitor human activity is unclear [120]. 
Activity data could be used as early predictors of disease severity and progression, in disease 
understanding, in care delivery or in monitoring post-surgery recovery in cardiac patients, 
pulmonary rehabilitation and others [121], [122]. Integration with other data to inform management 
is seldom done, often because the focus is on establishing the feasibility of monitoring activity and 
establishing an association between measured activity with short-term benefits. There is a need for 
validation and reliability assessment against existing clinical standards [121]. Accelerometers are 
often used for monitoring in outpatient settings but there is no consistency in devices used or in 
reported outcome measures[123]. Knowing what happens between clinic visits means interventions 
can be tuned to the needs of individuals, systems can be tailored to individual patients and 
monitored remotely [124]. Pervasive activity monitoring can be used in randomised control trials. 




Accurate and objective measures of outcome from wearable devices could reduce the number of 
subjects and the duration of treatment needed to observe an effect in a trial of a new therapy, 
although there is no experimental evidence to support this at present. It is functional status and 
quality of life that are important to the patient as well as life expectancy. Wearable devices may give 
more insight to a patient’s quality of life than current clinical methods to assess activity. 
 
1.10.2. Monitoring outcome 
 
Activity measures have been used in patients with AS. Green et al [125] examined the relationship 
between gait speed and activity of daily living. They showed that gait speed was independently 
associated with dependency for activities of daily living and this was thought to be a good objective 
measure for risk stratification. However, the patients were not studied after the intervention to see 
whether gait speed improved and if there were any relationship to outcome measures. Gait speed 
was assessed in a clinical environment under test conditions and it is likely that gait speed will be 
better in the patient’s own environment where they are more confident. It is already known that 
frailty is linked with an increase in morbidity and mortality after cardiac surgery [108], [109]. Studies 
have reported the use of activity sensors at home to monitor outcomes in specific applications. 
Toogood [126] studied 33 patients following hip arthroplasty using a Fitbit™ ankle accelerometer. 
There was good compliance with the device and increases in step counts were recorded up to 30 
days post operatively. Manson [127] used accelerometers to assess 12 patients with Parkinson’s 
disease, correlating results with the severity of dyskinesia. Uswatte[128] tracked changes in motor 
function in 20 patients after stroke and found that this can be used as a feedback tool for guiding the 
rehabilitation process. No published studies have used wearable technology to assess the functional 
state of the patient before and after aortic valve intervention; this application would be novel. There 
are disadvantages and challenges of implementing patient activity monitoring. There are hardware 
and software constraints, monitors need to be light-weight and low energy consumers, and there 




are safety requirements, patient burden, privacy issues and cost. However, activity monitoring and 
personal data collection offers the potential for patient engagement, personalising health care and 
offering clinicians real world assessments of their patients’ daily activity patterns. Monitoring the 
patient’s activity would give an objective measurement before and after intervention. More 
continuous monitoring, allowing identification of trends of activity, may be able to help detect 
deterioration or improvement in the patient’s condition. In the context of AS, monitoring the heart 
rate may also give an insight into the reduction of cardiac work, because a lower heart rate may be 
needed to produce the same cardiac output when performing activity. In this project a correlation 
between the severity of the stenosis, assessed by different techniques and the activity of patients 
will be sought.  
 
A model can be used to predict measurements in an exercise state, so tuning the model with patient 
activity data may help predict their expected capacity for work following intervention. However, 
since even elite athletes spend most of their time in a resting state, it is likely that assessing the rest 
state accurately is equally, if not more, important. 
 
1.10.3. Patient reported outcome measures  
 
Clinicians’ understanding of the effect of disease and treatment on patients’ daily lives is recognised 
to be poor. Standardised measures have been developed to assess symptom status, social function 
and mental health but the use of patient-reported outcome measures (PROMS) routinely in clinical 
practice is hindered, mainly by social, cultural, legal, and logistic barriers[111]. Therefore, such tools 
have often failed to improve care from the patient’s perspective. However, the use of PROMs in 
research and clinical trials is well established and can provide evidence on the burden of disease and 
the efficacy and cost effectiveness of treatments [112], [113]. It is likely that integrated approaches 




to data collection will help reduce patient burden and enable us to harness patient centred data 
alongside traditional outcome measures to tackle healthcare challenges. 
 
AS does not just affect physical health; it also has a significant effect on other aspects of life, 
including mental health. However, once in the severe category, the degree of stenosis does not 
appear to predict or correlate with disease burden on the individual patient[129]. This study used a 
health survey to assess an individual patient’s quality of life profile and compared it to the general 




Figure 1.16 Showing the effect of AS on quality of life in patients over the age of 70 years. Higher 
Norm based score = better quality of life. Adapted with permission from Van Geldorp et al [129]. 




Van Geldorp also showed that quality of life metrics seem to improve significantly at 12 months after 
aortic valve replacement.
 
Figure 1.17 Graph showing change in quality of life parameters following aortic valve replacement. 




1.11.  Computational modelling  
 
Computational modelling is the use of mathematics, computer science and physics to simulate and 
study complex systems [130]. In general, models use multiple parameters to represent the key 
components of a system. The aim is not to completely reproduce all aspects at all levels of detail, but 
rather to capture the ‘essence’ of the system in a specific context. A model should be ‘as simple as 
possible, yet as complex as necessary’[131]. In this section computational modelling in the context of 









1.11.1. What model and why? 
 
The haemodynamics of the circulation are complex, being controlled by a range of factors affected 
by mechanics, hormones and the neurological system. Creating in vivo experiments to display the 
complex interactions would be difficult, whereas computational modelling can account for these 
complex interactions and their effect [126]. By using an appropriate model, researchers can carry 
out thousands of simulated experiments in a safe (virtual) environment.  
 
If the model adequately represents the system being studied then it can be used to comprehensively 
explore the effects of changing any combination of the input variables in a way that is impossible in 
any clinical study for many practical reasons, including the numbers needed, time and cost. All 
interactions between elements that are represented in the model can be captured and analysed in 
detail [132]. A general model, representing an average individual, can be used to gain insight into the 
basic physiological processes. A personalised model, in which some of the parameters are tuned to 
reproduce measurements made in the individual, might be both diagnostic (the personalised 
parameters might themselves have diagnostic utility) and prognostic (the parameters can be 
extrapolated to describe other physiological states and/or to describe prospective interventions). 
 
1.11.2. Current use of modelling in clinical practice 
 
The use of computational modelling to support engineering design is well established in almost 
every industrial sector, including biomedical applications such as in designing heart valve prostheses 
[133]. However, although there are hundreds of research studies that have contributed to our 
understanding of haemodynamics and of disease processes [132], [134]–[136], computational 
modelling generally has yet to make a major impact upon clinical practice. One of the reasons is that 
it is difficult to personalise the model to represent an individual patient. Anatomical personalisation, 




based upon exquisite medical imaging, is increasingly available, but the challenge is the 
personalisation of patient physiology. Perhaps the most advanced of clinical applications is the CT-
FFR computation for coronary artery disease, developed and marketed by HeartFlow™, and recently 
recommended for clinical use by NICE in the UK [137], which allies an anatomical model and CFD to 
compute coronary blood flow. The recognition that it is the interplay between the local stenosis and 
the system characteristics that determines the contribution to the overall physiological burden of 
the disease is the fundamental factor underpinning the success of fractional flow reserve (FFR), in 
assessment of coronary disease[138]. In the context of coronary artery disease, the question is: by 
how much the flow to the myocardium is compromised by the disease. In the context of AS, the 
question might be the degree to which the heart must work harder to achieve the flows demanded 
by the system. 
 
1.11.3. Model Choices 
 
In developing a model strategy, the sophistication of the model with practical availability of clinical 
physiological data need to be balanced. Cardiac models have advanced significantly [139] and they 
are now among the best-developed theoretical representations of any organ [140]. However, to 
achieve its aims, the model must represent not just the anatomy of the heart and the diseased valve 
but also the systems physiology and the model has to be tuned to the individual, using the limited 
clinical data available. Anatomical description of the aortic valve can be available from medical 
imaging and obviously the valve characteristics will have the main effect on local haemodynamics. 
Three-dimensional information would be needed to build a truly patient specific model with the 
effects of valve disease on flow characterised. However, a local valve model needs ‘boundary 
conditions’ to describe the interaction with the rest of the system. The geometry of the aortic valve 
is important, but not in isolation from the proximal and distal haemodynamics of the circulation. 
Numerous vascular conditions, including coarctation of the aorta[141], [142], have been modelled in 




theoretical and in vivo experiments. However, idealised 3D geometries are often created without 
reference to a specific patient [143]. CFD models are the most commonly used but 3D fluid–
structure interaction models may be more accurate[144]. These require specific data concerning 
tissue characteristics and the effect of surrounding structures, and these data are often difficult to 
obtain noninvasively. If a model of the valve and the flow through it could be simulated, this would 
be the most accurate representation, and would allow factors such as pressure recovery to be taken 
into account, which are not included in current clinical methods such as ultrasound and the Bernoulli 
equation. 
 
Mathematical models of the cardiovascular system can be solved computationally to provide 
diagnostic measures or to predict disease evolution and the potential effects of interventions. A 
simple but effective system model is based upon an electro-hydraulic analogue [132], in which blood 
inertia and viscosity are represented by electrical inductance and resistance respectively and vessel 
compliance by capacitance. Pressure corresponds to electrical voltage, flow to electrical current, and 
volume to stored charge. The heart is represented by adding a power source to represent 
myocardial contraction. Valves are represented as resistances, with valve coefficients chosen to 
reflect the (nonlinear) resistance to flow. Often an ideal diode is used to represent normal valves, 
but it is also possible to characterise regurgitant valves. The valve coefficients in a systems model 
might be based upon formulae such as the Gorlin equation [145] or the results of more complex 
computational fluid dynamics analysis. In the current project it is the effect of the diseased aortic 
valve that is under investigation, which has a considerable impact on ventricular work. Only sparse 
physiological data are available to tune the model to the individual; therefore, the simplest possible 
mathematical model that is able to capture the basic interaction between the left heart and the 
systemic circulation in the presence of aortic valve disease will be selected. 
 
 





1.11.4. Systems model (Zero-dimensional, ‘lumped’ parameter) 
 
In a zero-dimensional (0D) model the elements of the system are described by simple electrical 
analogue models. They describe the global behaviour of the modelled system. The fundamental 
outputs of the model are pressure, flow and volume at discrete locations within the cardiovascular 
system, and each of these outputs varies over the cardiac cycle. As the name suggests, there is no 
representation of a spatial distribution of these quantities within any specific component; so, for 
example, the pressure throughout the left ventricle is represented as uniform at any instant in time. 
The equations describing the electrical analogue systems are a series of ordinary differential 
equations that represent the fundamental outputs and their temporal gradients. The first such 
model developed for cardiovascular application was the Windkessel model described in 1899 [146]. 
There are a number of validated models available [147], and it is important to select the right model 
for the question being addressed. If models have too many parameters, it is not possible to find a 
unique fit to the available clinical data.  
 
Extra resistance elements can be connected in series with the Windkessel model, which is often 
referred to as the Westkessel model [148]. This improves the performance of the model 
representing the systemic circulation. The overall resistance equals the total systemic vascular 
resistance. The capacitance represents elasticity and the storage properties of large arteries. Studies 
show this model provides a good representation of after-load but it can overestimate and 
underestimate some parameters[132]. Another drawback with this model is that the venous 
pressure is assumed to be zero. This will often be incorrect in patients with AS, as many will have 
LVH, diastolic dysfunction and pulmonary hypertension. Also, it cannot show pressure and flow 
changes in specific sections of the circulation as results are ‘lumped’ together. However, for the 
purposes of the current study, this type of model would provide reasonable accuracy and is simple 




enough to populate with clinical data that is obtained in routine practice. It has been widely used in 
cardiovascular simulations as the after-load to evaluate cardiac function under various pathological 
and physiological conditions [132]. The left ventricle and left atrium are often described by variable 
elastance models, which represent the relationship between chamber pressure and volume as a 
function of time and thus provide a simple description of the active contraction of the heart. There 
are alternatives, for example the single fibre model [149]. 0D models are frequently used to improve 
boundary conditions for 3-D models of pathology[136], [137] this could be achieved in this study. 
 
One of the first steps following model selection should be to perform a sensitivity analysis[150], to 
separate those parameters in the candidate model that have a significant impact upon model 
outcomes from those that have a minimal effect. The parameters that have a significant impact 
should be accurately represented and personalised. Conversely, parameters that do not have a great 
effect could be estimated using population based data. This is important, as to obtain certain data 
may subject patients to risk, as discussed in the case of exercise testing and invasive catheter 
pressure measurements, so knowing how important that data is allows a risk benefit analysis to take 
place. 
 
1.11.5. 3D valve model 
 
A local 3D model of the valve can be derived from the segmented medical image (see section 2.4.2), 
a process that is compatible with clinical routine [144]. If this is possible in our cohort, a non-invasive 
estimation of the pressure gradient using only the geometry of the valve, LVOT and proximal aorta 
may be obtained through computational fluid dynamics (CFD) calculations. CFD is a branch of fluid 
mechanics that involves solving mathematical equations that describe fluid motions in three 
dimensions [151]. Most analyses are based upon the governing equations of fluid motion; the 
Navier-Stokes and continuity equations. These should produce more physiological and accurate 




information about the haemodynamics through the stenosis than echocardiography because there is 
no operator-dependency upon Doppler alignment, avoiding the need for the many assumptions 
made during echocardiographic assessment, and pressure recovery could be taken into account. The 
relationship between flow and pressure can then be derived. CFD ‘solvers’, are used to solve the 
Navier-Stokes and continuity equations. For complex geometries analytical solutions often do not 
exist and an ‘approximate’ numerical solution is found by the solver. Because of their non-linearity 
(due to convective fluid acceleration), solutions often require the use of high performance 
computers and can take considerable time to run [136], [152]. However, CFD is not perfect. In 
response to an FDA initiative, 28 groups from the international CFD community performed 
independent simulations of a simple benchmark problem. This highlighted a significant amount of 
measurement error and variability in flow measurements to standardised methods [153]. Despite 
this, many believe that these equations and methods that are used in chemical, aerospace and 
aeronautic engineering and the automotive industry have emerged as valuable tools in biomedical 
engineering [136], [154]. Modelling blood flow in deforming vascular structures represents one of 
the major challenges in this field [155]. It can take days, even with major computational resource, to 
run complex 3D models [156]. For clinical utility, simplifications will be required and the application 
of an advanced form of reduced order modelling (ROM) to reduce the computational time to enable 
results to be produced in real time [157]. An alternative method of assessing the haemodynamics in 
more detail than echocardiography may be CMR 4D flow assessment (see section 1.4.2.2). 
 
1.11.6. Model Personalisation 
 
Several experiments have been carried out using simulated data or population average data and 
these have shown that models of the cardiovascular system, including when the system is diseased, 
such as with AS, are valid and can be effective tools in the assessment of patients. Few studies using 
animal data [158], and even fewer using human data, have been conducted. The process of 




personalisation of the parameters for these models, to make them clinically useful, is new and 
challenging [159]. Even lumped-parameter models often require many inputs and detail that are not 
available from sparse clinical data sets [156]. Hann described a process in which parameters are 
adjusted and their effect on the output measured. A focus can then be on collecting data that is 
important and readily available. Reducing the number of datasets required to run a model and 
focusing on data that are available in routine clinical practice means that less data needs to be 
simulated or obtained from population values. Sophisticated optimisation methods, similar to those 
described, and beyond the scope of this thesis, are used to tune the parameter values of the models 
to match measured flow distribution, pressures and measures of cardiac function. These inputs may 
derive from patient-specific data, population data, data from other models or assumptions [160] and 
provide information for quantities such as cardiac output and microcirculatory resistance [151].  
 
As an example of successful personalisation of a simple systems model, quantified personalised 
assessment of cardiovascular function has been made from the combination of limited clinical data 
with a cardiovascular model [161]. This small experiment, using only data that can be routinely 
acquired in clinical care, successfully identified patients with left ventricular systolic dysfunction in a 
group of seven patients undergoing coronary artery bypass grafting. The model limitations included 
the availability of clinical data, different pre- and post-operative sampling times and natural variation 
in the patient’s physiological state. More in-depth knowledge of a patient’s haemodynamic state 
given by the combination of clinical and modelling data may add value. 
 
1.11.7. Model validation 
 
Most studies utilising models combining clinical data have been validated in porcine experiments 
and clinical applications are limited without patient data based validation[161]. Validating 
computational models in clinical practice is challenging but is vital to clinical acceptance [141], [143], 




[162], [163]. A logical approach might be to replicate directly measured data, then to develop 
representative model parameters by training on a subset of data. This could then be used to 
accurately predict measurements from data not included in the fitting process [163]. A number of 
theoretical experiments, particularly in AS, address only the first step [61]. Some experiments claim 
that a model has been validated by clinical data, but models compared against limited data provide a 
plausible representation of the system under study only. Most models ignore age as a predictor of 
disease and therefore cannot be valid in all cases [164]. Models will eventually need to account for 
biological variations associated with inter-subject differences in experimental data.  
 
A model based upon the combination of the time-varying elastance representation of the left 
ventricle with a four-element Windkessel model has been used and validated in human and animal 
studies [165]. However, this model assumes that the aortic valve is normal, and is not applied in 
patients with AS. Some models include the effect of AS [166], [167], in which AS was represented by 
the increase in valve resistance (as the ratio of the instantaneous pressure to the trans-valvular flow 
rate).  
 
There has been an attempt at validating a coupled lumped-parameter model in the presence of AS 
using clinical data[168]. This was a small cohort study of only six patients. The ventricular-valvular-
vascular (V3) model consists of the time-varying elastance model of the LV combined with the 
instantaneous trans-valvular pressure-flow relationship for the aortic valve and a Windkessel 
representation of the vascular system. In this study the mathematical description of AS was 
incorporated into the V3 model without patient specific imaging data. Despite this, there was very 
good agreement between the estimated and the measured left ventricular and aortic pressure 
waveforms. The total relative error reported between estimated and measured pressures was 7.5% 
(SD 2.3). The authors claim that their model explicitly and accurately describes the behaviour of LV if 
nine cardiovascular parameters are known. There are several limitations of this study, not least the 




sample size. The aortic valve area was calculated and therefore not as accurate as measuring this 
directly from the patients. Also, data were obtained invasively at the time of intervention. If 
modelling is to be used to help guide decision making processes, then modelling needs to take place 
early in the patient journey and the invasive measurements described are not practicable. 
 
1.11.8. Pressure-volume Loops 
 
The outputs of computational models can be used to produce pressure-volume (PV) loops, from 
which a number of diagnostic parameters can be derived. An important challenge though, as 
described above, is how to personalise the model to represent an individual using the available 
clinical data. 
 
The use of pressure volume (PV) loops to assess cardiac haemodynamics was first described in 1895 
by Otto Frank [146], in which relationships between pressure and volumes were used to assess 
cardiac function. Ejection fraction is often used to classify ventricular function, but this single 
measure is a summary of many complex interactions including individual components such as LV 
volume, contractility and VA coupling. Parameters such as ejection fraction can be extracted from 
the PV loop, but other clinically important information including quantification of ventricular 
contractility, compliance and work can be assessed[169]–[173]. These parameters are inaccessible 
by other methods. The relative importance of each of these parameters in determining prognosis is 
currently unknown in the aortic stenotic population. Although considered to be the gold standard by 
many [171], the use of PV loops is not standard in clinical practice, for a number of reasons. 
Obtaining simultaneous recordings of pressure and volumes typically involves invasive techniques 
using conductance catheters [174]–[176]. This requires significant resources, exposes patients to 
potential risk and clinicians may not be familiar with the resultant parameters, which makes 
interpretation difficult. The use of invasive PV loops in AS poses an additional problem in that there 




are increased risks of crossing the diseased valve with a catheter [55]. However, there is growing 
interest in producing PV loops using non-invasive clinical data and physiological modelling concepts 
to create reliable and safe diagnostic tools which would overcome some of these issues. 
  
PV loops are produced by plotting the left ventricular pressure (Y axis) against left ventricular volume 
(X axis) over a cardiac cycle. As well as the standard measures such as stroke volume and ejection 
fraction, many other haemodynamic parameters may be derived that inform us about patients’ 
haemodynamics and are not routinely available in clinical practice; these are illustrated in Figure 
1.18. 
 
Measures such as ELVmax which represents contractility, and ELVmin which represents the 
compliance of the myocardial tissue, are derived from the gradients of the ESPVR and EDPVR 
respectively; stroke work and arterial elastance have all been shown to be useful diagnostic and 
prognostic markers in a number of studies[1], [7]–[12]. Therefore, a reliable and safe method of 
producing pressure volume loops would be desirable for the evaluation of the haemodynamics of 
these patients and could have diagnostic and prognostic implications. 
  





Figure 1.18 A schematic diagram of an idealised pressure volume loop. Point A is defined by the 
LVEDV and LVEDP, Point B is the start of ejection when the aortic valve opens, Point C is the end of 
ejection and systole when the aortic valve closes, Point D is the start of LV filling when the mitral 
valve opens. X is the maximum LV pressure. 
 
1.12.  Summary 
 
AS is common and associated with significant morbidity, mortality and healthcare costs. The valve 
haemodynamics are complex and current diagnostic imaging is suboptimal and does not fully 
represent the system physiology. Current guidelines are based upon limited population-based data 
much of which is historic, management decisions based on these are not particularly tailored to the 
individual. Timing of intervention in AS is key, as is the type of intervention which will affect the 
haemodynamics and therefore the outcome of these patients and there is an obvious need for 
better ‘biomarkers’ to inform decision making. Computational modelling could offer solutions to 
X 




some of the problems in current practice but its use in AS, thus far, has been limited, primarily due 
to the data available and the difficulty in personalising the physiology in these models. Pressure-
volume loops are the gold standard in assessing cardiac haemodynamics; if computational modelling 
could be used to produce non-invasive pressure-volume loops this could be a useful clinical tool for 
decision making. Studies have shown that modelling has promise in the healthcare setting and its 
ability to run simulations and be predictive could help identify the likely outcomes for patients. Use 
of other techniques that can model flow through the diseased aortic valve, such as 4D flow MRI 
assessment, have not been fully explored and there may be a possibility of exploiting this alone or in 
combination with a modelling process. 
 
Objectively measuring the effect of the disease and outcome of intervention is rarely done routinely 
in clinical practice. Most research to date has used tests such as the exercise tolerance test or six-
minute walk test to assess this. Pervasive wearable monitors may provide more information about 
the patient’s functional status and how the disease is impacting on a patient’s life. There is an 
obvious need to identify new markers of disease severity that may help guide clinicians in the 
decision-making process. 
 
Risk scores such as STS and EuroScore are frequently calculated when considering an intervention 
but it is the role of the clinician to weigh up both risks and benefits for that individual. It is 
sometimes unclear what the benefit to a specific patient may be. Questions frequently asked by the 
patient include the following. Will I be able to do more after the operation? Will my symptoms get 
better? Will my heart recover? What operation should I have? When should I have the operation? 
And will I live longer? In the future computational modelling may be able to help to answer at least 
some of these questions. 
 




1.13.  Hypothesis 
 
Computational modelling can aid in the diagnosis and management of AS by producing non-invasive 
pressure volume loops to study LV haemodynamics. Resultant parameters will be better associated 
with the patient’s symptoms and outcome following intervention. 
 
1.14.  Aims 
 
The aims of the current thesis are to answer the following questions: 
1. Can a simple, personalised, mathematical model of a patient with AS ‘measure’ cardiac work 
and power parameters that provide an effective characterisation of the demand on the 
heart in both rest and exercise conditions and predict the changes of these parameters 
following a prospective intervention? 
2. Can 4D flow MRI data provide novel diagnostic methods of AS and add to the 
haemodynamic assessment, negating the need for computational modelling? 
3. Does computational modelling have an advantage over and above current clinical 
assessment of AS? 
4. Do pervasive wearable monitors give a better insight into how AS affects a patient’s activity 
and how this changes following intervention? 
5. Can a decision support tool be created, using data generated in this study, that can be 













The study reported in this thesis was part of the larger multicentre EurValve project for which data 
was also collected from the German Heart Centre, Berlin and Catharina Hospital. The primary focus 
of this thesis, and of this chapter, is on the analysis of the Sheffield cohort of 22 aortic cases but, 
where relevant, reference is made to the wider study. 
 
2.1. Clinical Study Design and Management 
 
2.1.1.  Overview 
 
This section describes a prospective cohort study carried out at Sheffield Teaching Hospitals NHS 
Foundation Trust. This is a proof-of-concept study, with the resultant pilot data used to address the 
aims stated above. Although there is overlap with the multi-centre EurValve study, a number of 
extensions in terms of both data collection and in methods of analysis were specific to this work. 
 
Patients were recruited who had standard indications for aortic valve replacement according to 
ESC/EACTS guidelines[29], [31]. Relevant clinical, imaging, activity monitoring, six-minute walk test, 
and patient reported outcome measures were recorded. These data were collected prior to 
intervention, at discharge, and 3-4 months after intervention (early follow-up). After the initial 
follow-up phase, the results and patient feedback suggested that 3-4 months was not adequate to 
allow patients to recover fully, particularly after SAVR. Therefore, patients were invited to undergo 
activity monitoring for a further period at 12-18 months (extended follow-up) and report their 
longer-term outcome.  
 




2.1.2.  Ethics 
 
The study received a favourable opinion from the Health Research Authority and the Research Ethics 
Committee (17/LO/0283) and was permitted by Sheffield Teaching Hospitals NHS FT research and 
development board. 
 
2.1.3.  Inclusion and Exclusion Criteria 
Inclusion Criteria: 
• Informed consent obtained 
• Elective cases 
• Severe aortic valve disease 
• Patients may have concurrent coronary artery bypass grafting or other interventions such as 
surgery of the aorta and tricuspid valves. 
Exclusion Criteria 
• Age < 18 years  
• Inability or unwillingness to give formal consent 
• Emergency interventions 
• Active infective valvular disease or evidence of valvular damage by recent endocarditis 
• Valvular malfunction directly associated with aortic root disease 
• Moderate or severe mitral valve disease 
• Aortic regurgitation as the leading aortic valve pathology 
• Inability or unwillingness to complete follow up 
• MRI contraindications such as implanted pacemaker, metallic foreign bodies or implants or 
severe claustrophobia 
• CT contraindications such as iodine or contrast agent allergy, hyperhidrosis or pregnancy 
 




2.1.4.  Clinical Study Protocol 
 
The clinical study protocol included the recording of a comprehensive range of clinical parameters. 
Since the emphasis of the study was on physiological characterisation of the patient, special 
attention was paid to directly relevant data including pressures, flows and volumes, and measures of 
physical activity. Although not standard practice, most patients in the current cohort (20 out of 22) 
underwent cMR imaging because this is particularly valuable for physiological assessment, and one 
of the aims of the study was to evaluate whether cMR can offer any additional benefit in assessment 
of these patients compared with more standard techniques. A fundamental tenet of this study was 
that, in order to minimise obstacles to clinical uptake, it should exploit maximally the data that is 
captured in the routine clinical pathways, and this is reflected in the modelling protocols described 
in section 2.4.3. Due to variations in clinical practice it was expected that not all data will be 
available for all patients; this reflects reality. 
 
Patients underwent three initial phases of assessment: pre-intervention, discharge and post- 
intervention. The pre-intervention assessment, which could occur at any point from the time the 
patient was accepted for intervention to their procedure, typically occurred within 18 weeks. This 
consisted of 3D cardiac imaging. Resting blood pressure and heart rate were recorded at the time of 
imaging. Patients’ activity levels were recorded using wearable devices (see section 2.5) for at least 
14 consecutive days and as a secondary measure, the clinically validated six-minute walk test was 
performed. Quality of life was also measured using questionnaires. 
 
Following intervention, the same data were recorded 12-16 weeks after the intervention, when it is 
expected that most people would have recovered following their procedure. Although AHA 
guidelines suggest a recovery period of 4-8 weeks[177], local experience was that the recovery 




period is often much longer, so an initial follow- up period of 3-4 months was chosen. This is also 
consistent with the literature[119]. The flow through the study is illustrated in figure 2.1. 
 
Figure 2.1 Flow of patients through the study 
 
2.1.5.  Data management 
 
An extensive list of parameters relevant to valvular disease was developed by the author, a team of 
cardiologists and cardiothoracic surgeons and engineers from the EurValve project[178]. This list was 
extended further for the current study. Data were uploaded to a repository using a custom software 
environment (ArQ) developed by the Scientific Computing Department at Sheffield Teaching 
Hospitals NHS Foundation Trust, which also maintained the secure storage of all project data. In 
accordance with ethical approval, all data transmitted to ArQ was pseudonymised.  






Figure 2.2 Illustration of data stored in ArQ the EurValve database that was adapted to store data 
collected in Sheffield only, resulting in a repository for the data reported in this thesis. 
 
 
2.1.6.  Patient recruitment 
 
Recruitment commenced in August 2017. Patients were identified at the time of referral for 
intervention, to optimise the chances of recruitment and successful data collection. A shared 
spreadsheet listing potential patients for the study was created and populated by the cardiothoracic 
secretaries at the Northern General Hospital and this list was screened for suitability. When 
potential recruits were identified, they were approached either at the time of their initial outpatient 
consultation, at the pre assessment clinic or at their pre-intervention educational session. The 








2.1.7.  Clinical data  
 






Category Description Measured by Type 
Demographic Age 
 
Years Used together with 
derived parameters 
(BMI, BSA) for patient 
categorisation in analysis 
of study results and 
prediction of six-minute 
walk test distance 
Weight Scales Weight in Kg 






Grade I-IV Comparator to objective 
activity data, assessment 
of outcome and 














the house. Room 
transfers 
Input to the modelling 
process to model rest 
and exercise (HR, step 
count and six-minute 
walk test distance). 
Measure impact of 










quality of life 
Comparator to objective 
activity data, assessment 
of outcome and 










parameters in the 
mathematical model to 








LV end diastolic 
pressure 
Important determinant 
of diastolic function, 
used to personalise 
mathematical model 
(ELVmin). 
Cardiac catheter Continuous time 
series 
To construct measured 
Pressure-Volume loops 
and, depending on 
model analysis protocol, 




to personalise inputs or 






LV end diastolic 
and end systolic 
volumes 
Key parameters in model 
personalisation used in 
protocols 1,2 and 4. 
Continuous time 
series 
To construct measured 
Pressure-Volume loops 
and, depending on 
model analysis protocol, 
to personalise inputs 















time in systole and 
diastole. 
Contribute to description 
of the contractile 
characteristics of the 
heart chambers and to 
determination of the 
timing of events in the 





Echocardiography Calculate pressure 
gradient and valve 
resistance 
Input to the modelling 
process (protocols 1-3) 
and validation of 




CMR Velocities and 
flow through the 
aortic valve and LV 
blood pool kinetic 
energy 
Investigate new methods 
of assessment of AS 
severity and gain insight 
to haemodynamics. 
Anatomical Geometry 




Cardiac CT, TOE Images of the 
valve maximally 
open 
Input to an image-based 
modelling protocol 
(Protocol 4) 
Table 2.1 Table of concepts indicating the data collected in the study, method used and rationale 
behind this. 
 
The following sections present more detail on each of the concepts shown in table 2.1, providing 








2.1.7.1.  Basic demographics 
 
Factors that may influence the outcome of the patient and computational modelling process such as 
age, height and weight were recorded at the pre-assessment clinic prior to intervention. BMI and 
BSA were computed using standard calculations. 
 
2.1.7.2.  Symptoms  
   
Patient symptoms were determined either through direct consultation with the patient or from 
clinical records and were recorded using the standard New York Heart Association 
classification[179]; specific symptoms (syncope and angina) related to AS were also recorded. GP 
records, hospital records and direct patient consultation were used as sources for past medical 
history and a list of current medications were recorded.  
 
2.1.8.  Physical examination and blood pressure assessment 
 
A physical examination was carried out as part of routine care. The findings were available through 
the clinical record but were not specifically used in the study. Blood pressure assessment at the time 
of imaging was needed for the modelling process. Immediately prior to LV volumetric assessment, 
an average of three brachial artery pressures was taken using a GE Carescape V100 dinamap (GE 
Healthcare, Boston, USA). 
 
2.1.9.  ECG 
 
Standard 12 lead ECGs[180] were recorded prior to intervention during the patient’s clinical 
consultation and following intervention prior to discharge. Heart rate, rhythm and QRS duration 
were recorded. 




2.2.  Imaging 
2.2.1.  Cardiac ultrasound 
2.2.1.1.  Transthoracic echocardiogram 
 
2D echocardiograms were performed according to the British Society of Echocardiography guidelines 
for TTE examination [23]. Grading of AS was performed according to ESC guidelines using mean and 
peak gradients and EOA calculated by the continuity equation[24]. 
 
Echocardiograms were performed either by the author, an experienced cardiology trainee with 
experience in 3D echocardiography, or a BSE accredited cardiac physiologist (Mr Paul Edwards). 2D 
echocardiograms were performed using either the Philips Epiq 7 (Philips Healthcare, The 
Netherlands) or GE i95 or vivid 7 machines (GE Healthcare, Boston, USA). 
 
Where possible, studies were supplemented with additional 3D acquisitions of the proximal aorta, 
valve and left ventricle that could be used in the segmentation required for the processing of 
protocol 4 (see section 2.4.2.1). These were acquired using the Philips Epiq 7 machine and post-
processed in QLab 10 (Philips Healthcare, Best, The Netherlands). Left ventricular end diastolic 
volume and left ventricular end systolic volume and end diastolic volumes were also needed to 
populate the 0D-model in protocols 2-4. 
 
Timings of the cardiac cycle which were necessary for the mathematical protocol were recorded; 
they also enabled improved personalisation of the elastance model. These timings included LV 
contraction time, LV ejection time (ET), isovolaemic contraction time (ICT), isovolaemic relaxation 




































Figure 2.3 Timings of the cardiac cycle obtained by echocardiography, methods of data acquisition, 
and how they were calculated shown. The left panel shows typical mitral valve inflow and LV outflow 




Timing information was obtained from echocardiography due to the better temporal resolution with 
this modality compared to CT and MR. If patients had atrial fibrillation, measurements were 
averaged over 5 cardiac cycles, as is standard practice. 
 
3D images of the valve and LV were obtained from the PSAX and PLAX view respectively. All images 
were post processed using Philips QLAb 10 software (Philips Healthcare, The Netherlands). Time 
series volume data were required for modelling protocol 3. These data were obtained in case there 
were issues with CT or TOE acquisitions so those cases could still be processed. It was not possible to 




acquire adequate images of the valve for segmentation using MRI due to flow artefacts from the 
high velocity jets caused by the stenosis. 
 
 
Figure 2.4 Images from a 3D full volume TTE study performed on a subject unable to undergo cardiac 
MRI for LV volume analysis and time series data.  
 
2.2.1.2.  Transoesophageal  
 
These scans were performed using Philips IE33 machines in all patients that underwent SAVR in 
cardiac theatres when the patient was anaesthetised for surgery. 2D echocardiograms were 
performed to the standards specified by the British society of echocardiography[181]. Due to the 
improved spatial resolution 3D images of the valve and proximal aorta were acquired and used in 
preference to the TTE images for the model protocols in which 3D images were required and CT data 
were not available. Where image quality was good, this was used instead of CT and MRI imaging as 
there is better temporal resolution[167]. Some studies have shown them to be equivalent for 




volumetric assessment[168]. However, the use of TOE derived volumetric data was avoided due to 
the different (non-physiological) loading conditions under general anaesthetic. 
 
2.2.1.3.  Ultrasound data collection 
 
Data were extracted in raw DICOM format, at the highest resolution (uncompressed) to ensure 
compatibility with the segmentation process (see section 2.4.2.1). All DICOM data were uploaded to 
the trial connect platform (Telekom Healthcare Solutions, Bonn, Germany)[182].This is a 
telemedicine certified repository, which ensures de-identification of the data and made data 
available for the automatic segmentation process. 
 
2.2.2.  Cardiac magnetic resonance imaging (CMR) 
 
An MRI protocol was developed (see appendix i). CMR was performed prior to the intervention 
(within 16 weeks of the procedure) and repeated during the 3-4 month follow up period. A standard 
MRI safety questionnaire was administered before each MRI study. For the follow-up scan, the 
surgical material and prostheses used were recorded and these were checked for MRI compatibility. 
The total SAR and spatial gradient in the protocol was calculated to ensure patient safety. Scans 
were performed on a 3 Tesla Philips Healthcare Ingenia system equipped with a 28-channel coil and 
Philips dStream digital broadband MR architecture technology. The CMR protocol included baseline 
survey, cine images (vertical long axis, horizontal long axis, short‐axis contiguous left‐ventricle 
volume stack 3-chamber (left ventricular outflow tract (LVOT) views) and aortic valve views). Cine 
images were acquired during end-expiratory breath-hold with a balanced steady-state free 
precession (bSSFP), single-slice breath-hold sequence. The number of LV short-axis slices varied 
according to the size of each patient’s heart. 
 




Cine images had a spatial resolution of 2.5 × 2.5 mm2, a pixel size of 1.56× 1.56 mm2, and a slice 
thickness of 10 mm with contiguous slices for the short axis stack. Other imaging parameters were 
30 phases, echo time (TE) = 1.5 ms, repetition time (TR) = 3.05 ms, flip angle= 45°, the field of view 
(FOV) was 400 mm, and SENSE factor 2–3. All images were post-processed and analysed using offline 
research software called MASS (Version 2019 EXP, Leiden University Medical Centre, Leiden, The 
Netherlands). LV volumes and mass were measured from the short axis stack of bSSFP cine images in 
the standard way [183]. Time series volume data were generated by repeating the volumetric 
analysis in all 20 phases across the cardiac cycle.  
 
2.2.3.  MRI 4D flow assessment of AS 
 
To address the aims of the study the current diagnostic methods that are available in clinical practice 
were initially examined. 4D flow MRI may give insights into the valve haemodynamics and the effect 
on the ventricle. An exploration of what additional information could be gleaned from MRI with 4D 
flow analysis was undertaken before employing computational modelling. The following three 
sections describe the methods relating to 4D flow studies and analysis. 
 
2.2.3.1.  4D Flow Acquisition 
 
Initial VENC (velocity encoding) setting was estimated from TTE peak velocity and tested using a 
through-plane two-dimensional phase contrast acquisition. Further increments were added until 
aliasing disappeared across the aortic valve. Field-of-view was planned to cover the whole heart, 
aortic valve and ascending aorta. The 4D flow sequence used echo-planar imaging acceleration 
factor of 5 with no respiratory gating. This sequence has been validated by previous studies for 
valvular flow quantification in humans [170]. Other standard scan parameters were acquired voxel 
size = 3x3x3mm, reconstructed voxel size = 1.5x1.5x1.5mm, echo time (TE) = 3.5 ms, repetition time 




(TR) = 10 ms, flip angle 10°, the FOV 340x340 and 30 cardiac phases. Data pre-processing was done 
on the scanner for correcting phase offset errors such as eddy currents, Maxwell effects, and 
encoding errors related to gradient field distortions to avoid impairment of the measurements and 
inaccuracies in flow quantification [184], [185]. 
 
2.2.3.2.  4D flow pressure gradient assessment 
 
All three phase directions were screened for aliasing artefact, and if present this was manually 
corrected using established phase unwrapping methods [186], [187]. Any spatial misalignment with 
cine superimposition was manually corrected throughout the cardiac cycle prior to any 
quantification. The precise location of the maximum velocity (Vmax) in the aorta during systole was 
identified in the 4D flow data set and the velocity recorded in a similar method to Donati et al [38]. 
The maximum velocity determined in the 3D velocity data was used to determine the peak pressure 
drop by the simplified Bernoulli equation = 4(Vmax)2. 
 
2.2.3.3.  4D flow effective orifice area assessment 
 
For EOA estimation, Bernoulli principles and the law of conservation of flow at the level of vena 
contracta across all systolic phases where the valve is maximally open, were applied. Time resolved 
flow and velocity data were recorded and as flow = area * velocity, EOA was estimated using the 
following equation:  
EOA = Flowt / Vmaxt 
 where Flowt and Vmaxt are the flows and peak velocity measurements through the aortic valve at 
each of the recorded systolic phases (see figure 2.5). 
 




Acceleration of the blood through the valve in early systole and the deceleration of blood prior to 
valve closure was recorded. An estimate of EOA was acquired using a line of best fit for the linear 
relationship of flow and the velocity at the vena contracta and calculating the gradient of that line. 
Velocities at different flow rates throughout the systolic phases were recorded and used to reduce 
noise from the data, which may be higher if the EOA was calculated from one data point. Figure 2.5 
shows how the maximum velocity was identified and the EOA was calculated.  
 
 
Figure 2.5 Illustrates how the maximum velocity was identified and the EOA calculated from the flow 
and velocity measured during 4D flow CMR acquisition. 
 
 
2.2.3.4.  Left ventricular blood flow kinetic energy assessment 
 




× 𝜌 × 𝑉𝑣𝑜𝑥𝑒𝑙𝑣𝑣𝑜𝑥𝑒𝑙                                                                                    Eq. 2.1 
 
Where the ρ = density of blood (1.06 g/cm3), Vvoxel = voxel volume, and vvoxel the velocity magnitude. 
The total LV kinetic energy was then computed in each time step as the summation of the KE of all 
voxels in the left ventricle and plotted by the software as a time-resolved kinetic energy curve from 




which different KE parameters were derived. All KE parameters were normalized to LV EDV and 
reported in μJ/mL (LV KEiEDV). 
 
 
Figure 2.6 Case example of LV blood flow kinetic energy assessment. The top panel demonstrates LV 
blood flow KE assessment. Even though the pattern was different for systolic and diastolic KE curves 
after intervention, the average quantified values for kinetic energy are not significantly different. The 
second panel demonstrates a three-chamber image with superimposed particle tracing component 
analysis of the four LV blood flow components: retained inflow (yellow), residual volume (red), direct 
flow (green), and delayed ejection flow (blue). It is worth noting that the drop in direct and delayed 
flows was mainly observed in diastole. 
 
2.2.3.5.  LV blood Flow Component Analysis 
 
A previously validated technique which enables the separation of the left ventricular end-diastolic 
flow into four different functional components was employed [48]. LV short-axis cine stack, long-axis 
cine, and 4D flow images views were used for the analysis. The short-axis cine series was used to 
define the intraventricular blood particles. LV endocardial contours were manually traced in the end-
systolic (ES) and end-diastolic (ED) phases. The most basal short-axis slice in end systole was used as 




the inflow/outflow plane and particles were considered as invalid when they were below the 
inflow/outflow plane and outside the LV epicardial contours in ES phase.  
 
The end-diastolic blood flow was separated into four functional flow components, according to the 
transit of blood flow through the left ventricular chamber for the complete cardiac cycle: (1) direct 
flow is the volume of blood that enters the LV and is ejected during the same cardiac cycle, (2) 
delayed ejection flow is the volume of the ejected blood that enters the left ventricle from a 
previous cardiac cycle, (3) retained inflow is the volume of blood that enters the left ventricle but 
does not eject in the same cardiac cycle, and (4) the residual volume is the blood that resides in the 
LV over the entire cardiac cycle for at least 2 cardiac cycles. The results of particle tracing were 
reviewed visually, and data quality was checked as previously described[48]. After the quality was 
assessed, the KE of the volume of each flow component was calculated over a complete cardiac 
cycle. 
 
2.2.3.6.  Cardiac computed tomography 
 
Patients for whom the heart team considered TAVI underwent cardiac CT. This provided yet another 
method to obtain LV volume data across the cardiac cycle and for a 3D valve geometry. The superior 
spatial resolution compared with ultrasound and MRI may result in a greater accuracy in defining the 
anatomical shape of the valve, improving the precision of the 3D modelling. Images were acquired 
on an Aquilion ONE™, GENESIS Edition CT scanner (Canon medical systems Ltd, Crawley, UK) 
according to the local TAVI protocol developed by STH. For study patients, this protocol was adapted 
to ensure the mid systolic phase, where the valve is maximally open, was included enabling 
segmentation for the 3D model. Whenever possible, a prospectively gated scan was performed to 
minimise radiation exposure to the patient, scanning for 20-80% of the cardiac cycle. Data were 
saved to the hospital server in 10% intervals of the cardiac cycle. Scans were reported as part of 




routine clinical care; raw DICOM data were extracted and uploaded to the trial connect platform to 
enable the segmentation process. 
 
2.3. Intervention Data 
 
The type of intervention (TAVI or SAVR) and the technique used in each procedure were recorded. 
The make, and size, of the prosthesis implanted were also recorded. For the modelling process the 
effective orifice of the replaced valve was also required. Since this varies depending upon the size of 
the patient and the aorta, the manufacturer’s stated EOA was indexed for the individual’s body 
surface area (see appendix iv). 
 
2.4. Computational Modelling methods 
 
This section describes a series of four protocols for the computation of pressure, volume and flow in 
the compartments of the left heart and systemic circulation from which LV pressure-volume loops 
and other measures were derived. The purpose of the multiple protocols is to support analysis for 
multiple levels of available clinical data and computational resource. The results for each protocol 
are discussed and compared in section 3.7. 
 
2.4.1.  Lumped parameter model of left side of heart and systemic circulation 
 
The lumped parameter 0D model (see section 1.11.4) illustrated in figure 2.7 was used to represent 
the circulation. This was based upon the validated lumped-parameter cardiovascular model with 
Westkessel after-load [147] and is similar to the model used by Garcia et al[168] where AS was 
modelled as an increase in AV resistance. This model was used as the basis for protocols 2, 3 and 4, 
the differences being in which data were used to personalise the model (see section 2.4.1) and how 




the valve resistances were computed or measured. For protocol 2, the valve resistance was 




















Figure 2.7 Lumped parameter model of the left side of the heart and systemic circulation. 
 
This model simulates the flow of blood through the left heart and systemic circulation and describes 
the temporal distribution of pressure, flow and volume in its four compartments. The model is based 








P1 pressure within ventricle 
Q1 flow through aortic valve  







P4 pressure within atrium 
Q5 flow through mitral valve  
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Electrical  Fluid dynamics  
Voltage, V (volts) 
 
Pressure, P (mmHg) 
Current, I (amps) Flow rate, Q (ml/s) 
 
Resistance, R (Ω) R (mmHg . s /ml) 
Charge, Q) (Coulomb) 
 
Volume, V (ml) 
 
Capacitance, C (Faraday)  Compliance, C (ml mmHg) 
 
Table 2.2 Analogous electrical and fluid dynamic metrics. 
 
The inputs to the model are the parameters that describe the contractility and compliance of the left 
ventricle and left atrium, the resistive and capacitive properties of the systemic circulation, the 
pressure/flow characteristics of the aortic and mitral valves, the mean circulatory filling pressure 
(correlating with total blood volume) and the heart rate. Direct outputs are the pressure, flow and 
volume in each of the four compartments at every instant in time. Derived outputs including 
extrema data (for example systolic and diastolic pressure, LVEDV and LVEDV and peak left 
ventricular power) and integral data (for example cardiac output and cardiac work) are computed 
from the direct outputs. Based upon the principles of mechanics a series of twelve equations were 
derived, one for each valve, two for each chamber and six for the systemic circulation, supporting 
the computation of the twelve fundamental variables. The following sections outline the principles 
underpinning the model and illustrate the derivation of some of the equations. 
 




There is one equation for each of the valves, describing the relationship between pressure gradient 
and flow. The purpose of the valves is to prevent backwards flow when they are closed, and so the 
equations for forward flow are different to backward flow. For clinical purpose it is often assumed 
that the pressure gradient is proportional to the square of the flow (see section 1.3.2). The same 
assumption is made for protocol 2, so for each valve there is a single input variable of this constant 




of proportionality. For this study it is assumed that there is no regurgitation, and so the flow is, in 
principle, set to zero when the flow reverses (in fact for numerical reasons associated with the 
stability of the solver the gradient/flow curve is smoothed close to the point of zero pressure 
gradient but this has no significant effect on results).  
 
2.4.1.1.2. Systemic circulation 
 
As illustrated in figure 2.7, the systemic circulation is composed of two capacitors and a resistor. 
Based on the principles of Ohm’s law as discussed in section 1.11.4, for a resistor, Pressure(P)= 
Flow (Q) x Resistance (R). Continuity dictates that the flow in the systemic resistor is Q1 − Q2 and so: 
p2 −  p3 =  R(Q1 − Q2)                                                          Eq. 2.2   
The rate of change of charge on a capacitor is the flow of charge onto it and so, for the proximal and 
distal systemic capacitors in the current model: 
𝑑𝑉2
𝑑𝑡
= Q2                                                                                  Eq. 2.3 
𝑑𝑉3
𝑑𝑡
= Q3                                                                                    Eq. 2.4 
The equation for a capacitor dictates that charge is proportional to voltage (Capacitance= Charge 
/Voltage); therefore, flow is proportional to rate of change of pressure. 
Q2 =  C2  
𝑑p2
𝑑𝑡
                                                                          Eq. 2.5 
Q3 =  C3  
𝑑p3
𝑑𝑡
                                                                          Eq. 2.6 
Finally, for continuity: 
Q1 − Q2 − Q3 = Q4                                                              Eq. 2.7 









2.4.1.1.3. Heart chambers 
 
The cardiac chambers are described by time-varying elastance models. In these models it is assumed 
that the elastance, defined as the chamber pressure divided by the chamber volume (or the inverse 
of compliance), is a known function of time. For the left ventricle: 
𝑝𝐿𝑉(𝑡) − 𝑝𝐿𝑉,0 = E𝐿𝑉(𝑡) ∙ (V𝐿𝑉(𝑡) − V𝐿𝑉,0)                                                       Eq. 2.8 
 
Usually the pressure offset, pLV,0, is assumed to be zero. The volume offset, VLV,0, is representative 
of the volume that the ventricle would have if the pressure were to reduce to zero. It might be 
estimated from the point of intercept of a line through the end systolic and end diastolic points on 
the PV loop with the volume axis (see figure 2.9, point Vi,P0). In the current study it was taken to be 
5 ml for all subjects[132]. 
 
First described by Suga and Sagawa[176], the time-varying elastance model represents the heart 
chambers as elastic structures with a stiffness that varies over the cardiac cycle to represent 
contraction and relaxation. The prescribed instantaneous relationship between pressure and volume 
is pre- and afterload independent. The subject-specific shape and amplitude of the curve provides a 
measure of the contractility and compliance of an individual’s heart. Typically, the maximum (active 
contractility) and minimum (passive compliance) values of elastance are assumed to be available 
from clinical measurements, and the exact shape of the curve over time in between these extremes 
depends on the mathematical function that is chosen to describe it. In the current study, two 
formulations were examined. The first was a Shi double cosine model [124], characterised by two 
half cosines, one for the rise phase and one for the relaxation phase, with subject-specific timing 
points. The second was a double Hill equation [164], [177], [188] in which four constants describe 
the rise and fall phases, again between maximum and minimal elastance values. Mynard [178] and 
Seeman [164] have each proposed values for the constants to reflect average LV mechanics, but they 




can be personalised to provide characteristic measures for each individual. Figure 2.8 illustrates the 
form of the elastance curve with Mynard’s constants. If it is assumed that the contraction starts at 
time zero and that the pressure offset is zero, the variable elastance model with the Shi function has 
five parameters (volume offset, maximum and minimum elastance and two, timing parameters) and 
the double Hill models have seven.  
 
There are two equations for each chamber; the elastance equation and a continuity equation that 
equates the net flow to the change of volume. 
 
Figure 2.8 Two Hill functions (H1 and H2, grey lines) are used to construct an input elastance curve 
(black line), where  determines the time shift and m controls the slope of each Hill function. 
Reproduced with permission from Mynard et al[189]. 
 
The choice of elastance model and its effect upon the elastance profile and on the results of the 









2.4.1.2.  Model Outputs 
 
The personalised model in protocols 2-4 produces the following outputs: 
 
Output Parameters Produce 
Pressure distribution p1 , p2 , p3 , p4 Pressure as a function of time 
Flow distribution Q1 , Q2 , Q3 , Q4 Flow as a function of time 
Left Ventricular Volume V1 LV Volume as a function of time 
Left Atrial Volume V3 Atrial volume as a function of time 
   
Pressure gradients Dpvalve , dpvent/dt Spatial and temporal gradients 
Volume parameters PV Loop Ejection fraction, End diastolic volume, 
regurgitant volumes 
Ventricular work PV Loop Work done by ventricle 
Peak ventricular power PV Loop Peak power produced by left ventricle  
Wasted ventricular energy PV Loop Wasted potential energy crossing the 
stenosed valve. (Bottom left triangle of 
graph) 
 
Table 2.3 Illustrating model outputs. Parameters in bold were used to tune the model in the 
optimisation process. 
 
This enables plots of pressure, flow and volume over the cardiac cycle in the left atrium, left 
ventricle. The left ventricular pressure and volume data produced were the main focus in this thesis 
to assess cardiac function. Values for P1 (LV pressure) and Q2 (flow through the aortic valve) were 
obtained (see figure 2.7) over a complete cardiac cycle, thus producing PV loops for the LV ventricle. 
The PV loop gives a wealth of information about the heart, including the end-systolic pressure-
volume relation (ESPVR) and end-diastolic pressure-volume relation (EDPVR), from which the 
gradients of these lines give an estimate of the contractility in and compliance of the left ventricle. 
The area under the PV curve represents work, and the maximal rate of change of work per second 
represents the peak power exerted by the left ventricle. These parameters were correlated with 
symptoms and outcome. 
 




Protocol 1 uses measured time-series volume data and LV pressure data derived from mathematical 
formulae (see appendix iii). PV loops were produced in Microsoft Excel and stroke work, stroke 
power, peak LV power, total myocardial work and wasted energy were calculated. Figure 2.9 
illustrates a typical PV with 5 points of the loop (V1,P1 -V5P5) identified to help illustrate how these 












2.4.1.2.1. Left ventricular elastance measures 
 
Maximum left ventricular elastance (ELVmax) 
ELVMax: is a measure of systolic contractility and is measured at the point on pressure-volume loop 
where the ratio of pressure and volume is the highest, upper left of the PV loop. This is similar to the 
gradient of the end systolic pressure volume relationship measured at the time of aortic valve 
closure. As shown in figure 2.9 it may be approximated by either P3/V3 or (P3/(ESV-Vi). 
 
Minimum left ventricular elastance (ELVmin) 
ELVMin: is measured at the point on pressure-volume loop during passive filling where the ratio of 
pressure and volume is the lowest (the greatest increase in volume with the least increase in 
pressure). This typically is the gradient of the end diastolic pressure volume relationship and as 
shown in figure 2.9 can be approximated by either P4/V4, P5/V5 or (P5/(EDV-Vi). The inverse 
1/ELVMin provides an assessment of the left ventricle’s compliance in diastole and can be used as a 
measure of diastolic function. 
 
Total myocardial work and power 
Total myocardial work is given by the pressure volume area (PVA), which is the area shaded grey. 
This is the area under the PV loop and the potential energy or wasted energy. Total myocardial 
power is the energy/work done per unit time. This was calculated using the following method: 
 
For consecutive data points on the PV loop a triangle can be formed with a point though the volume 
intercept. Figure 2.9 illustrates an example of this with a triangle defined by points Vi,P0, V1,P1 and 
V2,P2. The area of this triangle is given by the formula (V2*P1-V1*P2)/2. PVA is the sum of all the 
triangles formed by the data points, therefore:  
 
Total myocardial work = PVA= (
𝑉𝑛∗𝑃𝑛−1−𝑉𝑛−1∗𝑃𝑛
2
)                                                        Eq. 2.9 




Total myocardial power = (
𝑉𝑛∗𝑃𝑛−1−𝑉𝑛−1∗𝑃𝑛
2
) 𝑑𝑡⁄                                                         Eq. 2.10 
 
dt is given by the interval time at which the data points were acquired over the cardiac cycle. In this 
study LV volumes were measured across 20 phases. To ensure the data wraps around, 21 data points 
were plotted with the first point the same as the last giving 20 time intervals. The length of these 
intervals is determined by the heart rate. Therefore,  dt= (60/heart rate(bpm))/20. 
 
Stroke work and wasted energy 
Stroke work is the useful energy that contributes to cardiac output. This is the area under the PV 
loop which is given by the PVA minus the wasted energy defined by the triangle formed by ViP0, 
V3,P3 and V4P4 and indicated by the white dashed line in figure 2.9. 
 
Wasted energy can be calculated using the following formula: 
 
𝑊𝑎𝑠𝑡𝑒𝑑 𝑒𝑛𝑒𝑟𝑔𝑦 =  ((𝐸𝑆𝑉 − 𝑉𝑖 ∗ 𝑃3)/2 – (𝐸𝑆𝑉 − 𝑉𝑖 ∗ 𝑃4)/2)                            Eq. 2.11 
 
𝑊𝑎𝑠𝑡𝑒𝑑 𝑝𝑜𝑤𝑒𝑟 =  ((𝐸𝑆𝑉 − 𝑉𝑖 ∗ 𝑃3)/2 – (𝐸𝑆𝑉 − 𝑉𝑖 ∗ 𝑃4)/2)/𝑑𝑡                       Eq. 2.12 
 
Stroke work can be calculated using the following formula: 
𝑆𝑡𝑟𝑜𝑘𝑒 𝑤𝑜𝑟𝑘 =  𝑇𝑜𝑡𝑎𝑙 𝑚𝑦𝑜𝑐𝑎𝑟𝑑𝑖𝑎𝑙 𝑤𝑜𝑟𝑘 –  𝑊𝑎𝑠𝑡𝑒𝑑 𝑒𝑛𝑒𝑟𝑔𝑦 
 
𝑆𝑡𝑟𝑜𝑘𝑒 𝑤𝑜𝑟𝑘 =  (
𝑉𝑛∗𝑃𝑛−1−𝑉𝑛−1∗𝑃𝑛
2
) − ((𝐸𝑆𝑉 − 𝑉𝑖 ∗ 𝑃3)/2 – (𝐸𝑆𝑉 − 𝑉𝑖 ∗ 𝑃4)/2))        Eq. 2.13 
 
Peak left Ventricular power  
Is the maximum work done by the LV per unit time and given by the maximum result from: 
𝐿𝑉 𝑃𝑒𝑎𝑘 𝑝𝑜𝑤𝑒𝑟 =  ½(𝑉𝑛 ∗ 𝑃𝑛−1 − 𝑉𝑛−1 ∗ 𝑃𝑛)/2))/𝑑𝑡                                              Eq. 2. 14 





2.4.1.2.2. Parameter personalisation (model optimisation) 
 
Most analyses reported in this thesis were performed using the double Hill model for ventricular 
elastance (7 parameters) and the Shi double cosine model for atrial elastance (5 parameters). 
Together with the three systemic circulation parameters, one parameter for each valve, the mean 
circulatory pressure and the heart rate, there were 19 input parameters. The purpose of the model 
is to compute the outputs, including the LV PV loop and the cardiac energetics parameters, for each 
individual. Some of the outputs, including for example the LVEDV and LVESV, were measured in the 
clinical workflow. This offers the opportunity to tune, or personalise, some of the model inputs so 
that the outputs are matched. The selection of which parameters to tune is made based on an 
analysis of the sensitivity of the target outputs to each of the inputs (section 2.4.1.2.3). For protocol 
2 the heart rate was set based on measured values and target (measured) outputs were: left 
ventricular end systolic and end diastolic volumes, mean arterial blood pressure, diastolic blood 
pressure, estimated LVEDP (using the same method as protocol 1) and peak transvalvular gradient. 
The input parameters that were personalised were maximum and minimum LV elastance, systemic 
resistance and proximal compliance, aortic valve quadratic coefficient and mean circulatory filling 
pressure. 
 
There are many methods by which estimates of the input parameters that most closely reproduce 
observed outputs can be made. The implementation of the model for this study was performed in 
MATLAB Version R2018b, MathWorks Inc, USA, which supports several alternatives. For the work 
reported in this thesis the number of inputs that were personalised was exactly equal to the number 
of clinically observed outputs that were used for this tuning, utilising a multi-dimensional Newton 
method, with relaxation to improve stability and with analytical function derivatives. This method 
starts from an initial estimate of the parameters, for which generic values for a normal healthy 




individual were chosen and updates the estimates iteratively until the error in the solution of the 
equations is less than a threshold value. This was chosen to be much less than the error margins on 
the clinical measurements. The coding was carried out by members of the EurValve consortium, and 
its execution and analysis for the study cohort was performed by the author. 
 
2.4.1.2.3.  Sensitivity analysis 
 
There were not enough data to personalise all parameters in the model, and furthermore the 
personalisation process is more robust when focused on only the most important parameters whilst 
setting the remaining ones to mean or population levels. Sensitivity analysis ranks the input 
parameters with respect to their effect on selected output parameters. The simplest way to perform 
a sensitivity analysis is to change each input parameter, one at a time, and record the effect on each 
output. Figure 2.10 below illustrates the sensitivity of the basic model, varying around a population 
mean. The number in the matrix is the proportional change of output per change in input. It is 
computed by increasing the input by 1% and recording the change in output. An output increase of 
1% would produce a matrix value of 1, and an output decrease of 0.5% would produce a matrix value 
of -0.5. The columns associated with the target outputs are highlighted green and the matrix values 
indicating an absolute value of sensitivity of greater than 0.5 are highlighted gold. 
















































































































































































































































































































































































































































































































































































































































































































Value 6.3 145 55 90 0.62 119 6.8 10.0 1432 9027 1.40 11.5 0.0 119 80 102 93 9.7 90.0 89.9 10 2 0.1 0.05 0 0.00 0.00 0.00 0 0.00 0.00 0.00 0.065 0.398 0.498 0.977
1 Heart Rate 0.407 -0.288 0.220 -0.599 -0.311 0.205 -0.374 -0.292 0.642 -0.234 0.763 0.604 0.000 0.205 0.550 0.323 0.403 -0.270 -0.592 -0.599 0.381 0.746 0.030 0.265 -0.357 0.000 0.000 0.000 -5.248 0.000 0.000 0.000 -0.029 -0.009 -0.001 0.017
2 Elvmin -0.810 -0.757 -0.673 -0.808 -0.052 -0.742 0.310 0.208 -0.735 -1.643 -1.643 -1.516 0.000 -0.742 -0.709 -0.728 -0.723 0.050 -0.807 -0.800 -1.402 -1.530 -2.305 -0.673 28.575 0.000 0.000 0.000 2.339 0.000 0.000 0.000 0.013 0.000 0.009 -0.005
3 Elvmax 0.289 -0.097 -0.710 0.278 0.375 0.239 -0.246 -0.093 0.874 0.612 0.612 0.993 0.000 0.239 0.199 0.238 0.216 -0.056 0.285 0.279 1.281 0.634 1.651 1.032 4.119 0.000 0.000 0.000 -3.956 0.000 0.000 0.000 -1.567 -0.002 0.001 0.000
4 Systemic Arterial Resistance -0.560 -0.265 0.235 -0.571 -0.306 0.221 -0.121 -0.267 -0.330 -0.269 -0.269 -0.243 0.000 0.223 0.566 0.344 0.419 -0.312 -0.563 -0.572 -0.952 -1.015 -1.546 -1.280 -2.608 0.000 0.000 0.000 -4.053 0.000 0.000 0.000 -0.029 -0.011 -0.001 -0.001
5 Systemic Arterial Capacitance -0.295 -0.343 -0.403 -0.306 0.037 -0.455 -0.343 -0.348 -0.411 -0.643 -0.643 -0.355 0.000 -0.455 -0.083 -0.321 -0.241 -0.363 -0.299 -0.305 -0.259 -0.410 -0.527 0.117 4.347 0.000 0.000 0.000 -3.723 0.000 0.000 0.000 -0.029 -0.011 0.002 -0.001
6 Mean circulatory filling pressure 0.988 0.954 0.902 0.986 0.032 0.992 0.870 0.988 0.955 2.031 2.031 1.939 0.000 0.992 0.995 0.991 0.994 1.019 0.985 0.988 1.675 1.862 2.813 0.767 0.710 0.000 0.000 0.000 -1.312 0.000 0.000 0.000 -0.006 0.000 0.000 0.010
7 Start of left ventricular contraction (fraction of cycle) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
8 Peak of left ventricular contraction (fraction of cycle) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
9 End of left ventricular contraction (fraction of cycle) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
10 Volume offset in LV pressure equation 0.000 0.034 0.091 0.000 -0.034 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
11 Elamin -0.198 -0.182 -0.159 -0.196 -0.014 -0.176 0.008 -0.190 -0.249 -0.389 -0.389 -0.366 0.000 -0.176 -0.166 -0.172 -0.170 0.072 -0.199 -0.187 -0.344 -0.379 -0.572 -0.183 32.729 0.000 0.000 0.000 -1.377 0.000 0.000 0.000 -0.010 0.000 0.009 -0.008
12 Elamax[mmHg/ml] 0.091 0.083 0.069 0.091 0.008 0.077 -0.023 0.086 0.130 0.176 0.176 0.166 0.000 0.077 0.071 0.075 0.073 -0.082 0.092 0.091 0.161 0.177 0.268 0.091 -1.889 0.000 0.000 0.000 1.057 0.000 0.000 0.000 0.007 0.000 -0.001 0.012
13 Start of left atrial contraction [-] -0.343 -0.311 -0.260 -0.341 -0.031 -0.289 0.077 -0.322 -0.385 -0.659 -0.659 -0.620 0.000 -0.289 -0.265 -0.281 -0.275 0.310 -0.345 -0.326 -0.600 -0.660 -0.996 -0.340 51.692 0.000 0.000 0.000 -2.972 0.000 0.000 0.000 -0.022 -0.001 0.015 0.170
14 Peak of left atrial contraction [-] 0.317 0.284 0.240 0.311 0.027 0.266 -0.086 0.298 0.471 0.612 0.612 0.575 0.000 0.266 0.242 0.258 0.252 -0.301 0.321 0.310 0.561 0.617 0.934 0.320 ###### 0.000 0.000 0.000 4.161 0.000 0.000 0.000 0.028 0.001 -0.001 0.592
15 End of left atrial contraction [-] 0.192 0.187 0.152 0.209 0.022 0.168 -0.053 0.183 0.251 0.379 0.379 0.355 0.000 0.168 0.159 0.164 0.163 -0.109 0.194 0.209 0.335 0.370 0.558 0.178 50.444 0.000 0.000 0.000 1.610 0.000 0.000 0.000 0.011 0.000 -0.001 0.270
16 Volume offset in LA pressure equation [ml] 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
17 Aortic Valve quadratic coefficient -0.001 -0.001 0.001 -0.002 -0.001 0.002 -0.001 -0.001 -0.008 0.036 0.036 -0.049 0.000 0.001 0.002 -0.001 0.001 -0.001 -0.002 -0.001 0.691 0.909 0.831 0.794 -0.069 0.000 0.000 0.000 -0.775 0.000 0.000 0.000 -0.001 0.001 0.000 0.000
18 Aortic Valve linear coefficient 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
19 Aortic Valve regurgitant quadratic coefficient 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
20 Aortic Valve regurgitant linear coefficient 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
21 Aortic Valve smoothing threshold 0.000 0.000 0.000 0.000 0.000 0.001 0.001 0.000 0.019 0.000 0.000 0.001 0.000 0.000 -0.001 0.000 -0.001 0.000 0.001 0.000 0.002 0.033 0.009 0.009 -0.058 0.000 0.000 0.000 1.321 0.000 0.000 0.000 0.003 0.002 0.000 0.000
22 Aortic Valve smoothing polynomial order 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
23 Mitral Valve quadratic coefficient -0.013 -0.011 -0.009 -0.012 -0.001 -0.010 -0.127 -0.011 -0.021 -0.018 -0.018 -0.022 0.000 -0.010 -0.008 -0.009 -0.009 0.022 -0.013 -0.012 -0.023 -0.025 -0.037 -0.019 2.053 0.000 0.000 0.000 -0.226 0.000 0.000 0.000 -0.002 0.000 0.000 0.011
24 Mitral Valve linear coefficient 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
25 Mitral Valve regurgitant quadratic coefficient 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
26 Mitral Valve regurgitant linear coefficient 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
27 Mitral Valve smoothing threshold -0.001 -0.001 -0.001 -0.001 0.000 -0.001 0.000 -0.001 -0.002 -0.002 -0.002 -0.002 0.000 -0.001 -0.001 -0.001 -0.001 0.002 -0.001 0.000 -0.002 -0.002 -0.003 -0.001 2.342 0.000 0.000 0.000 -0.019 0.000 0.000 0.000 0.000 0.000 0.000 0.000
28 Mitral Valve smoothing polynomial order 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
29 Venous/Pulmonary Capacitance 0.057 0.056 0.053 0.057 0.002 0.059 0.029 0.058 0.052 0.120 0.120 0.113 0.000 0.059 0.059 0.058 0.059 0.070 0.057 0.057 0.096 0.107 0.160 0.040 -1.333 0.000 0.000 0.000 -0.172 0.000 0.000 0.000 -0.001 0.000 -0.001 0.001
30 Systemic Arterial Capacitance Unstressed Volume 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
31 Venous/Pulmonary Capacitance Unstressed Volume 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
32 n1 (Double Hill model of LV) -0.030 -0.012 0.019 -0.031 -0.019 0.001 -0.007 -0.012 -0.676 -0.073 -0.073 -0.310 0.000 0.001 -0.031 -0.030 -0.017 -0.024 -0.032 -0.031 -0.495 0.161 -0.346 -0.274 -2.308 0.000 0.000 0.000 -1.720 0.000 0.000 0.000 1.528 0.017 -0.001 0.000
33 n2 (Double Hill model of LV) 0.003 -0.003 -0.012 0.002 0.006 -0.013 -0.352 -0.004 -0.139 0.008 0.008 -0.083 0.000 -0.013 0.010 0.000 0.000 -0.035 -0.002 0.002 -0.137 -0.099 -0.189 -0.197 -2.403 0.000 0.000 0.000 -4.819 0.000 0.000 0.000 -0.027 0.090 -0.202 0.000
34 Tau1f (Double Hill model of LV) 0.000 -0.005 0.005 -0.011 -0.006 -0.013 0.000 0.002 -0.554 -0.047 -0.047 -0.349 0.000 -0.013 -0.001 -0.019 -0.006 -0.008 -0.004 -0.012 -0.533 -0.219 -0.500 -0.454 -2.205 0.000 0.000 0.000 -4.321 0.000 0.000 0.000 -0.029 0.021 -0.001 0.000
35 Tau2f (Double Hill model of LV) 0.020 -0.042 -0.128 0.010 0.053 -0.084 0.328 -0.037 -0.594 -0.043 -0.043 -0.527 0.000 -0.084 0.076 0.017 0.008 0.183 0.018 0.022 -0.848 -1.754 -1.137 -1.095 40.442 0.000 0.000 0.000 -2.721 0.000 0.000 0.000 -0.029 0.987 1.017 0.000
Figure 2.10 An example of the sensitivity matrix used in the study. The amber highlighted cells are 
parameters that the model is particularly sensitive to. The columns in green indicate the 
measurements that the model was tuned to. The top six parameters were personalised 
 
Based upon this analysis, the parameters selected for personalisation were: 
• Maximum elastance of the left ventricle 
• Minimum elastance of the left ventricle 
• Mean circulatory filling pressure 
• Systemic resistance  
• Systemic proximal compliance 
• Aortic valve coefficient (for protocol 2) 
 
Whenever possible, these values were derived directly from clinical measurements. Remaining 
inputs are set at population means or at pre-determined values based on initial exploration of the 
model results and using sophisticated optimisation methods[151]. In the EurValve project a more 
sophisticated sensitivity analysis, recognising nonlinear interactions, was performed by colleagues at 




the Technical University of Eindhoven, but in this case it confirmed the selection indicated by this 
simpler process.  
 
2.4.1.2.4. Modelling in the exercise state 
 
As discussed previously, modelling has the advantage of being predictive and simulations can be run 
to predict the effect of exercise on the patient’s physiology. By extending the model to consider 
exercise, predictions can then be made about the patient’s expected exercise capacity post 
intervention which could be used to help counsel the patient. This was achieved using data from the 
six-minute walk test and Philips Health Watch (see sections 2.4.1.2.5 and 2.4.1.2.6). A number of the 
parameters in the model change under exercise conditions. Work by Professor Hose (see appendix 
iv) allowed application of 0D models to study exercise physiology and enable extrapolation from a 
model tuned in the rest state to the exercise state This work was based on studies by Chantler[190] 
and Bombardini[191] who studied the effects of exercise on several parameters relevant to the 
model, including heart rate, left ventricular end systolic elastance, arterial elastance and systemic 
resistance. The exercise state could be modelled in protocols 2-4. 
 
2.4.1.2.5. Combining activity data  
 
Equations were derived for the parameters in the model under exercise conditions (see appendix iv). 
Using these patient specific exercise states could be modelled. This was performed using activity 
data obtained during the study. The true rest state of the patient (Metabolic equivalent (MET)=1) 
could be extrapolated backwards from the examination state using the resting heart rate from the 
Philips Health Watch (see section 2.5.3).  
 
(Heart Rate_exercise) = (0.7464∙(PWR)_exercise+1)∙(Heart Rate_rest)                      Eq. 2.15 
 




Power-to-weight ratio (PWR) was calculated from the level of activity achieved by the patient. The 
maximum elastance, arterial elastance and capacitance was then personalised. The exercise capacity 
of the patient in terms of METS was calculated from the six-minute walk test and the true rest state 
of the patient from the Philips Health Watch. This activity data was used to personalise the rest 
exercise state pre-intervention. Rest states (MET=1) were used to compare pre and post 
intervention. 
 
The predictive post-intervention exercise capacitance in terms of METs can be compared with the 
measured activity levels for the patients in the study (see section 3.9.4). 
 
2.4.1.2.6. Modelling after intervention 
 
In the predicted post-intervention data several assumptions were made. It was assumed that, when 
symptoms develop in severe AS, the heart is working at (or close to) its maximum capacity. It was 
also assumed that, following an intervention, if required, the heart could work as hard as it did 
before the intervention. The energy initially wasted in overcoming the resistance of the stenotic 
valve could then be converted to useful energy and the increase in exercise capacity could then be 
calculated. In the model, the cardiac work was therefore fixed following intervention and 
extrapolated backwards using the exercise formula (section 2.4.1.2.4 and appendix iv). Maximum 
activity levels after intervention could then be predicted. Following intervention, either through 
homeostatic mechanisms or medical therapy, there would be an effort to maintain mean arterial 
pressure and therefore organ perfusion. The coefficients of the implanted aortic valve were used; 
these were derived from the stated indexed EOA of each valve implanted (see appendix iv) and the 
valve coefficient personalised for each patient to model the post intervention state. 
 
 




2.4.2.  Three-dimensional valve model 
 
The model is highly sensitive to the input of peak pressure gradient across the valve (see section 
2.4.1.2.3.). Therefore, an accurate assessment of this parameter is critical. As discussed there are 
number of limitations in using echocardiography to assess peak pressure gradient (see sections 
1.4.2.1 and 1.11.5). A local 3D valve model using segmented medical images and CFD can accurately 
define the pressure flow relationship through the valve overcoming many of these limitations. A 3D 
valve model was therefore developed using the steps described below.  
 
2.4.2.1.  Segmentation and mesh formation 
 
Segmentation is the process of identifying and separating areas of interest from clinical images. 
Geometric representations of structures from which data can be extracted can then be 
reconstructed. These define the physical bounds of the region of interest in the model. If images are 
acquired over a cardiac cycle the process needs to be dynamic and track anatomical motion or, as in 
the case of this project, be captured during a specific cardiac phase. This required ECG gating and the 
images used were those where the aortic valve was maximally open. This process results in a 
parameterised model of the aortic valve with few values that describe the aortic valve. Trained 
software identifies the edges of structures and a generic mesh is adapted; this is a method of 
‘simulated search’ [182]. A shape-constrained deformable model which relies upon a pre-defined 
shape space, with deviations allowed to give flexibility, is used to segment the areas of interest. This 
works with the different imaging modalities (CT and echocardiography) that are used in this project. 
The rest of the heart and other valve anatomy may be captured by additional post-processing steps 
that extract information from the segmentation results - such as chamber volumes, annulus 
dimensions and aortic valve area. 
 




A mesh was formed by dividing the geometry into a number of discrete volumetric elements or cells. 
With flow problems which are unsteady, solutions are required where the position is a function of 
time. Temporal discretisation involves the integration of terms in different equations over a time 
step. This is required as the numerical stability and accuracy of the analysis are influenced by both 
temporal- and spatial-refinement[183]. The mesh and time-step captured the important 
haemodynamic behaviour of the valve with the final solution independent of the mesh parameters. 
Highly refined meshes were needed to produce more accurate results, especially in regions with high 
pressure and flow gradients such as in AS but this was at the expense of increased simulation times. 
 
2.4.2.2.  Computational fluid dynamics 
 
The segmented valve and geometries of the inflow and outflow tracts from either 3D TOE or CT 
image acquisitions were used to run CFD simulations using ANSYS Fluent software (ANSYS Inc. 
Pennsylvania, United States). The CFD software solves the steady state equations of fluid flow 
(Navier-Stokes and continuity) in three dimensions using the conservation form of the finite volume 
method. Inputs to the CFD simulation are the pressure volume relationship described by the time 
varying elastance model, the radius of the valve and the valve stenosis severity described by the 11 
parameters given by the segmentation process, the outputs being the pressure flow relationship in 
the aorta. 
 
A steady-flow protocol was used to achieve an adequate representation of valve characteristics. 
Gorlin and Gorlin have shown that the pulsatility of flow can be ignored and that equations that are 
derived from steady flow through fixed orifices are adequate to predict effective orifice area[145]. 
The analysis enabled the computation of the pressure gradient across the aortic valve as a function 
of the flow, allowing implementation in a clinically oriented workflow. An outlet section was created 
by the extrusion of a distal plane of the segmented ascending aorta, by a distance of six equivalent 
diameters along the local tangent to the centre line. The inlet boundary condition was the flow, or 




the point-by-point velocity normal to the inlet plane (zero velocity in plane), at each position on the 
proximal boundary. For the latter, the assumption of plug flow was made (zero velocity at the ‘wall’ 
boundary, constant velocity at all other nodes). The flow, or the equivalent velocity, was prescribed 
at five flow rates, to span the range of likely flow rates over the cardiac cycle in patients at rest, with 
low flow or during exercise. These were: 2.7 L/min (low flow), 5.4 L/min, (typical cardiac output), 
12.5L/min, 25.0 L/min, a typical peak flow rate and 50.0L/min, and (a flow rate seen during extreme 
exertion). A quadratic curve was fitted to the resulting pressure flow relationship giving the linear 
and quadratic resistive coefficients of the aortic valve that were used in the 0D model. The pressure 
gradient across the valve for a given flow (personalised using the elastance model) could then be 
calculated. The outlet boundary condition was a static pressure of zero applied at the distal plane. 
For the purposes of the analysis blood was assumed to be a Newtonian fluid with a density of 1060 
kg/m3 and a viscosity of 0.004 Pa. The Reynolds number was estimated using the equivalent 
diameter at the minimum area of the valve, and when this was less than 1000, laminar flow was 
assumed. When the Reynolds number exceeds this, a normalised SST (shear stress transport) 
turbulence model was employed. The models produced the distribution of pressure and flow 
through the diseased valve. Post-processing was carried out to extract the static pressure at one 
hundred equally-spaced points along the centre line and the static pressure drop from a position on 
the centre line one diameter proximal to the valve plane to three diameters distal to the valve plane, 
where the diameter is defined as the equivalent diameter at the root of the valve. Due to the 
amount of computational power required to run these calculations, the average time to run a CFD 
simulation was 24 hours. To make a clinically useful workflow, cases were run on a high-
performance computer, Prometheus (Cyfronet, Krakow, Poland) or by using a reduced order model 
that was created during the EurValve project[192] (see section 2.4.2.4). This reduced the 








2.4.2.3.  Boundary conditions 
 
Boundary conditions are applied physiological parameters (which may vary over time) that define 
the physical conditions at the inlets and outlets within the model. Inlet and outlet boundaries 
conditions must be specified and precisely representing the physiological behaviour at the 
boundaries of a model is critical to its accuracy. In this study they were based on patient specific 
data, population data, lower order physical models such as the elastance model and OD models 
described above. Where possible individual patient data will be used in preference to ensure the 
modelling process is as personalised as possible. 
. 
2.4.2.4.  Reduced order models derived from 3D models 
 
A reduced order model (ROM) was used in the clinical decision support tool to enable near real-time 
processing. This was made available by ANSYS (ANSYS Inc., Canonsburg, PA, United States) and 
provides approximate values for CFD simulations for an individual patient using pre-computed CFD 
results in what can be described as a giant look-up table. As mentioned previously, the aortic valve 
can be described by just a few parameters, for example; annulus diameter, aortic valve area, valve 
aortic angle. All permutations can be created in advance to run CFD simulations. When a valve is 
segmented, the precomputed results from the CFD simulations can be found instantaneously for a 
valve the same as, or extremely similar to, those of that patient. This serves to substitute the lengthy 
CFD calculations that would be impractical in a clinical setting. 
 
2.4.3.  Analysis protocols 
 
Four protocols were developed of varying complexity. This was to enable all cases to be processed 
even if there were missing data and medical images could not be segmented accurately. It also 




enabled comparisons to be made to see whether increased complexity in the modelling process 
altered the overall results or conferred additional benefits.  
 
2.4.3.1.  Protocol 1  
 
This was the simplest protocol and required only a few clinical measurements and assumptions 
about the shapes of the LV and aortic pressure curves as a function of time. The clinical inputs are 
systolic and diastolic blood pressure, peak AV gradient and CMR-derived LV volume data. The 















Figure 2.11 Schematic of the process undertaken to produce the PV loop in protocol 1 . Full details of 
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The PV loop (see figure 1.18) has four segments: AB is the period of isovolumetric contraction, BC is 
ejection, CD is isovolumetric relaxation and DA is filling. The isovolumetric segments with no valvular 
regurgitation are straight lines, and the filling phase is also assumed to be a straight line 
representing the filling of the ventricle like the loading of a linear spring. Thus points A, B, C and D 
fully define these three phases. The ejection phase can be assumed to be quadratic in form, passing 
through points B and C. A typical model-derived LV, LA and aortic pressure curves are illustrated in 


















Figure 2.12 a) Typical time-series pressure curves for a patient with AS. Points A, B, C and D 
correspond to the timing points in figure 1.18. b) Piecewise quadratic representation of the PV loop 
derived from NIBP, Peak AV gradient and the timing of maximum AV pressure drop in one patient in 
the study using the derived formula in appendix iii. 
 
Point A: LVEDP was estimated using the Nagueh formula[193], where: 
  
LVEDP = 1.9 + (1.24 · E/E')                                                                            Eq. 2. 16 
 
 
E and E’ were measured using pulsed wave Doppler of mitral inflow and tissue Doppler imaging at 
the mitral annulus respectively in the standard way[193][194]. 
 


















Points B and C: Points B (aortic valve opening) and C (aortic valve closing) occur when the aortic and 
ventricular pressures cross over. The pressure at point B is the minimum pressure in the aorta. The 
maximum pressure in the aorta might exceed that at point C but the curve illustrated is typical and 
the maximum aortic pressure and is a reasonable estimate of that. Minimum and maximum aortic 
pressures were taken to be diastolic and systolic cuff pressures measured at the time of imaging. An 
average of three brachial artery pressures was taken using a GE Carescape V100 dinamap (GE 
Healthcare, Boston, USA).  
 
Point D: The mitral valve opens, and the LV starts to fill. This can be extrapolated from the LVEDP , 
knowing the volume intercept at a pressure of 0mmHg, from the literature [195], [196]. 
 
Segment BC: The shape of the aortic pressure curve during the ejection phase is reasonably 
represented by a quadratic equation passing through the points of crossover with the ventricular 
pressure curve and with the maximum at the end of the ejection phase. The LV pressure in the 
ejection phase, illustrated in figure 2.12b, is assumed to be piecewise quadratic in form, passing 
through points B and C and with a specified (measured, echocardiography) peak AV gradient. 
Detailed derivation of the quadratic coefficients defining the ejection phase is presented in appendix 
iii.  
 
2.4.3.2.  Protocol 2 
 
Protocol 2 utilised the methods described in section 2.4.1 to describe the aortic valve and 
circulation. Contraction of the heart chambers was represented by the elastance model with Mynard 
constants[189]. The aortic valve quadratic coefficient in this protocol is added to the parameters to 
be personalised based upon a measurement of the gradient through the aortic valve using the 2D 




transthoracic Doppler assessment. The output of LV volume was tuned to the end diastolic and end 
systolic volumes given by CMR imaging. 
 
2.4.3.3.  Protocol 3 
 
The same modelling process as in protocol 2 was applied, but in this case time series LV volume data 
were used from all 20 phases acquired during CMR. This resulted in more data points and enabled 
more accurate tuning of the model and personalisation of the constants for the ventricular elastance 
model. In addition to the parameters personalised in protocol 2, the double-Hill LV elastance 
constants n1, Tau2, the parameters for the atrial elastance model (producing the atrial kick) and the 
mitral valve coefficient were tailored to the individual. If the measured and model data are well 
matched, this increases the confidence in the model results. Figures 2.13 and 2.14 illustrates the 










Figure 2.13 This shows an example of measured elastance (blue) with a double-Hill model that has 
been personalised showing an excellent fit. 
 
 




a)                                                                                         b) 
 
Figure 2.14 Shows the model output tuned to (a) to LVEDV and LVEDD without time series (Protocol 
2) and (b) the measured time series volumes (Protocol 3), illustrating with time series data there is an 
excellent fit of the modelled volumetric data to the measured data. 
 
 
2.4.3.4.  Protocol 4 
 
Protocol 4 was the same as protocol 2, except that the valve coefficients were not based 
upon personalisation to reproduce a measured gradient, but 3D CFD analysis of the diseased 
valve. The valve geometry was defined by segmentation of medical images of the valve in 
the open configuration. The pressure gradient over the valve was computed for five flow 
rates, and a quadratic equation fitted to the results. The gradient at zero flow is zero, and so 
a linear term (pressure gradient proportional to flow) and a quadratic term (pressure 
gradient proportional to flow squared) were computed and the valve was characterised by 
these two coefficients.  
 
There are a number of flaws in using continuous wave Doppler and the simplified Bernoulli 
equation to estimate the transvalvular pressure gradient across the aortic valve, as 




discussed previously. Imaged-based segmentation and CFD assessment could overcome 
some of them[42]. Using images of the aortic valve acquired from either CT or TOE, the 
aortic valve was segmented along with the LVOT and the proximal aorta, when the valve 
was maximally open. Using CFD modelling with Ansys Fluent™ software, and the boundary 
conditions described by the 0D model ( personalised elastance model and the systemic 
vascular resistance), an image-based gradient across the diseased valve for the individual 
patient was produced.  
 
2.4.4.  Summary of processing steps for modelling protocols 2-4. 
 
The primary modelling protocol, followed for each individual recruited to the study, was as follows: 
1) Seven key clinical observations, including heart rate, were recorded for the individual at the 
time of image acquisition for LV volumes and 6MWT assessment (the examination state). 
2) Personalisation of the parameters in the mathematical model to represent the individual in 
the examination state was performed. 
3) Derived parameters including left ventricular stroke work and power, wasted energy and 
minimum and maximum LV elastance from the pressure-volume loop were computed in the 
examination state. 
4) Based upon published associations in the literature and measurements of the patient heart 
rate during the observation period prior to intervention, extrapolation to represent the true 
rest state and an activity state reflecting what the patient actually achieved was undertaken. 
5) Derived model parameters in rest and active states were computed. 
6) Virtual intervention was performed, replacing the valve coefficient for the diseased valve 
with a coefficient representative of a candidate valve for a prospective intervention. It was 
not expected that there would be a significant change in mean arterial pressure (MAP) post-




intervention, either because of autoregulation or medical therapy, the MAP for the post-
intervention rest state was fixed to the pre-intervention level. 
7) Predicted parameters in the post-intervention rest state were computed. 
8) These parameters were extrapolated to predict the activity state for the post-intervention 
condition assuming that heart rate is the same as the pre-intervention level. 
9) Derived parameters in the active state post-intervention. 
10) As a further extension, derived parameters were computed in the active state under an 
alternative hypothesis that left ventricular work rather than heart rate is maintained post 
intervention (to address the question of how much more flow might be generated by the 
heart for the same work expenditure). 
 
2.4.5.  Validation 
 
In our cohort, ten patients underwent TAVI implantation. It is routine practice to cross the valve and 
obtain LV pressures prior to valve deployment, so PV loops with invasive pressure data and volume 
data obtained from CMR were produced to validate the protocols. Cardiac catheterisation was 
performed using standard techniques via the femoral artery (14). 7-french pigtail catheters were 
placed in the aortic root and the left ventricular (LV) cavity and simultaneous pressures were 
recorded[179]. Analysis was performed by the Xper CardioFlex system (Philips Healthcare, The 
Netherlands). Although MRI measured LV volumes are more accurate than assessment by 
conductance catheter[180], [181] they were not performed simultaneously. Therefore, they were 
normalised for cardiac cycle length and pressure data synchronised with the LV volume data. The PV 
loops were produced in Microsoft Excel™ with the following parameters calculated: 
- Stroke work 
- Stroke power 
- Peak power 




- Wasted energy 
- Maximum LV elastance  
- Minimum LV elastance 
  
The accuracy of personalisation of the model was assessed by calculating the standard error of the 
modelled parameters that were tuned from measured data (peak pressure gradient across the valve, 
EDV, ESV, diastolic blood pressure and mean arterial pressure). 
 
Protocol 4 (the coupled 0D-3D model) was used in cases in which there was a high level of 
confidence in the clinical data and when an accurate segmentation of the valve was possible. This 
was a clinical judgement made by the author after assessing the data, the quality of the imaging and 
comparing the segmented valve geometries to the appearance of the valve in the raw image data 
(see sections 3.2.2 and 3.2.3). This quality control check was introduced as the segmentation process 
is crucial to obtaining accurate results in this model and had the greatest potential for the 
introduction of error. The multiscale model results included the peak gradient of the aortic valve, 
which is completely image and model dependent, not measured using ultrasound. Comparing the 
results of the model in terms of pressure gradient with the pressure gradient obtained by ultrasound 
formed the basis of validation in this protocol. When the model results predicted post-intervention 
gradients and activity levels these were correlated with measured data to assess the predictive 











2.5. Activity Data 
 
2.5.1.  Wearable pervasive monitoring 
 
Two activity monitors were used in the project: the commercially available Philips Health Watch 
(Philips N.V, Koninklijke, Netherlands) and Sphere wearable technology, research equipment 
developed by the University of Bristol. These have different capabilities. The Philips Health Watch 
can detect heart rate, step count, calculate energy expenditure. The Sphere health wearable is a 
global positioning system that is capable of tracking and characterising the movement of a patient 
around their home. Descriptions of how the devices work and where they were employed in the 
project are detailed below. 
 
2.5.2.  Sphere activity monitoring system 
 
Fig. 2.15 shows the equipment used to monitor activity around a patient’s home. 
 
Figure 2.15 Showing the Sphere equipment used to monitor patients around their homes 
 
The Sphere kit was designed and validated by a team of scientists within the Department of 
Electrical and Electronic Engineering, , University of Bristol[197] for the EurValve project. It was set 




up, calibrated and data collected by the author in the homes of the 22 patients with AS. The 
wristband uses a piezo-electric tri-axial accelerometer and communicates with ‘Gateways’ using 
Bluetooth low energy giving a received signal strength indicator (RSSI). Each Gateway has a different 
RSSI that is roughly correlated with distance. ‘Gateways’ communicated with the router using a Wi-Fi 
connection, transmitting hourly, which allowed near real time monitoring to ensure that, they were 
functioning, and that data were being collected. It also gave information regarding the battery status 
of the wristbands so patients could be advised regarding charging. Data were copied from the SD 
card, within each ‘Gateway,’ and transmitted securely every night to servers at the University of 
Bristol providing a safety-net to prevent data loss. The data from the SD card were manually 
downloaded and then uploaded to a secure cloud space. The raw data were downloaded and 
processed by Ryan McConville (Computer Scientist, University of Bristol) using training data and 
algorithms that had been specifically developed and data on step count, room transfers within the 
house, time outside the house and number of times the patient exited the house were recorded and 
transferred back to the author in a CSV file for analysis. Verbal and written instructions were given to 
the patients to help them use the equipment (see appendix v). Since many of the patients were 
unwell and elderly, they required help setting the equipment up, which entailed multiple patient 
visits. Due to the limited number of equipment kits (10) and the 66 periods of monitoring required, 
the kits were retrieved, and data downloaded after each two-week period. Patients were advised to 
wear the wristband 24 hours a day for a minimum of 14 days during each of the three phases of the 
study, taking it off when bathing or showering and charging it at that time. This duration was 
considered to be adequate in order to gain insight into a patient’s daily routine.  
 
2.5.3.  Philips Health Watch 
 
The Philips health watch is a commercially available product that can continuously track activity. It 
has FDA approval for medical use after being tested against a number of reference standards [198]. 




The device uses a piezo-electric tri-axial accelerometer to measure motion, similar to the Sphere 
wristband, and green light-emitting diodes and a photodiode to create a photoplethysmogram. The 
accelerometer output and the photoplethysmogram signal are analysed to determine heartbeat, 
activity type, steps taken, and are used as input for estimation of energy expenditure when the 
patient’s weight and height are programmed into the watch. Patients were asked to wear the watch 
for 24 hours a day for 14 days, coinciding with the Sphere wristband. The watch was pre-programed 
for each patient and therefore required no set up by them. Other than wearing the watch with good 
skin contact only charging the watch via the USB charger was required. 
 
Using an iPod™ with a software application supplied and installed by Philips Research Centre, 
Eindhoven, it was possible to communicate with the watch, uploading patient characteristics such as 
age, height, weight and resting heart rate for the estimations of energy expenditure and it was also 
possible to use this application to download the data from the watch. Raw data were processed by 
HH (Philips Research, Eindhoven) and graphs and CSV files were produced from which the analysis 
was performed. After experimenting with the devices, it was found that the watch could hold 
approximately 14 days of data on its internal memory, after which the previously stored data was 
overwritten; for this reason, the watch was retrieved at the same time as the Sphere equipment and 
data downloaded at that point. 
 
2.5.4.  Six-minute walk test 
 
The 6MWT is a validated clinical tool. Based on our population demographic, it was selected to 
measure activity as opposed to the exercise tolerance test. This has previously been used to assess 
severity of AS and the response to treatment in a number of studies[117], [199], [200]. The tests 
were carried out according to the guidelines outlined by the American Thoracic Society[201]. All 




tests were performed by the author at the same location to avoid bias. Patients who had poor 
mobility either prior to intervention or after intervention did not undergo the 6MWT at that stage. 
 
The 6MWT was performed at baseline and used as an input to the model to simulate exercise 
conditions and then repeated four months following intervention. The post-intervention result was 
then compared with the predicted exercise capacity from the model. Distance recorded during a 
standard 6MWT [202]was converted into METs using the formula METs = [0.1 x speed (m∙min-1) + 
3.5mLO2∙kg∙min-1] ÷ 3.5mLO2∙kg∙min-1 [203]. These data were used as an input to model the 
exercise state; the extrapolation was based on previous published data (see appendix iv). Predicted 
6MWT performance was calculated for each patient and used to compare their activity with an 
average age, gender, height and weight matched population prior to intervention and following 
valve replacement. To calculate the predicted 6MWT distance the following validated formulae were 
used[204]–[206]. 
 
For male participants:  
6MWT distance (m) = (7.57 × height(cm) – (5.02 × age) – (1.76 × weight(kg)) – 309                 Eq.2. 17 
Lower limit of normal = Distance walked – 153 
 
 
For female participants: 
6MWT distance(m) = (2.11 × height(cm) – (2.29 × weight(kg)) – (5.78 × age) + 66                   Eq. 2. 18 
Lower limit of normal = Distance walked – 139 
The results were recorded on a data sheet and entered onto the ArQ database. Metrics recorded 
included: The predicted distance, the achieved distance, the converted metabolic equivalent, a Borg 
scale assessment of effort reported by the patient, the pre- and post-test heart rate, blood pressure 
and O2 saturations. 
 




2.6. Patient reported measures 
 
2.6.1.  Minnesota ‘living with heart failure’ questionnaire  
 
This questionnaire has been validated for use with patients with valvular heart disease undergoing 
treatment[207] [208]; therefore it was used in this cohort. Physical, emotional, and social items were 
totalled separately using a previously validated method[209]. Scores were calculated pre- and post -
intervention. Patients were asked to complete the questionnaire at the pre-intervention visit and 
again at 3-4 months following intervention. A comparison was made between the patient reported 
physical activity and the objective active measurements made from the 6MWT and with the 
pervasive activity monitoring. 
 
2.6.2.  World Health Organization Quality of Life—abbreviated version of the 
WHOQOL 100 (WHOQOL_BREF) 
 
Symptoms are key to determining treatment strategy and since the patient’s view of the disease, 
and the impact of the disease is now thought to be of the utmost importance, a second quality of life 
questionnaire (WHOQOL- BREF) was administered in conjunction with the Minnesota ‘living with 
heart failure’ questionnaire. This questionnaire was developed to reflect cultural differences of the 
patient cohort with quality of life defined as the “individuals' perceptions of their position in life in 
the context of the culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns”[210]. The WHOQOL- BREF questionnaire was selected as it 
assesses other aspects of life such as financial status, the home environment and access to 
healthcare, which is not covered in the Minnesota ‘living with heart failure’ questionnaire. Again, the 
results are given as a total quality of life score which is broken down into four domains: physical 
health, psychological, social relationships and environment. As before, this was compared with other 
metrics that measured the physical activity of the patient. 




2.7. Development of a clinical decision support system  
 
 
The content of the clinical decision support system was decided upon by a clinical panel, including 
the author, that was part of the EurValve Consortium. The design and creation of the CDSS was 
developed in conjunction with Therenva (Rennes, France) as an extension of their already existing 
product, Endosize™ [211]. It incorporates clinical and imaging data with data from wearable activity 
monitoring devices, parameters from the modelling process as a result of the work in this thesis. It 
also includes clinical guidelines from the European Society of Cardiology, commonly used risk scores 
and a case-based reasoning tool. Case-based reasoning uses complex statistical analysis (beyond the 
scope of this thesis) to search a database of cases of AS that have previously undergone surgery with 
the outcome of that intervention recorded to find a case that is similar to the details that were 
entered. It returns ‘cases like yours’ with a similarity index and details what happened to the patient 
in that scenario. The tool was developed and validated by a team at the University of Rennes, France 
[212]as a wider part of the EurValve project. The platform allows clinicians to run different 
simulations at the bedside or clinic, such as assessment of patient haemodynamics during exercise 
or assessing treatment effects such as the reducing blood pressure or replacing the valve. 
 
The content and presentation of the decision support tool is illustrated below. 
 






Figure 2.16 Illustrating CDSS flow chart to guide clinicians through the European Society of 





Figure 2.17 Shows a screenshot of the risk scores within the CDSS (Logistic EuroSCORE, EuroSCORE II 
and STS score), which can be automatically populated from the patient’s electronic record. 





Figure 2.18 Demonstrating the results for one patient of the case-based reasoning tool (CBR), a 
similarity index is displayed for five cases, a score of 1 would be identical to the criteria. It also shows 




Figure 2.19 Showing a summary of some of the activity data captured by the Philips Health Watch 
and the Sphere device from the University of Bristol (UBRIS).  





Figure 2.20 A screenshot demonstrating modelled PV loops using protocol 4 with the resulting 
parameters. The exercise state and post-intervention state are predicted. 
 
2.8.  Evaluation of the clinical decision support system 
 
A randomised controlled experiment was performed as part of the EurValve project and was 
designed and conducted by the author together with Dr Marcus Kelm (Berlin) and Dr Jo Zelis 
(Eindhoven). The purpose was to examine the impact on management decisions that could be made 
when practising cardiologists and cardiothoracic surgeons, with experience in treating valvular 
disease, were presented supplementary information from the CDSS. The experiment was performed 
retrospectively, when decisions had already been made, so that the results did not influence patient 
care. Three cases were selected that had already undergone intervention at participating centres, 
where modelling and activity data was available. Cases were chosen in order to reflect clinical 
heterogeneity, with respect to age and severity of disease. The number of cases selected was limited 
to allow participants enough time to assess each case. Clinical details of the cases are shown in 
appendix vii.  




For each case, two datasets were produced. The first dataset (control) included conventional clinical 
information and imaging data currently recommended as standard diagnostic work-up in clinical 
practice guidelines. The second dataset (experimental) included information from the decision 
support system.  
 
The study was powered to identify the difference in decisions made between the experimental and 
control group and required at least 36 participants. This was based on a predicted effect of 10% 
difference between the two groups in terms of the primary endpoint. Given the lack of similar 
evaluations in the literature, this could not be based on previous empirical studies. Cardiologists and 
cardiothoracic surgeons were eligible for inclusion in the study if they had frequent exposure to 
patients with valvular heart disease. Pilot testing was conducted by cardiologists who were members 
of the EurValve project, to ensure readability and interpretability of the case summaries and 
accompanying questions. Each centre sought a minimum of 12 participants. Each participant 
reviewed cases selected at random. Whether study participants received the first or second dataset 
was dependent on their group allocation, as described below. The randomised controlled trial design 
was used to improve the internal validity of the study. We used a web-based survey platform 
(JotForm, JotForm Inc. San Francisco, CA, USA) for participants to record their decisions and views of 
the CDSS. This was selected based on reliability, ease of creation, and ease of use and collection of 
responses.  












Figure 2.21 Shows an excerpt from the JotForm questionnaire platform and the format in which the 
results are received from the participants. 
 
Randomised allocation was completed centrally; the investigators could not foresee the assignment. 
Randomisation was at the case-level and was therefore repeated three times for each participant 
(i.e. each participant completed three randomised evaluations by the end of the study). Thus, it was 
possible for a study participant to be randomized to the experimental group for one case and the 
control group for another. This design ensured that each clinician would be exposed to the clinical 
decision support tool and they were asked to evaluate its content.  
 
First, participants were given an outline of the project and verbal consent to take part was obtained. 
The cases were then presented, and the clinicians were asked to complete a web-based 
questionnaire about the decisions they would make and the utility of the CDSS features. Finally, the 
participants were asked about their current role and experience in managing valvular heart disease.  




Questions were devised to explore participants’ willingness to recommend intervention in the 
presented cases depending upon the type of information presented to them (experimental vs. 
control). Participants were first asked whether they felt there was a guideline for intervention for 
each case and then whether they would intervene or not based on the information presented. The 
primary endpoint was “decision to intervene”, referring to a clinician decision to recommend either 
surgery or catheter lab (collectively, “intervention”) as opposed to follow-up with or without 
medication (“no intervention”). Each of the participants were then asked to rank the utility of each 
component of the CDSS. 
 
2.9.  Statistical analyses 
 
2.9.1.  Protocol comparisons and validation 
 
Statistical analysis was carried out using IBM SPSS® Statistics version 25 software. Results of the 
three protocols are presented in tables with means and standard deviations. Due the limited data 
for comparison protocol 4 was analysed separately and differences between this and measured data 
were explored. Differences between the protocols were analysed using Friedman’s statistical test in 
non-parametric data and one-way ANOVA for parametric testing. Where there were missing data, a 
mixed-effects analysis was performed. A value of P<0.05 was used to define a significant difference. 
Any significant differences between the protocols were investigated with either Dunn’s or Holm-
Sidak’s tests for pairwise comparisons, to identify which protocol differed. Residual (standard errors) 
from the model optimisation process were calculated using MATLAB version R2018B.  
 
2.9.2.  Correlations between modelled and measured  
 
Pearson or Spearman correlations were reported depending upon the normality of the data. Level of 
agreement was deemed poor for intra-class correlation coefficient in the range of 0.00 to 0.30, weak 




between 0.31 and 0.50, moderate between 0.51 and 0.70, strong between 0.71 and 0.90, and 
excellent between 0.91 and 1.0 [213]. 
 
2.9.3.  4D flow data 
 
Statistical analysis was carried out with IBM SPSS® Statistics version 25 software. Continuous 
measurements are presented as median with interquartile ranges (IQR). Normality of data was 
assessed by the Shapiro–Wilk test. Given the non-normal distribution of the data, a paired 
nonparametric two-tailed test (Wilcoxon signed-rank test) was used for paired analysis. The Mann-
Whitney test was used for all continuous variables to compare differences between two different 
procedure options of the aortic valve replacement (TAVI and SAVR), for categorical variables, P-value 
was calculated using Chi-squared T-Test. Correlation between variables was assessed using the 
Spearman correlation coefficient (rho), a value of P < 0.05 was considered significant.  
 
Comparison of variables amongst different NYHA classes was performed using Kruskal-Wallis H test. 
A Jonckheere-Terpstra test was carried out to find which specific groups of these independent 
variables were significantly different from each other. Results with a P values of < 0.05 were 
considered statistically significant.  
 
2.9.4.  Evaluation of clinical decision support system. 
 
Descriptive statistics were used to compare the experimental and control groups at baseline. 
Differences between study groups in terms of outcomes were then evaluated using Fisher’s exact 
test for proportions, and chi square analysis with categories adjusted to avoid cells with <5 expected 
values. Statistical significance was defined as a P value of <0.05 assuming a 2-tailed hypothesis. All 




analyses were repeated for sub-groups according to the experience level of participants. Statistical 






























3. Results  
3.1.  Baseline Patient Characteristics 
 
Twenty-two patients met the inclusion criteria and were recruited to the study. The patients’ 
characteristics are shown in Table 3.1. Haemodynamics were modelled using Protocols 1-3 (section 





Mean±SD or number 
Post-Intervention 
Mean±SD or number 
 Difference 
T-Test P Value 
Age (years) 76±11 76±11  
Gender (female/male) 17/5 17/5  
Weight (Kg) 69.1±15.5 69.2±14.2 >0.05 
Height (m) 1.6 ± 0.1 1.6±0.1 >0.05 
BSA (m2) 1.75 ± 0.2 1.67±0.4 >0.05 
BMI (Kg/m2) 26.8 ±5.1 26.8±5.0 >0.05 
Rhythm (NSR/AF) 14/8 15/7 >0.05 
Diabetes 4 4  
CKD  8 8  
Systolic Blood Pressure 
(mmHg) 
150 ±18 151±16 >0.05 
Diastolic Blood Pressure 
(mmHg) 
75±10 77±13 >0.05 
Previous MI 0 0 >0.05 
Smoking status (current/ex) 0/5 0/5 >0.05 
NYHA Class  2.14±0.47 1.22±0.43 <0.05 




CCS Class 1.62±0.59 1 <0.05 
Syncope 1 1 >0.05 
Peak Gradient 69±24 21±13 <0.05 
Mean gradient 35±14 10±7 <0.05 
MRI LV ejection fraction 57±13 58±15 >0.05 
Table 3.1Patient characteristics pre- and post-intervention at 3-4 month follow up. 
 
During this study, one patient was found to have only moderate AS and therefore did not undergo 
aortic valve replacement and was not included in the post-intervention analysis. Eleven patients 
underwent SAVR and 10 underwent TAVI. Patients who underwent TAVI were declined SAVR due to 
high operative risk. These were older (mean age 83 vs 69 years), had more severe stenosis (mean 
TTE derived EOA 0.5cm2 vs 0.82cm2 and were frailer and physically limited (6MWT distance achieved 
268m vs 432m)) than patients who undergoing surgery. Two patients had disabling strokes, one had 
vascular complications and two patients had poor mobility post-intervention which meant they 
could not complete a 6MWT. These patients were excluded from the activity analysis. 
 
For the extended follow-up period at 12-18 months, 17 patients were invited to take part. Patients 
with disabling strokes were excluded as they could not perform activity monitoring and three 
patients died during the follow up period. Of the 17 patients invited, ten patients accepted the 
invitation. Table 3.2 shows the major adverse events during the study divided into TAVI and SAVR 
groups. 
 









SAVR 0 0 0 0 0 1 0 
TAVI 0 2 2 0 1 0 3 
Table 3.2 Indicates the number of major adverse events that occurred in the cohort by treatment 
type. 




3.2.  Imaging  
 
3.2.1.  Transthoracic echocardiography 
 
From the standard BSE dataset, four metrics were used to assess the severity of AS and further 
metrics (E/A and E/e’) were obtained to assess the diastolic function and compliance of the left 
ventricle. These could then be used for comparison with the ELVmin produced by the modelling 
process. All patients underwent transthoracic echocardiography with the peak and mean gradient 
recorded. E/A was not performed in patients with atrial fibrillation and there were inadequate 
Doppler signals for the analysis of E/e’ in three patients: missing data were excluded from the 
analysis. The mean and standard deviation of the results pre- and post-aortic valve intervention are 
presented in table 3.3. Significant differences post-intervention are indicated by a p value of <0.05. 
 






Peak gradient (mmHg) 69 (26) 21 (13) <0.05 
Mean gradient (mmHg) 35 (14) 10 (7) <0.05 
Aortic valve area (cm2) 0.68 (0.23) 1.52 (0.41) <0.05 
Dimensionless Index 0.22 (0.05) 0.49 (0.12) <0.05 
e/a 1.15 (1.12) 0.96 (0.31) >0.05 
e/e’ 17.4 (8.3) 16.5 (6.5) >0.05 
LVEDP* 22.7 (9.1) 22.3 (7.5) >0.05 
Table 3.3 TTE derived data showing the severity of AS, indicators of diastolic dysfunction and 
intraventricular pressure pre and post intervention. *LVEDP was measured by echocardiography 
using the Nagueh formula. 
 
Results were tested for normality using the Shapiro-Wilk test (alpha =0.05). A paired two-tailed T-
test or Wilcoxon rank paired test was performed as appropriate. Significant decreases in peak and 
mean gradients were seen following intervention, with median differences of 47mmHg and 25mmHg 




respectively. The EOA increased significantly with a difference of 0.79cm2 (p<0.001). Figure 3.1 





































































































































































Figure 3.1 Box plots showing the trend of the transthoracic echocardiogram parameters recorded in 























Figure 3.2 a) a continuous wave Doppler trace showing a peak gradient of 65mmHg, a mean gradient 
of41mmHg and velocity time integral of 93cm used in the continuity equation. b) a pulse wave 
Doppler trace from the LVOT view showing the peak velocity and VTI used to derive the dimensionless 
indices and the LVOT velocity time integral used in the continuity equation. This shows a calculated 
EOA of 0.6cm2. c) a parasternal long axis image showing the measurement of the LVOT diameter 













Figure 3.3.Illustrating the assessment of diastolic function and inputs to the LVEDP calculation in one 
patient. a) A pulse wave Doppler of mitral inflow showing the measurement of E and A waves. b) and 








3.2.2.  Transoesophageal echocardiography 
 
 
TOE was performed in all patients undergoing surgical valve intervention. As patients were under 
general anaesthetic no haemodynamic information was obtained from these images but it was 
assumed that the diseased valve would still open maximally under general anaesthesia. This 
assumption is supported by data from Handke et al who suggest the valve opens maximally at 
relatively low flow rates[214]. 3D images were obtained for 11 patients and used to create a 
parameterised model of each patient’s valve, inflow and outflow tracts. Upon visual inspection of 
the geometries, six patients (55%) were found to have adequate representations of the valve to 
enable accurate CFD simulation and processing of cases using protocol 4. Table. 3.4 shows the 
findings when the segmented geometries were reviewed along with the clinical images. An 
assessment of suitability for processing for using protocol 4 was made, with the data either accepted 
or rejected. Figure 3.4 demonstrates an appropriate and inappropriate segmentation in two patients 






















Figure 3.4 Shows appropriate segmented mesh from 3D TOE images for case 12 (green box ) with 
correct identification of the restriction of the non-coronary and left coronary cusp leaflets with fusion 
at the base and a inappropriately segmented mesh for case 17 (red box) where there is failure to 
identify fusion of leaflets with an eccentric orifice. 
Case  Segmentation review and recommendation 
01 Due to USS drop out secondary to calcification the segmentation process was 
unable to identify fusion of right and non-coronary cusp leaflets, resulting in a 
different orifice shape and overestimation of orifice area. Rejected 
02 Heavily calcified valve. However, fusion at the bases of the leaflets identified 
with appropriate orifice area and shape Accepted. 
05 Restriction of right and left coronary cusp leaflets identified. Appropriate orifice 
area and shape. Accepted 
06 Fusion at the base and restriction of the non-coronary cusp leaflet identified. 
Accepted 
07 Calcification and restriction of the non-coronary cusp not identified. Valve 
appears fully open on segmented geometry with overestimation of orifice area. 
Rejected. 
09 Fusion of the right and left coronary cusp leaflets with eccentric orifice, not 
identified during segmentation process. Rejected 
12 Calcification and restriction of the non-coronary and left coronary cusps 
identified resulting in appropriate shape and size orifice. Accepted. 
13 Calcification and restriction of leaflets identified resulting in appropriate shape 
and size orifice. Accepted. 
17 Bicuspid valve with fusion of the right and left coronary cusp leaflets with 
eccentric orifice. Not identified during segmentation. Rejected 
20 Leaflet geometry correctly identified with appropriate orifice area and shape. 
Accepted 
21 Unable to segment due to corruption of data. Rejected 




3.2.3.  Computed tomography 
 
 
CT imaging was part of the clinical protocol for all TAVI patients, and these images were 
expected to support segmentation to extract LV volumes. One surgical patient who was not 
able to undergo MRI and who did not undergo TOE also had CT imaging. Out of the 11 patients 
that underwent CT scanning, it was only possible to segment the valve, inflow and outflow 
tracts accurately in 5 patients (45%). Table 3.5 gives the explanation why images were excluded 
and figures 3.5 gives an example of acceptable segmentation that was included and an 
unacceptable case that was rejected. 
 
Case  Segmentation review and recommendation 
03 Tricuspid valve, leaflets calcified but no fusion all leaflets open but are 
restricted good representation of orifice. Accepted 
04 Tips of leaflets open but calcification and fusion of commissures not 
identified during segmentation resulting in large orifice area in 
segmented model. Rejected 
08 Relatively symmetrical calcification and restriction of all 3 leaflets 
identified with appropriate shape and size of orifice. Accepted 
10 Base of right coronary cusp leaflet and non-coronary cusp leaflet 
fused. Base of non-coronary cusp leaflet and left coronary cusp leaflet 
fused. Not identified during segmentation. Rejected. 
11 Orifice area and shape similar to that of segmentation. Accepted  
14 All leaflets open reasonably well, does not appear significantly 
stenosed. Consistent with segmentation. Accepted. 
15 Valve severely calcified with a small orifice which is obscured. Not 
identified at segmentation resulting in overestimate of orifice area. 
Rejected. 
16 Severely stenosed valve with fusion of the leaflet orifice cannot be 
identified during segmentation process. Rejected 
18 Valve heavily calcified with fusion of leaflets. Right and non-coronary 
cusp leaflets more mobile and open better not identified at 
segmentation. Rejected 
19 RCC leaflet opens well, other leaflets restricted but do open, Good 
representation in segmented model. Accepted. 
22 Valve heavily calcified particularly the non-coronary cusp leaflet. 
Difficult to identify the orifice accurately. Rejected 
Table 3.5 Findings when the segmented geometries from CT were compared with the clinical images. 
 





Figure 3.5 Shows an appropriate segmented mesh for case 08 (green box) with correct identification 
of the restriction of the leaflets from the CT acquisition and an inappropriately segmented mesh from 
CT for case 15 (b)(red box).The valve is heavily calcified with the small orifice obscured. The 
segmentation process has not identified the orifice due to calcification leading to an overestimate of 
the orifice area. 
 
3.2.4.  Magnetic Resonance Imaging 
 
Standard metrics, including LVEDV, LVESV, ejection fraction and LV mass, obtained from CMR images 
are presented in table 3.6. Three patients who did not have follow-up imaging are excluded from this 
analysis: one did not undergo intervention and two had disabling strokes (one of whom also had a 
pacemaker implanted).  





 P value 
 Mean (SD) Mean (SD)  
LVEDV 133 (42) 133 (40) >0.05 
LVESV 58 (35) 62 (38) >0.05 
LV Mass 135 (44) 115 (38) <0.0001 
Ejection Fraction 57 (13) 57 (15 >0.05 
Table 3.6 Mean and standard deviations (SD) of the LVEDV LVESV, LV mass and ejection fractions of 
19 patients who were able to undergo MRI imaging pre and post intervention. 
 




The only significant change pre- and post- intervention was a regression of LV mass, with mean 
reduction of 20 g post intervention. A paired two tailed t-test showed this to be significant 






























































































































Figure 3. 6 Box plots of how the standard CMR parameters measured change following intervention. 
 
 
In sub-group analysis of the eight patients that had impaired LV systolic function (defined as an 
ejection fraction <55%,) there was a trend of improvement of ejection fraction following 




intervention with the average ejection fraction in these patients rising from 45 to 50% but this failed 
to reach significance (p=0.4).  
 
3.3.  Measured pressure-volume loop 
 
 
During the TAVI procedure 10 patients had invasive LV pressures and invasive pressure gradients 
across the aortic valve recorded. Of these 10, nine patients had adequate data for analysis and 
production of a PV loop using time series LV volume from their MRI scan prior to the procedure. 
Catheter measurements are presented in table 3.7. An example of the measured PV loop is shown in 

















215 (40)  11(9)  23 (12)  64 (26)  69 (25) 
Table 3.7 Mean and standard deviation of invasive LV pressure measurements from cardiac 
catheterisation during the TAVI procedure. 
 
 
Figure 3.7 Measured PV loop for one patient in the study who underwent TAVI (case 8). 
 




3.4.  Outcome measures 
 
3.4.1.  Activity Data 
3.4.1.1.  Six-minute walk Test 
 
The 6MWT was used as the reference test. The results pre- and post-intervention are presented in 
table 3.8. The achieved walk test was compared with the age, gender, height and weight predicted 
values[205], [206]. The effort during the test was recorded using the Borg scale[215], 1 being 
minimal effort and 10 being maximal effort. The difference pre- and post- intervention was assessed 













Table 3.8 Average six-minute test results with standard deviations of patients that were able to 
perform the test pre and post intervention. Statistical significance was determined by a two-tailed T-
test <0.05 is significant. 
 
 
The results show that there was no significant change in the distance achieved in the 6MWT 
following intervention with patients remaining below their predicted six-minute walk distances. 
However, despite there not being an improvement in the distance, patients appeared to find the 
distance easier to achieve as reflected by a lower Borg scale score following intervention (p= 0.05). 
The results shown are average data for both TAVI and SAVR cohorts, a separate analysis of TAVI and 
SAVR patients indicated that there was no significant difference between the two modalities of valve 






Predicted 6MWT distance (m) 429 (87) 455 (102) >0.05 
Achieved 6MWT distance (m) 364 (125) 352 (157) >0.05 
Achieved vs predicted 6MWT 
distance (m) 
-65 (93) -98 (159) >0.05 
Borg Scale 3.4 (1.8) 2.7 (1.7) 0.05 




intervention (p=0.29), and SAVR patients 434m pre- and 451m post-operatively (P=0.23). Although 
not significantly different, there was a trend for improvement following SAVR and a trend for decline 
at 3-4 months following TAVI. 
 
3.4.1.2.  Sphere data 
 
Using the activity monitoring kit described in section 2.5.2 the raw accelerometer and received 
signal strength indicator data was processed by the team at University of Bristol. This enabled the 
time spent walking, sitting and lying to be determined. In patients for whom successful calibration of 
the device was achieved (65%), we were able to localise the patient within the home and enable 
calculation of number of room transfers, how many times the patient exited the house and the 
duration of time spent out the house. These data could be used as a marker of function. Data were 
collected pre-intervention, at discharge, at 3-4 months following surgery (early follow-up) and at 12-
18 months (extended follow-up.)  
 
On average, the patients wore the sphere watch with valid data for 16.5 days in the pre-intervention 
period, 14.7 days at discharge, 14.6 days at early follow-up and 15.5 days at extended follow-up, 
showing good compliance with the device. The mean and standard deviations of the parameters 


















Metric  Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Room transfers 80 (31) 68 (25) 75 (32) 57 (37) 
Times exited home 1.5 (2.3) 0.7 (0.8) 0.9 (0.9) 4.1 (4.2) 
Duration outside 
home (hours) 
2.4 (1.7) 2.0 (2.0)) 3.1 (3.0) 3.1 (2.6) 
Time spent walking 
(hours) 
0.8 (0.5) 0.6 (0.3) 0.7 (0.1) 1.0 (0.4) 
Time spent sitting 
(hours) 
7.4 (2.0) 8.2 (2.0) 7.4 (2.5)  6.1 (1.6) 
Time spent lying 
(hours) 
11.9 (2.5) 11.6 (2.9) 11 (3.1) 11.9 (4.6) 
Table 3.9 Mean and standard deviations of activity parameters measured by the Sphere kit pre 
intervention, at discharge, early and late follow-up. 
 
 
The durations of certain activities varied between patients depending on their age, comorbidities, 
mobility and disease severity. A one-way ANOVA mixed-effects analysis with the Geisser- 
Greenhouse correction showed no significant difference between any of the metrics over the 4 time 
periods (p>0.05). A Holm-Sidak’s multiple comparisons test showed that, except for a significant 
reduction in room transfers in the post discharge period (p=0.05), there were no significant 
differences in the means when each of the time periods were compared with each other. 
 
Although no statistically significant difference was found in the Sphere activity metrics, some trends 
were apparent (figure 3.8). There was a reduction in time spent walking, duration outside the home 
and number of times exited the house following discharge in the recovery period with an increase in 
sitting time. Time spent walking then increased as did times exited the house and duration outside 
the home at early follow up. Time spent sitting also reduced at early follow up. At extended follow-
up the average time spent walking, outside of the house and number of times exited the house all 




increased beyond pre-intervention levels with the average time spent sitting falling below pre-






















3.4.1.2.1. Case study illustrating the Sphere results 
 
The raw data from the Sphere kit was obtained at one-minute intervals during the period of 
monitoring. Accelerometer and received signal strength intensity measurements were combined to 
localise the patient within the home and determine their activity. Figure 3.9 shows typical 































































































































































































































































































Algorithms were created (by RM) and trained to recognise patterns producing the patient’s activity 
data. 
 
Figure 3.9 Illustrating the raw data from the Sphere kit which can Identify both time of activity from 
the accelerometer data and the location from the received signal strength indicator. 
 
 
Typical trends of activity type are illustrated across three phases for this case in figure 3.10 below. 
This demonstrates that prior to the procedure, the patient spent a lot of time laying down; following 
the procedure, although the patient spent more time sitting, they also were able to walk more and 
mobilise outside the home more frequently. In the six-minute walk test this patient was able to walk 
268 metres before the intervention, and 330 metres at early follow-up corroborating the results. 
 
Figure 3.10 Inferred time spent lying, sitting, walking and time spent outside the home during the 
three phases of deployment with 95% confidence intervals indicated. 
 
Accelerometer measurements RSSI measurements 




Furthermore, the data collected had a time stamp enabling it to be broken down into individual days 
to monitor progress and identify trends in certain activities. Figure 3.11 shows how this patient’s 
walking activity varied throughout the week pre- intervention and again at early follow-up.  
 
 
Figure 3.11 Bar chart showing how a patient’s walking activity in the study varied throughout the 
week pre-intervention and the follow up period given insight to the patients’ habits and lifestyle. 
 
 
The location and the amount of time that the patient spent in a location was also determined (see 
figure 3.12). This showed that, prior to the operation, the patient spent more time in the bedroom 
than afterwards; and conversely, post-discharge the patient spent more time in the living room and 
less time outside the house. In the early follow-up period, the patient spent more time in the kitchen 



















Figure 3.12 Shows a heatmap of the location of the patient in three monitoring periods. Each 
rectangle represents a single day within the monitoring period. The colour scale on the right shows 
the duration the patient stayed in that room in minutes that day. 
 
3.4.1.3.  Philips Health watch data 
 









Metric  Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Average resting Heart rate 
(bpm) 
64 (9) 65 (7) 63 (9) 60 (9) 
Average heart rate (bpm) 71 (8) 71 (8) 70 (8) 70 (9) 
Average daily step count 3915 (1978) 2800 (1760) 4142 (2587) 4403 (2784) 
Average daily active energy 
expenditure (kcal) 
622 (172) 522 (134) 657 (219) 778 (404) 
Average daily total energy 
expenditure (kcal) 
1977 (393) 1948 (343) 2100 (475) 2129 (715) 
Cardiovascular Energy 
Expenditure Slope 
0.30 (0.09) 0.25 (0.08) 0.27 (0.07) 0.27 (0.06) 
Average Sleep time (hours) 8.5 (1.6) 8.7 (2.1) 8.5 (2.0) 7.7 (2.1) 
Average daily time spent in 
light activity (mins) 
221 (87) 159 (91) 215 (87) 219 (73) 
Average daily time spent in 
moderate activity (mins) 
69 (71)  
33 (42) 
49 (43) 101 (85) 
Average daily time spent in 
high activity (mins) 
0.4 (0.9) 0.2 (0.3) 0.2 (0.7) 2.5 (3.3) 
 
Table 3.10 Shows the mean and the standard deviations metrics derived from the Philips health 
watch during the four observations of the study. 
 
 




A one-way ANOVA with mixed effects analysis and a Geisser- Greenhouse correction were used to 
determine significant differences between the four periods of observation. These were to handle the 
missing data and the assumption that there was not equal variability of the differences between the 
groups. Due to the limited data obtained in the extended follow up group again this data was 
treated in a separate analysis of the data. A Holm-Sidak’s multiple comparisons test was performed 
to assess the differences in the means between each group. There was no significant difference in 
the average resting heart rates across the four periods. Figure 3.13 illustrates that there was a 
significant decrease in step count during the post discharge period compared to the pre-intervention 
period with a mean difference of 1115 steps (p=0.01). This recovered significantly at the early follow 
up period with a mean increase of 1342 steps (p=0.04). There was no significant difference in the 













Figure 3.13 Graph indicating the mean and standard deviations of the step count of patients over the 
periods of observation. Following discharge there is a trend of improvement. 
 
 
There was a significant decrease of active energy expenditure in the post op period compared with 
the pre-intervention period with a mean reduction of 100kcal (p=0.04); this recovered in the follow- 
up period. There was a trend of improvement in active energy expenditure into the extended follow-
up period, but this failed to reach significance (figure 3.14). There was no significant difference in 




total energy expenditure across the four monitoring periods but again there was a trend of 
















































Figure 3.14 Graph showing the mean and standard deviations of the total energy expenditure (black) 
and active energy expenditure (grey) over all periods of observation. Following discharge there is a 
trend of improvement.  
 
 
The cardiovascular energy expenditure slope (CEES), calculated by assessing the relationship of heart 
rate and energy expenditure (see figure 3.18), has been suggested as a marker of cardiac efficiency 
[216]. As shown in the figure, cardiac efficiency improved significantly immediately after 
intervention with a mean difference of 0.05 (p=0.03). An increase in efficiency is sustained in the 
follow-up periods compared with pre-intervention.  
 
There was no significant difference in length of sleep during the periods of monitoring. The time 
spent performing light activity, moderate activity and high activity followed similar patterns with a 
reduction of activity initially following intervention and a sustained increase in all activities in the 
early follow up and extended follow up periods. There was a statistically significant reduction in light 
and moderate activity at discharge with mean difference of 62 minutes (p=0.0004) and 37 minutes 
(p=0.05) respectively. This recovered in the follow up periods illustrated in figure 3.15. 











































Time performing moderate activity
Time performing light activity
 
Figure 3.15 Graph illustrating the mean and standard deviations of minutes spent performing 
moderate activity (grey) and light activity (black) over all periods of observation. Following discharge 
there is a trend of improvement. 
 
 
3.4.1.3.1. Case study illustrating the Philips Health watch results  
 
The Philips watch records data every minute so, like the Sphere kit, can record daily trends. Figure 















Figure 3.16 Raw data from the Philips Health Watch for one of the patients over a 13 hour period 
giving insight to the patient’s lifestyle. This patient’s heart rate, respiratory rate and step count 
dropped in the afternoon at about 1530, possibly explained by sleep. There is a period at about 2100 
hours with increased heart rate and step count, possibly explained by the patient getting up and 
going for a walk. 
 
The spread of heart rate and respiratory rate measurements was analysed as demonstrated in figure 
3.17. This patient had an average heart rate of 78 bpm and resting respiratory rate of 15 breaths per 
minute. At rest the patient had inappropriate tachycardias (6% of all recorded heart rates at rest) 
which may indicate an uncontrolled heart rate, atrial fibrillation or sinus tachycardia ,for example, 
due to the patient being unwell. 





Figure 3.17 Graphs indicating range and density (log scale) or frequency of observations related to 
heart rate and respiration rate over one day of monitoring. 
 
Heart rates during different activities can be obtained and used to calculate the CEES as seen below 
(Figure 3.18). The gradient of the slope (the heart rate per energy activity) gives the cardiac 
efficiency marker CEES[216], which in this case is 0.1788. 





Figure 3.18 Shows heart rate and total energy expenditure for one patient over a monitoring period. 
Each red dot is a single observation recorded every minute. Heart rate and total energy expenditure 
are plotted on a log scale to produce a linear relationship. The gradient of this line in this case 0.179 
is the CESS value. 
 
 
3.4.1.4.  Combining activity data information 
 
Because data from the Philips Health watch and Sphere data were time-stamped, they were 
combined to give a more holistic overview of the patients’ activity. In Figure 3.19, the patient sleeps 
in the bedroom for about nine hours, going to bed at 0030 hours. The patient returns to the 
bedroom for four periods during the day but does not appear to be asleep. The patient spends time 
outside the house with an increase in activity between 1830 and 2030 hours. 





Figure 3.19 Illustrating how the Philips Health Watch data and Sphere data can be combined to give 
an overview of the patients’ activity with physiological measurements. 
 
3.4.2.  Quality of life data 
 
Patient reported measures were recorded at two time-points; once before intervention and again at 
3- 4 months following intervention. 
 
3.4.2.1. Minnesota ‘Living with Heart Failure’ Questionnaire 
 
Questionnaires were completed prior to and after the intervention. The mean scores and standard 
deviations are recorded below as percentage with 100 being the best score indicating perfect quality 
of life in that domain. The total quality of life score is also recorded. 
 
 





Mean percentage (SD) 
Post-intervention 
Mean percentage (SD) 
Physical quality of life 62 (24) 66 (23) 
Emotional quality of life 62 (28) 61 (30) 
Social quality of life 81 (16) 78 (13) 
Total quality of life 65 (21) 67 (21) 
Table 3.11 Showing the mean and standard deviations of the percentage scores of the MLHFQ pre and post 
intervention at early follow up. Scores were devided into physical, emotional and social categories and an 
overall score calculated. 
 
One-way ANOVA testing with Holm-Sidak’s multiple comparisons found no significant difference 
between the domains of quality life or the total quality of life score pre- and post- intervention. The 
results are illustrated in figure 3.20. 
 








































Figure 3.20 The percentage score in the Minnesota ‘living with heart failure’ questionnaire pre-
procedure and during the early follow-up period.  
 
 
3.4.2.2.  WHOQOL  
 
WHO QoL BREF questionnaires were completed prior to and after intervention at the same time as 
the Minnesota living with heart failure questionnaires. The transformed scores are presented out of 
100 ,for the four standard domains. The average total score is also presented. 






Mean (SD)  
Post-intervention 
Mean (SD) 
Physical domain 46 (17) 51 (9) 
Psychological domain 58 (12) 51 (10) 
Social domain 64 (16) 66 (16) 
Environmental domain 71 (12) 70 (14) 
Total quality of life 60 (11) 60 (11) 
Table 3.12 Showing scores out of 100 from the WHOQOL-BREF questionnaire for the cohort. Results 
are divided into the four standard domains with an overall quality of life score stated. 
 
There was no significant change evident following intervention using one-way ANOVA analysis. The 












































Figure 3.21 Bar chart illustrating the change of quality of life scores pre-intervention and during early 
follow-up. The difference in the means for physical, psychological, social, environmental and total 
scores are shown with the standard deviations indicated. 




3.5.  Diagnostic capability of 4D flow MRI  
 
Eighteen patients had adequate 4D flow data available for analysis. 4D flow derived peak gradient, 
EOA and LV blood flow kinetic energy assessment were calculated using methodology described in 
section 2.2.3. These were compared with the NYHA class and six-minute walk test distance achieved 
along with the standard transthoracic echocardiographic, and for some cases invasive, pressure 
measurements. The results of this sub-study are presented below. Table 3.13 details the 
demographics of the patients included in this analysis. 
 









 Median±IQR Median±IQR Median±IQR P value 
Age (years) 74±16 82±11 68±8 0.01 
Gender (Female) 14 (77.77%) 8 (100%) 6 (60%) 0.05 
BMI (kg/m²) 27.7±7.55 23.35±9.75 28.1±4.4 0.32 
Systolic BP (mmHg) 152±18.25 150.5±14 156.5±25 0.63 
Diastolic BP 
(mmHg) 
75±15 70.5±15 76±14 0.45 
HR (bpm) 64.55±10.8 63.2±11 64.85±11 0.94 
IHD 1 (5.55%) 1 (12.50%) 0 (0%) 0.26 
DM 4 (22.22%) 2 (25%) 2 (20%) 0.81 
Hypertension  12 (66.66%) 7 (87.50%) 5 (50%) 0.10 
TTE mG (mmHg) 36±9 40±11 32±8 0.12 
TTE PG (mmHg) 70.07±22.68 76±27.5 64±11 0.22 
6MWT (m) 357.5±103 318±96.5 409±182 0.02 
NYHA 2±0 2±1 2±0 0.46 
Table 3.13 Patient demographics. For all continuous variables, P-value was calculated using a Mann-








3.5.1.  4D flow pressure gradient and effective orifice area assessment 
 
3.5.1.1.  Invasive pressure gradient validation 
  
Across the whole cohort, 11 invasive catheter datasets were available for evaluation, 
including three measured post-intervention. The peak pressure gradients obtained from 4D 
flow CMR was comparable to the invasive pressure gradients (54±26mmHG vs 50±34mmHg, 
P=0.67). In contrast, for the 13 cases with concomitant Doppler TTE and invasive studies, the 
Doppler TTE significantly overestimated the pressure gradient across the aortic valve 
((61±32mmHG vs 50±34mmHg, P=0.0002) (figure 3.22). In addition, there was significant 
bias (-18.6mmHg, P<0.01) when compared with catheter measurement (figure 3.23). Both 
Doppler TTE- and 4D flow CMR- derived pressure gradients demonstrated association to the 
corresponding invasive assessment (r=0.95, P<0.01; r=0.63, P=0.04). Using a cut-off of 
64mmHg peak pressure gradient for defining severe AS, invasive assessment was in better 
agreement with 4D flow CMR (weighted Kappa = 0.25, 95% CI -0.39 to 0.89) than with 
Doppler TTE (weighted Kappa = 0.16, 95% CI -0.16 to 0.47).  
 
 





Figure 3.22 Histogram demonstrating the mean-plots of the peak pressure gradient across the aortic 




Figure 3.23 Bland-Altman plots for pressure gradients by 4D flow CMR and Doppler TTE against 
invasive study. 
 
3.5.1.2.  EOA validation 
 
Both 4D flow- and Doppler TTE- derived EOAs were comparable (1.1±0.5cm2 versus 1.2±0.4cm2, 
P=0.10, bias=-0.11, P=0.10) (figure 3.24). In addition, the 4D flow-derived EOA demonstrated a good 
correlation with Doppler TTE-derived EOA (figure 3.25) for both pre-/post- valve intervention cases. 





Figure 3.24 Histogram and Bland-Altman plots for EOA for TTE and 4D flow methods. 
 
 
Association with six-minute walk test 
There was a significant negative correlation between the 6MWT and the 4D flow CMR- derived peak 
pressure gradient (r=-0.45, P=0.01), the 6MWT was also significantly associated with the 4D flow 
CMR- derived EOA (r=0.54, P=0.002). However, the Doppler TTE- derived peak pressure gradient and 
EOA did not demonstrate any significant association with the 6MWT. The 4D flow derived EOA 
showed good correlation with the 6MWT (0.54, P=0.01) as demonstrated in figure 3.25. 
 
Association with NYHA functional status  
Doppler TTE and 4D flow pressure gradients were found to have a significant positive correlation 
with NYHA classification (r=0.74, P<0.001; r=0.56, P=0.001 respectively). TTE and 4D flow EOAs were 









 NYHA  6MWT 
 R* P-value  R* P=value 
6MWT (m) -0.099 0.60    
CMR parameters 
LVEDV (mL) 0.15 0.45  0.36 0.05 
LVESV (mL) 0.13 0.52  0.24 0.19 
LV mass (g) 0.33 0.08  0.13 0.49 
LV SV (mL) 0.14 0.46  0.36 0.05 
MR EF (%) -0.10 0.60  -0.23 0.22 
 
Peak PGTTE (mmHg) 0.74 <0.01  -0.26 0.16 
EOATTE (cm2) -0.74 <0.01  0.45 0.02 
 
Peak PG4Dflow (mmHg) 0.56 <0.01  -0.45 0.02 
EOA4Dflow (cm2) -0.51 <0.01  0.54 <0.01 
Table 3.14 Shows correlations between standard CMR and TTE parameters and 4D flow derived peak gradient 
and EOA with 6MWT and NYHA class. *Spearman's rho correlation coefficient 
 
 
Figure 3.25 Correlation matrix summarising the association between the 6MWT distance walked with 
the severity of stenosis assessed by TTE and 4D flow CMR- derived PG and EOA. 6MWT distance 
correlates with 4D derived pressure gradient and effective orifice area pre- and post- intervention. 
Both TTE and 4D flow CMR measurements demonstrate correlation to each other. 
 




Association with relative LV mass change  
There was a statistically significant correlation between the relative mass change and the 4D flow 
pressure gradient change following intervention (r= 0.64, p= 0.04), whilst no significant relation with 
other imaging parameters was found (see table 3.15). 
 
 R* P-value 
LV EF (%) 0.27 0.40 
Peak PG4Dflow (mmHg) 0.64 0.04 
EOA4Dflow (cm2) 0.25 0.45 
Peak PGTTE (mmHg) 0.56 0.06 
EOATTE (cm2) -0.08 0.79 
Table 3.15 Association of relative LV mass change to relative change in other imaging markers 
pre/post aortic valve intervention. The relative pressure gradient change pre/post valvular 
intervention, determined by 4D flow CMR correlated with the relative change of LV mass. 
*Spearman's rho correlation coefficient  
 
3.5.2.  Left ventricular blood flow kinetic energy assessment 
 
Table 3.16 provides a full summary of LV KE parameters indexed to end diastolic volume before and 














LV blood flow kinetic energy assessment 




 Relative change 
(%) 
P-Value 
Average KEiEDV (μJ/ml) 12.0±3.4  11.2±4.6  -8.21±24.62 0.52 
Average systolic KEiEDV 
(μJ/ml) 
10.3±3.8  11.8±5.0  -1.41±49.48 0.85 
Average diastolic 
KEiEDV (μJ/ml) 
12.5±2.9  11.8±6.3  -15.05±44.21 0.27 
Peak E-wave KEiEDV 
(μJ/ml) 
23.9±22.1  21.6±10.0   -2.40±62.61 0.38 
Peak A-wave KEiEDV 
(μJ/ml) 
17.0±19.2  18.1±13.6  3.70±74.78 0.91 
TD for peak E-wave 
(Base→Mid) (ms) 
14±48  2.5±9.75  -54.10±91.67 0.04 
Direct KE (μJ) 4.91±5.07  1.86±1.72  0.50±0.45 0.01 
Delayed KE (μJ) 2.46±3.13  1.38±1.15  0.45±0.61 0.03 
Retained KE (μJ) 1.07±0.79  0.91±0.94  0.145±0.90 0.859 
Residual KE (μJ) 0.84±1.38  0.98±0.81  -0.08±1.36 0.790 
Quantitative and qualitative Functional assessment 
6MWT (m) 390±130  405.5±195.5  3.78±22.61 0.83 
NYHA 2±0  1±0  -50.0±16.67 0.00 
Table 3.16 Paired comparison of pre- and post-operative changes in cardiac haemodynamics, imaging 
parameters and functional parameters at 3-months (n=12). *Wilcoxon test (paired samples).; KE, kinetic 
energy; KEiEDV, kinetic energy indexed for LV end-diastolic volume; LV, NYHA, New York Heart Association 
classification; PG, pressure gradient; TD, time delay; TTE, transthoracic echocardiogram; 6MWT, 6-minute walk 
test. 
 
After intervention, there was no significant change in the values of average LV KEiEDV (12.0 ± 3.4 vs 
11.2 ± 4.6 μJ /mL), average systolic LV KEiEDV (10.3 ± 3.8 vs 11.8 ± 5.0 μJ /mL), and average diastolic 
LV KEiEDV (12.5 ± 2.9 vs 11.8 ± 6.3 μJ /mL), (P=0.52, P=0.85, P=0.27 respectively). Furthermore, there 
were no significant changes in the early and late diastolic (E and A waves) peaks (P=0.38, P=0.91 
respectively). The relative drop in mitral flow KE parameters (from base to mid-ventricle and from 
mid-ventricle to apex) were also not significant (P=0.27, P=0.15).  




Early diastolic time delay (TD) 
The delayed time for the travel of the blood from the base to mid-ventricle during the early diastolic 
phase (TD) decreased significantly after the valve procedure (14 ± 48 vs 2.5 ± 9.75 msec, P=0.04) 
(Table 3.16). Figure 3.26 shows the change of TD and some CMR functional parameters before and 
after the intervention for all the patients. 
 
Flow components analysis 
The calculated volumes of LV inflow and outflow were well matched (41.76 + 17.69 vs 42.11 + 18.07 
ml, p=0.59. The KE of both direct flow and delayed flow was reduced significantly after the 
intervention (p=0.01, p=0.04 respectively) (Figure 3.26), whereas no significant changes were found 
for the LV KE of the other two components (Table 3.16). 
 
Association with 6MWT 
There was a significant negative correlation between the 6MWT and the average LV KEiEDV (r=-0.53, 
p=0.003), average diastolic KEiEDV (r=-0.53, p=0.003), and peak E-wave KEiEDV (r=-0.38, p=0.04). 




Figure 3.26 Scatter-matrix demonstrating data distribution for the 6MWT and its association with LV 








Table 3.17 shows how standard CMR metrics and LV blood flow KE parameters correlate with 
qualitative and quantitative functional data 
 
 NYHA  6MWT 
 R* P  R* P 
CMR parameters 
LVEDV (mL) 0.15 0.45  0.36 0.05 
LVESV (mL) 0.13 0.52  0.24 0.19 
LV mass (g) 0.33 0.08  0.13 0.49 
LV SV (mL) 0.14 0.46  0.36 0.05 
LV EF (%) -0.10 0.60  -0.23 0.22 
Left ventricular kinetic energy assessment 
Average KEiEDV (μJ/ml) 0.05 0.82  -0.53 <0.01 
Average systolic KEiEDV (μJ/ml) -0.07 0.71  -0.31 0.09 
Average diastolic KEiEDV (μJ/ml) 0.06 0.77  -0.53 <0.01 
Peak E-wave KEiEDV (μJ/ml) 0.15 0.44  -0.38 0.04 
Peak A-wave KEiEDV (μJ/ml) -0.22 0.25  -0.20 0.29 
TD for peak E-wave (Base→Mid) (ms) 0.21 0.28  0.02 0.94 
The kinetic energy of LV blood flow components 
Direct flow KE (μJ) 0.25 0.23  -0.02 0.94 
Delayed flow KE (μJ) 0.17 0.42  -0.09 0.64 
Residual flow KE (μJ) 0.01 0.96  0.06 0.77 
Retained flow KE (μJ) -0.35 0.09  -0.16 0.43 
Table 3.17 Correlation of both qualitative (NYHA functional class) and quantitative (6MWT) physical 
endurance to all haemodynamic and CMR imaging parameters. BP, blood pressure; HR, heart rate; 
KE, kinetic energy; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVESV, left 
ventricular end-systolic volume; SV, stroke volume; EF, ejection fraction; NYHA, New York Heart 
Association classification; TD, time delay; 6MWT, 6-minute walk test. 
 
The 6MWT did not correlate with the KE of the four blood flow components. There was a positive 
correlation between the 6MWT and both LVEDV and SV (r=0.36, p=0.05; r=0.36, p=0.05 




respectively). However, the LVESV, LV mass, and EF did not show any significant correlation with the 
6MWT (p=0.18, p=0.49, p=0.22, respectively)  
 
Association with NYHA classification 
There was no significant association between the imaging parameters and the patient’s symptoms 
assessed by NYHA classification (table 3.17). 
 
Association with LV remodelling 
From the LV KE parameters, only the preoperative average KEiEDV showed a significant correlation 
with the absolute change in LV mass post-operatively (p=0.02) (table 3.18). 
Pre-operative CMR metrics Absolute change in LV mass post-operatively 
 R* P 
Routine assessment 
LV EF (%) 0.36 0.25 
Mean TTE PG (mmHg) 0.11 0.73 
LV blood flow kinetic energy 
Average KEiEDV 0.67 0.02 
Average systolic KEiEDV 0.5 0.1 
Average diastolic KEiEDV 0.22 0.5 
Peak E-wave KEiEDV 0.56 0.06 
Peak A-wave KEiEDV 0.03 0.93 
TD for peak E-wave 
(Base→Mid) 
-0.53 0.07 
The kinetic energy of LV blood flow components 
Direct flow KE -0.26 0.43 
Delayed flow KE -0.44 0.18 
Retained flow KE -0.23 0.5 
Residual flow KE 0.07 0.83 
*Spearman's rho correlation coefficient   
Table 3.18 Correlation of LV mass change pre/post aortic valve replacement to imaging parameters. 
KE, kinetic energy; LV, left ventricular; EF, ejection fraction; PG, pressure gradient; NYHA, New York Heart 
Association classification; TD, time delay; TTE, transthoracic echocardiogram. 
 




Preoperative routine assessment (LV EF and mean TTE PG) did not show any significant changes with 
LV remodelling postoperatively (p=0.25, p=0.73 respectively) (figure 3.27). 
 
Figure 3.27 Scatter matrix demonstrating an association of LV remodelling post SAVR/TAVI is associated with 
pre-intervention LV blood flow KE (LVKEiEDV) only and not with other standard parameters such as LV EF or AV 
mean pressure gradient. 
 
 
3.6.  Computational modelling 
 
All 22 patients were successfully processed through modelling protocols. The following section 
describes the results of both analysis of components of the model and the resultant haemodynamic 
parameters derived from the modelling process. 
 




3.6.1.  Elastance model comparison 
 
Two LV elastance models were investigated, namely; the Shi double-cosine model and the double 
Hill formulations. For the latter formulation three sets of constants were studied, the Mynard and 
Seemann constants from the literature and personalised constants based on optimisation to match 
measured volume profiles. The differences in the elastance curves for one case are illustrated in 
figure 3.28, together with the measured elastance curve in the same patient. 
 
 
Figure 3.28 Elastance model comparison. This graph shows curves for the four different elastance 
models examined in the same patient compared to the measured data (yellow). 
 
This shows that the Shi cosine elastance model and the double-Hill model with Seemann constants 
model give a different shaped curve to the measured data, particularly early in the contraction 
phase. The double cosine model has a delay before the contraction starts strongly and, in contrast, 




the double Hill model with Seemann constants increases quickly but has a relatively flat plateau 
around the period of maximal elastance. The double-Hill elastance model with Mynard constants 
and customised constants produce very similar shapes. The upslope of the curve in both are similar 
to the measured data. The timing of the peak elastance is later in both models compared to the 
measured data, resulting in a slightly steeper downslope. This pattern was observed for the majority 
of patients. 
 
3.7.  Comparison of model protocols 
 
All cases were processed with protocols 1-3. Parameters which describe LV haemodynamic 
properties and may have diagnostic and prognostic utility were calculated. These are listed in table 
3.19. The mean and standard deviations are stated, as is the overall difference between the groups 
and inter-group differences. Normality was tested using the Shapiro-Wilk test. A Freidman analysis 
with Dunn’s multiple comparison test was performed in cases of non-parametric data. One-way 
ANOVA with Holm-Sidak’s multiple comparisons were used for parametric data. 
 
 
Table 3.19 Haemodynamic parameters produced from protocols 1-3 in all 22 patients and from 
measured data available in 9 patients. # J/beat, *Watts, LV= Left ventricle. Superscript letters denote 
the different protocols from which the data is calculated, where used within the main body of the 






Protocol 2 (OD 
no time series 
data)b 
Mean (SD) 
Protocol 3 (OD 








Stroke work#  1.41 (0.36) b,c 1.48 (0.40) a 1.49 (0.40) a 1.34 (0.54) 0.03 
Wasted work#  0.53 (0.34) c 0.55 (0.36) c 0.59 (0.37) a,b 0.63 (0.31) <0.01 
Peak power* 17.56 (8.37)  14.19 (4.61)  14.34 (4.02)  14.99 (6.49)  0.11 
Stroke Power*  1.56 (0.46) b,c 1.64 (0.50) a 1.64 (0.50) a 1.69 (0.70) <0.01 
Wasted Power* 0.56 (0.33) c,d 0.59 (0.35) c 0.63 (0.35) a,b 0.80 (0.41) a <0.01 





2.22 (0.66) a,c 2.27 (0.68) a,b 2.49 (0.85) a <0.01 
Maximum elastance¥ 4.23 (2.17) 4.39 (2.57) 4.42 (2.56) 3.78 (1.43) 0.13 
Minimum LV elastance¥  0.16 (0.1) b,c 0.18 (0.12) a 0.18 (0.12) a,d 0.17 (0.13) c <0.01 




There was no significant difference between the results obtained using the four different methods 
used to derive maximum LV elastance (ELVmax). For the key parameter of stroke work there was no 
significant difference between any of the protocols and the value derived from the measured data. 
Wasted work (the area of the triangular segment between the isovolumetric relaxation portion of 
the PV loop and the point indicating the LV volume under zero pressure) was significantly less when 
assessed using protocol 1 compared to using protocols 2 and 3, but the absolute percentage 
difference in the means is less than 10% and, since wasted work is typically of the order of one third 
of total ventricular work, these differences are unlikely to be significant in terms of diagnostic utility. 
  
Stroke power and wasted power are calculated by dividing stroke work and wasted work, by the 
length of the of the cardiac cycle. Power and work parameters will show the same relation unless 
the heart rate used for the computations is different. For the modelled protocols the rest state was 
extrapolated from the heart rate obtained by the Philips Health watch. Stroke power was similar 
when calculated using the 0D model and the measured data but there was a tendency of protocol 1 
to underestimate this parameter. Although there was a difference in the value produced for wasted 
power from protocols 2 and 3, both were broadly comparable to the values from the measured data.  
 
The results obtained for peak LV power were similar using all four protocols and also similar to the 
measured data. LV power can also be assessed over the cardiac cycle using the measured data (see 
figure 3.29, for an illustrative case). The PV loops in figure 3.29 indicate, for all the protocols 
assessed, that peak LV power occurs in the early ejection phase just after the valve opens (red, 
yellow and green data points), this is consistent with the measured data. 
 









Figure 3.29 Left: PV loops produced in one patient using different protocols and measured data. Peak 
LV power occurs early in the ejection phase in all loops indicated by the red, yellow and green 
markers. Right: Indicates that LV power follows a relatively smooth curve over the cardiac cycle, the 
0D models produce a curve to the measured data with the peak occurring earlier, capturing the 
ejection period. 
 
Stroke power was similar when calculated using the 0D model and the measured data. There was a 
tendency of the ‘no model’ protocol to underestimate this parameter. Wasted power, calculated 
using protocols 2 and 3 was comparable to the values derived the measured data. When calculated 
using protocol 1 the value of wasted power was significantly different from that of the measured 
data. Total myocardial work was significantly lower when calculated using the ‘no model’ protocol. 
Total myocardial power was also significantly underestimated using protocol 1; and there was also a 
difference between protocols 2 and 3, but no significant difference with either when compared to 
the value from the measured PV loop. 
 
In summary, all methods used to derive maximum elastance gave similar results. Assessment of 
stroke work, wasted work and peak power could be performed using any of the three protocols with 
confidence, as assessed against the measured data. The maximum significant mean difference in 
stroke work and wasted work between protocols were 0.08 (p<0.05) and 0.06 (p<0.05) Joules per 
beat, respectively. There was a tendency to underestimate stroke power and wasted power using 




protocols 1-3, and protocols 2 or 3 were preferable, because there was no significant difference 
between the values produced by these and the measured data. All of the protocols successfully 
calculated total myocardial work, but protocol 1 was inaccurate in calculating total myocardial 
power. 
 
Upon review of the model results presented here, protocol 2 produced the most similar results to 
the measured data for all parameters. The accuracy of protocol 2 was assessed further by calculating 
the residual errors in achieving the target clinically measured parameters, following an optimisation 
process. The residual errors were very small, increasing the confidence in the model. The average 
residual errors when converging on the target values were as follows: LVEDV (0.5%), LVESV (0.3%), 
LVEDP (0.03%), diastolic BP (0.1%) MAP (0.02%) PG (0.02%). For these reasons, and with reference 
to the computing power and time needed to tune the model to the time-series volume in protocol 3, 
protocol 2 was selected as the standard protocol for predictive simulation. Protocol 1 could not be 
used for this purpose. For consistency, protocol 2 was also used for comparison with activity data to 
investigate modelling for diagnostic purposes and correlation with activity metrics. 
 
3.8.  Protocol 4 
 
Protocol 4 was not performed in all cases used due to problems with image acquisition and 
inaccurate segmentation. The processes of this protocol are illustrated in this section in a case where 










3.8.1.  Segmentation process 
 
The Philips automated segmentation process was used to provide a mesh of the regions of interest 
from which the CFD model could be run. This was successful in 50% of cases. The results for one case 
are illustrated in figure 3.31. 
 
 















Figure 3.30 Illustrating the results of the automated segmentation process for one of the patients in 
the study. a) A slice from a cardiac CT obtained with structures identified through the segmentation 
process. b) The mesh created of the left ventricle (LVOT used in CFD simulation), aortic valve and 
proximal aorta. c) The aortic root and valve orifice produced in the same patient viewed from two 
different angles. 
 
3D clinical images, in this case from cardiac CT, were de-identified and supplied to Philips. Aortic 
valve parameters could be extracted. These were then used to run the CFD simulation to obtain the 
pressure flow relationship through the patient’s valve and provide the valve coefficient, used as an 










3.8.2. CFD simulation results  
 
A screenshot illustrating velocity and pressure fields from one of the CFD analyses used to 




Figure 3.31 Screenshot from the CFD analysis of aortic valve flow for the example case. 
 
Simulations were run at four different flow rates and the results fitted with a quadratic curve 
resulting in the pressure flow relationship for that patient (see figure 3.33). 
 





Figure 3.32 The resulting pressure flow relationship with a quadratic curve fitted to the results. 
 
These data were used along with the other input parameters required to execute the 0D model. 
Based upon a quadratic fit to the pressure-drop as a function of flow rate yielded by the CFD 
analyses, the relationship between pressure and flow was characterised as:  
Δ𝑝=𝑎1𝑄+𝑎2𝑄2  
 
Where 𝑎1= 0.00074 mmHg.s/ml∶ 𝑎2= 0.02101 mmHg.s2/ml2  
 
These parameters represented part of the augmented data for this patient. Both the values and the 
ratios of these coefficients provided information on the nature of the flow and the effective orifice 
area was also be derived from these coefficients.  
 
The coefficients were used as an input parameter to the 0D model and the cardiac and systemic 
parameters were personalised by the optimisation process in MATLAB. This resulted in the patient-
specific parameters listed in table 3.20.  











Table 3.20 Showing the personalised parameters that resulted from the CFD simulations and 




Figure 3.33 Screenshot of the execution of the 0D model in MATLAB for this case while protocol 4 was 
processed. 
 
The pressures and volumes were tuned to target values. Figure 3.34 shows graphically how well the 
tuned results matched the target values using equal weighting when tuning for both left ventricular 
pressure and volume. The dashed line shows the results after the model was tuned with the 
available measured patient data. There was a close fit generated by the model for both pressure and 
Heart 











volume [ml]  
0.73  3.74  1.50  1.26  215.90  




volume. The shapes of the waveforms are similar. The main differences were the higher end-
diastolic and lower end systolic LV volume in the tuned data. These were required to enable the 
pressure waveform to be reproduced. 
 
 
Figure 3.34 Graphs showing modelled data (tuned) to measured data for pressures (left) and volumes 
(right) over one cardiac cycle. 





Figure 3.35 Shows the measured PV loop and modelled PV loop produced by protocol 4 in the pre-
intervention state. 
 
Results from the 11 processed cases are presented in table 3.21. 
 
Table 3.21 The haemodynamic parameters produced by protocol 4 for the 11 patients for which 
processing was possible. 
Case Stroke work 
(Joules/beat) 











SA02 2.53 2.19 14.37 0.10 1.94 
SA06 2.12 2.44 18.69 0.14 5.68 
SA03 2.10 3.23 11.60 0.09 3.01 
SA14 1.02 1.56 10.92 0.30 10.07 
SA13 1.57 1.81 15.79 0.17 8.65 
SA11 1.48 1.93 11.81 0.19 4.52 
SA19 1.23 1.23 10.43 0.18 1.64 
SA12 1.33 1.56 9.33 0.12 1.96 
SA05 1.71 1.88 13.60 0.04 2.01 
SA20 1.77 1.77 10.60 0.12 1.50 
SA08 1.30 1.63 8.64 0.19 3.87 





Data produced from Protocol 4 were compared with the results of these parameters available from 
the measured data, and a two tailed paired t-test was performed. The means, standard deviations 













1.65 (0.45) 1.72 (0.34) 0.54 
Stroke power (Watts) 1.93 (0.54) 2.14 (0.55) 0.93 
LV peak power 12.34 (3.00) 15.01 (4.38) 0.42 
Minimum elastance 0.15 (0.07) 0.13 (0.07) 0.62 
Maximum elastance 4.08 (2.94) 4.52 (1.34) 0.52 
Table 3.22 Displaying the haemodynamic parameters produced by protocol 4 compared with the 
measured data where this was available. P value calculated using a two-tailed paired t-test. 
 
There was no significant difference in any metric when the modelled data was compared to the data 
derived from invasive measurement of pressure and volume assessment from MRI in this sample. 
Due to the limited number of patients that had invasive data for comparison, further validation was 
sought by comparing the measured pressure gradient using transthoracic echocardiography with the 
gradient produced by the model in protocol 4. This parameter was used for validation because it was 
not used as an input in this protocol. 
 





Figure 3.36 Graph showing the model derived aortic valve gradients using protocol 4 and the 
measured gradient from transthoracic echocardiography for each patient with appropriate images 
for segmentation from either CT (red) or TOE (blue). The dashed orange line shows where the points 
would lie if the measurements were identical. 
 
The model and measured data were in good agreement, with a significant positive Pearson 
correlation coefficient of 0.8 (p=0.003) and R2 0.64. The Bland Altman plot below shows that one 

















Figure 3.37 Bland-Altman plot showing the relationship between the measured gradients by 
transthoracic echocardiography and the computed gradients. 




3.9.   Diagnostic utility 
 
Image-based modelling (protocol 4) may be used to assess the gradient across the valve as shown 
above. As discussed in section 1.3, AS is a systemic disease and plays only one part in the loading of 
the left ventricle that results in a patient’s symptoms. The parameters produced by the model may 
correlate better with patient symptoms. This hypothesis was tested by first comparing the disease 
severity in terms of aortic stenotic gradients with activity metrics, and then by comparing the model 
parameters with these same activity metrics.  
 
3.9.1.  Association of standard clinical parameters with activity measures 
 
Peak pressure gradient 
Peak gradient was negatively correlated with 6MWT distance achieved (r= -0.61, p= 0.004) but not 
with any other activity metric, degree of symptoms, LV ejection fraction or LV mass. 
 
Mean pressure gradient 
Mean gradient was negatively correlated with the 6MWT distance achieved (r=-0.52, p=0.02) but not 
with any other activity metric, degree of symptoms, LV ejection fraction or LV mass. 
 
Effective orifice area 
EOA showed a weak, but significant, correlation with 6MWT distance (r=0.57, p=0.01). It was also 
weakly correlated with total energy expenditure (r=0.61, p=0.02). It did not correlate with any other 










Ejection fraction was negatively correlated with the amount of time spent sleeping and the cardiac 
efficiency slope (r=-0.65, p=0.01 and r=-0.56, p= 0.04 respectively). There was no correlation with 
any other activity metrics, or the patient reported symptoms. 
 
LV mass 
There was no association with any activity metrics or LV ejection fraction. 
 
3.9.2. Modelling as a diagnostic tool 
 
Because AS is a systemic disease, it is difficult to assess severity purely by examining the anatomy 
and using standard imaging methods. However, one can expect that the more severe the disease 
and the effects on the patient’s physiology, the more limiting it is in terms of functional capacity. 
This is akin to the argument of anatomical vs functional severity of coronary artery disease. The 
following model-derived parameters take into account the total physiological burden of AS. 
 
ELVmin 
A significant and strong negative correlation was identified between ELVmin and the total energy 
expenditure of the patients measured by the Philips health watch (r=-0.73, p=0.002). This also 
correlated with LV mass (r=0.74, p=0.001) and step count (r=-0.62, p=0.003). A negative correlation 
with the six-minute walk distance achieved was seen (r=-0.62, p=0.002). 
 
ELVmax 
There was a strong negative correlation with LV mass (r=-0.84, p=0.0002) and step count (r=0.58 
p=0.03). Although there was correlation with ejection fraction (r=0.77, p=0.0001), there was no 
correlation with between measured EF and any activity metric. 
 





LV work was significantly associated with LV mass (r=0.59, p=0.006), the total energy expenditure of 
the patient (r=0.76, p=0.001) and the six-minute walk test distance achieved (r=0.58, p=0.006). 
 
LV peak power 
A significant positive correlation was found with both step count (r=0.66, p=0.007) and total energy 
expenditure (r=0.61, p=0.002). There was no correlation with LV mass. 
 
Wasted energy 
A strong correlation with LV mass was found (r=0.79, p=0.0002). There was no association with any 
activity metrics. 
 
3.9.3.  Assessment of left ventricular failure  
 
ELVmax, which may be a better assessment of the global contractile function of the LV than ejection 
fraction (see section 1.11.8), exhibited a correlation with ejection fraction in this cohort (r=0.77 
p=0.05). In healthy men and women, in the resting state, reported values of ELVmax are 2.3 ± 1.0 
mmHg/ml [194], [215]. Within this range, only 33% had a normal ejection fraction. In adapting to AS, 
the normal response is for the contractility (ELVmax) to increase in patients with preserved ejection 
fraction, which was found in 75% of the cohort. Four patients had modelled elastance greater than 
twice the upper limit of normal, indicating that these ventricles were well adapted, continuing to 
function effectively in the presence of increased load. These data are illustrated in figure 3.39. 
 





Figure 3.38. Graph illustrating the relationship between ejection fraction and ELVmax. Shaded areas 
represent low ELVmax (dark red), normal range of ELVmax (light red), up to 2 times the upper limit of 
normal of ELVMax(orange), above 2 times upper limit of normal (green). Falling ELVmax may 
represent LV failure, Rising ELVmax may represent normal adaptation to AS. 
 
The following observations were made on the outcomes after intervention in the context of the 
measured ejection fraction and computed ELVmax prior to intervention. First, in patients with 
reduced ejection fraction with either normal or low ELVmax, ejection fraction improved in only three 
out of eight patients. It returned to the normal range in only one patient. Second, one patient had 
elevated ELVmax but a reduced ejection fraction, and following aortic valve replacement the 
ejection fraction rose from 41% to 81%.  
 
3.9.4.  Modelling as a predictive tool 
 
The model can be used to: predict the reduction in valve gradient post-intervention; ‘measure’ 
cardiac work and power characteristics in the rest state, based upon personalisation of model 
parameter; predict quantitative changes in these cardiac energetic parameters under exercise 
Normal adaption to aortic stenosis 
Indication of LV failure 




conditions pre-intervention and under both rest and exercise conditions post-intervention; and infer, 
from the changes in cardiac energetics’ the degree to which activity might be increased if left 
ventricular work were to be maintained. 
 
3.9.4.1.  Illustrative results for one case 
 
For this individual, the measured peak and mean AV pressure gradients at rest pre-intervention were 
89mmHg and 62 mmHg, and post-intervention they were reduced to 10 mmHg and 5 mmHg, 
respectively. The model predictions for this case, post-intervention, were 11 mmHg and 4 mmHg. 
Figure 3.40 shows modelled PV loops for this patient, at rest and in an exercise state, both pre- and 
post-intervention. 





Figure 3.39 A patient in this study with PV loops in the rest, exercise pre and post intervention with 
characteristic changes in the PV loop seen. 
 
The loops show the changes. Following intervention there is a slight increase in cardiac output and a 
reduction in LV pressures (the loop moves down and to the left). During exercise there is an increase 
in cardiac output, but the LV pressures required to generate this are significantly higher. Following 
intervention, during exercise, there would therefore be expected to be a significant improvement in 
cardiac output without the large rise in LV pressures seen prior to intervention. For this patient the 
model predicts that, under a specified candidate valve replacement: the work done by the left 
ventricle would reduce by 18%; the peak power would reduce by 7%; the wasted energy that does 




not produce cardiac output would reduce by 8%; and alternatively, if the left ventricular work were 
to remain at the same level as pre-intervention, activity (measured by the MET parameter) could 
increase by 34%. 
 
The underpinning hypothesis, is that there is a correlation between improved cardiac energetics, 
(and the related potential to use it more effectively, rather than waste it in pumping past a diseased 
valve) and measured activity following recovery from the intervention. Data against which this 
hypothesis can be tested is presented in the following section.  
 
3.9.4.2.  Prediction of post intervention gradient and activity for the cohort 
 
Figure 3.41 shows the comparison between model-predicted, post-interventional gradient with 
catheter measurements. The model-predicted, post intervention, peak gradient correlated well with 
the measured peak gradient and was significant (r= 0.68 p=0.001). The coefficient of determination 
was 0.5. 
 





Figure 3.40 Graph showing the correlation between the measured and predicted peak gradients 
following valve replacement. 
 
 
It is expected that a patient has a mild residual stenosis following valve replacement. Using a 
threshold of 20mmHg for a peak gradient post intervention, indicated by the bold horizontal and 
vertical lines in the figure, the model has a sensitivity and specificity of 89% and 83% respectively. In 
predicting a gradient below 20mmHg the model has a 92% negative predictive value. A Bland-Altman 
plot (figure 3.42) shows reasonable agreement between the measured and predicted post- 
intervention peak gradient with a bias of 2mmHg. 
 



















Figure 3.41 Bland-Altman plot showing the agreement between the measured and model residual 
peak gradient following valve replacement. There was a systematic bias of 2mmHg with a standard 
deviation of 10.9. 
 
The predicted exercise by metabolic equivalents and measured metabolic equivalents achieved 
following intervention, derived from the 6MWT distance achieved, were correlated with a 
coefficient of variation of 0.7, as illustrated in figure 3.43. 
 
Figure 3.42 Graph illustrating the correlation between the measured exercise capacity in metabolic 
equivalents (METs) measured post valve replacement with the exercise capacity predicted by the 
model. 
 




There was a good agreement between the measured and predicted MET values for a patient after 
intervention. The model had a bias of 0.5 METs but tends to over predict the MET achieved post 
intervention.  
 


















Figure 3.43 Bland-Altman plot showing the agreement between the measured and model predicted 
exercise capacity. There is a systematic bias of 0.5 METs with a standard deviation of 0.4 with model 
overestimating exercise capacity. 
 
3.10.   Evaluation of clinical support system 
 
Modelled haemodynamic data and activity data produced in this thesis were used to augment 
standard clinical data, guidelines, and risk scores and were presented to clinicians in a clinical 
decision support system along with a case-based reasoning tool (see section 2.7). The objective was 
to investigate whether such data would influence the decision-making process of clinicians. The 
results of this clinical experiment are presented below. 
 
3.10.1.  Demographics of participants 
 
Forty-five clinicians participated. Of these, 18 were based in the UK, 14 in Germany and 13 in the 
Netherlands. 73% of the cohort were cardiologists with an interest in valve disease, 27% were 
cardiothoracic surgeons. Sixty percent had greater than five years’ experience of managing heart 




valve disease. The time taken to review each case with enhanced data was, on average, twenty 
minutes. 
 
3.10.2.  Utility of the clinical decision support tool components 
 









Figure 3.44 Illustrating how useful participants found the activity data, modelling and simulation 
data and interaction with the simulation tool. 
 
 
3.10.3.  Influence on the decision-making process 
 
Case 1 was selected as having borderline indication valve intervention according to 2017 ESC/ EACTS 
guidelines following independent assessment of three clinicians including the author. Table 3.23 




















Interaction with the simulation tool














Timing (evidence to treat or not) -/+ + + 
Severe AS and Symptoms (IB) - + + 
Severe low flow , low gradient (mean<40mmHg) AS 
with reduced EF (IC) 
- - - 
Low flow , low gradient AS with normal EF (IIaC) + (SVi 32 by 
MRI) 
- - 
Symptomatic patients with low flow, low gradient AS 
and reduced EF without contractile reserve, severe AS 
confirmed by calcification (IIa C) 
-* -* -* 
Intervention should not be performed in patients with 
severe comorbidities when the intervention is unlikely 
to improve QOL or survival (III C) 
- - - 
*no confirmation of calcification presented to participants 
Table 3.23 Guideline indication according 2017 ESC/ EACTS guidelines for each aortic valve disease 
case assessed. Judged by experienced clinicians in the study team (Dr Gareth Archer, Dr Marcus Kelm 
and Dr Jo Zelis). 
 
When presented with the standard clinical information, a guideline indication for valve replacement 
was thought to exist by 75% of respondents for case 1, 100% for case 2 and 88% for case 3. When 
presented with enhanced data which included the modelling and activity data, the decisions 
changed. This is illustrated in figure 3.45. 
 
Figure 3.45 Shows the difference in management decision made by clinicians when conventional data 
is supplemented with enhanced data in the experimental group for each of the three cases examined. 






In Case 1, there was a difference between the experimental and control group in terms of 
intervention or not (38.4% vs. 76.5%, respectively; OR: 0.19, 95% CI: 0.03 – 1.18, p=0.035). There 
was a trend towards conservative management in case 2(70% vs. 86%; OR 0.37, 95% CI: 0.11-1.2, p = 
0.06). In sub-group analyses, findings were not affected by the experience level of participants. The 
certainty of decisions made was also improved when enhanced information was given, as shown in 
figure 3.46.  
Figure 3.46 Shows how certainty in decisions made is improved when presented by additional 
information in the clinical decision support software. 
 
 
3.10.4. Clinical need and feedback 
 
Seven percent of clinicians felt that information from standard techniques was always enough to 
make clinical decisions about valve replacement, whereas 69% felt that an advanced prognostic 
(predictive) simulation of the expected outcome, which included the expected exercise tolerance 
after treatment, simulated haemodynamics at rest during exercise following intervention, and the 
best matching device or treatment option, would be helpful. Ninety-six percent felt that advanced 
diagnostic tools such as daily activity and quality of life profile, the energy efficiency of the 
myocardium and the patient specific haemodynamics of the patient under rest and exercise 
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Participants were invited to leave free text comments about the clinical decision support system. 
Overall, it was felt that the clinical decision support system would be a useful addition to the heart 
team, with one participant predicting that it may replace some of the work of the heart team. 
Clinicians indicated that it may increase in certainty in decision making especially in borderline cases 
and asymptomatic cases. Providing an overview of the whole patient by combining anatomical and 
physiological information appears very useful to the majority. Participants liked the concept of 
utilising activity data and modelling data to predict outcome but there was the overwhelming 





















CHAPTER 4  
 
4.  Discussion 
 
This work was designed as a pilot study to investigate whether non-invasive pressure volume loops 
could be created using mathematical and computational models in cases of AS and whether they 
had advantages over standard diagnostic techniques and novel imaging techniques such as 4D flow 
MRI. There was also an exploration of how the functional assessment of these patients, to which 
these techniques were compared, may be undertaken using both standard techniques and novel 
wearable devices. In summary, it was found that mathematical and computational models could be 
produced and may be helpful in the diagnosis of and management of AS, particularly in the timing 
and type of intervention, and the likely impact on the patients haemodynamics. These techniques 
have several advantages over standard clinical measures that do not take into account the global 
haemodynamic burden of this systemic disease and are not predictive. 4D flow MRI examination 
may give more insight to the haemodynamic effects of AS and provide different ways to assess the 
severity of AS. Wearable devices giving insight into a patient’s lifestyle and the effect of the disease 
on the individual monitoring trends in patients may help in identifying when medical intervention is 
needed and help determine the frequency of clinical review. Clinical decisions support systems that 
help present patient-specific data may be helpful to clinicians in the management of AS and can 
influence the decisions made.  
 
4.1.  Study design and patient cohort 
 
 
The number of patients recruited to the study was small; however, this is comparable to similar 
studies[168] and large amounts of clinical, simulated and functional capacity data were obtained for 
each patient. An important tenet of this study was that the model could add value within a routine 




clinical care pathway, in which incomplete data is common. Even within this well-controlled study 
there were a number of patient, procedural, technical and logistical issues which resulted in missing 
data. These are discussed in the relevant sections below, as are the attempts made to mitigate the 
effects. Consequently, although some of the associations investigated reached statistical 
significance, several other trends require larger and appropriately powered clinical studies for 
confirmation or otherwise.  
 
The average age of the cohort, 76, was typical and representative of the demographic present with 
calcific AS. There was a greater proportion of female patients in the study than male (77 vs 23%). 
Thirty-two percent had atrial fibrillation, which is not unexpected in a population that have 
increased pressures in the left side of the heart [217]. The beat to beat variability was not 
represented in the model, but clinical data for model personalisation or validation were averaged 
over five cardiac cycles and an arrhythmia rejection protocol was applied to MRI data to mitigate for 
this problem. Blood pressure in this patient cohort was not well controlled, and this tended to 
further amplify the load on the ventricle beyond that directly attributable to the AS. This may 
account for some of the differences in the associations with activity and positive remodelling and 
underpins the hypothesis that it is the total load on the ventricle that is important.  
 
The TAVI cohort were older, frailer and had more severe disease that the patients undergoing SAVR. 
There were peri-procedural complications in several patients that underwent TAVI. Two patients 
were unable to complete the study due to disabling strokes. Two further patients had femoral access 
complications that required further surgical intervention and affected mobility. One patient had 
osteoarthritis and was unable to attempt the 6MWT. These patients were excluded from the activity 
analysis, which could also have influenced and biased the results. Due to deaths during the study, 
complications and a poor response to the invitation to participate, there was a limited number in the 




extended follow-up group. Although trends could be identified, the small numbers and resultant 
large standard deviations meant that significant differences were difficult to identify. 
 
Despite no known prior contraindications, two patients were not able to undergo MRI pre-
intervention. One was claustrophobic and was unable to complete the scan. One had previous facial 
reconstruction with metal plates and the scan was abandoned. Alternative imaging protocols were 
used so that their other data could be included in the study. LV volumes that were essential for the 
processing of the modelling protocols were obtained by gated cardiac CT in one case, and 3D 
transthoracic echocardiography in the other. This introduced some variability of the assessment of 
LV volumes, which could have affected the results, but the alternative techniques have been 
reported to produce comparable results [218].  
 
4.2.   Imaging 
 
4.2.1. Transthoracic echocardiography 
 
As expected, transthoracic echocardiography showed a significant reduction in peak and mean 
gradients following intervention. The magnitude of the reduction differed depending upon the type 
and size of the valve implanted, the surgical technique and patient size. The gradient also depends 
upon other haemodynamic factors such as heart rate and systemic vascular resistance. These are not 
usually taken into account in routine clinical practice but could be in the modelling process. This 
study highlights that this measure is dependent upon such factors and, ideally, when gradients are 
reported this should take into account both heart rate and loading conditions. 
 
Doppler derived measures are well recognised to overestimate the gradient across the aortic 
valve[38] and this may explain some differences in the measured and the modelled gradients seen. 
None of the transthoracic 3D acquisitions yielded images that could support accurate segmentation 




of the valve anatomy. This was mainly due to poor image resolution and artefacts from calcification 
and arrhythmias. This is important because, ideally, the modelling process should operate with 
routine non-invasive clinical data. This can be the case for protocols 1-3 but, to run an image-based 
protocol such as protocol 4, either more invasive tests such as transoesophageal echocardiography, 
or tests that require ionising radiation such as CT, would be needed.  
 
It is recognised that, as the left ventricle adapts to the increase in afterload due to AS, it 
hypertrophies, and this is associated with reduced myocardial compliance and diastolic dysfunction. 
This was evidenced in this cohort by the pseudo-normalised E/A ratios in the majority of patients 
indicating grade 2 diastolic dysfunction, with significantly elevated E/e’ ratios with an average of 
17.4 (normal range 6.5±3.7)[219] and elevated LVEDP when calculated using the Nagueh formula. 
Following valve replacement, although there is a trend in reduction of E/e’ in the early follow up 
period, this was not significant and still remained abnormal. This differs from a study which found 
that diastolic function was significantly affected in patients with severe AS before surgery but 
returned toward normal early and late after AVR.[220]. My findings are consistent with the study by 
Gjertsson et al which showed that diastolic function was unchanged following intervention despite a 
reduction in LV mass [221]. In that and the present study no attempt was made to control for 
hypertension following surgery which may contribute to persistent diastolic dysfunction. In the 
current study there was no significant difference between the systolic and diastolic blood pressures 
before and after intervention; so it could be the effect of valve replacement that is being observed, 
or perhaps hypertension has a greater influence on diastolic dysfunction than AS. Early follow-up in 
both these studies was two years and the method of assessing diastolic function was different which 
makes it difficult to make comparisons. There is no specific guidance as to how optimally to assess 
diastolic dysfunction following aortic valve replacement. When using tissue Doppler imaging, 
perhaps rather than averaging the septal and lateral velocities as is the norm and has previously 
been suggested following AVR[222], only the velocities at the lateral valve annulus should be used. It 




is likely that the sewing in of the replacement valve would affect the motion of the tissue at the 
septum and therefore the inaccuracies of these measurements could be why there was no 
correlation of diastolic parameters with modelled parameters or exercise capacity. 
 
The Nagueh formula used to calculate LVEDP and used as an input to the modelling process has a 
number of flaws, including the fact that it has not been validated in atrial fibrillation (32% of our 
cohort) or in patients with AS[193]. However, the relationship between E/e’ and LVEDP has been 
extensively studied in the AS population by Dalsgaard et al[223]. There is a clear relationship and 
therefore the method used to estimate LVEDP seems reasonable. The measured and derived LVEDP 
were also consistent (see section 3.3) which again gives confidence in the results.  
 
4.2.2. Transoesophageal echocardiography 
 
This technique can produce accurate data for segmentation (six out of eleven examinations in this 
cohort). It is probably superior to CT, which is limited by calcification in identifying the valve orifice. 
With development in the imaging and post-processing software, it is likely that the images will 
improve, making this technique even more suitable for use in the segmentation process. It also 
provides accurate data for LV volumetric assessment but was not used in this cohort because the 
patients underwent TOE under anaesthesia immediately prior to valve replacement and were under 
the influence of various medications that would affect the preload and afterload and hence the LV 
volumes. All protocols, including protocol 4, could be run entirely with data derived from a standard 
TOE not under anaesthetic conditions. A small number of patients undergo TOE as a work-up to 
aortic surgery, so it would not be part of routine practice as was intended when this project was 
conceived. It is also rather invasive, so the benefit of the examination would need to be apparent, 
with validation in larger cohorts and eventually studies looking at the outcome of patients. A benefit 
of using this modality of imaging is that there is no ionising radiation, in contrast to cardiac CT. 
 




4.2.3.  Computed tomography 
 
It was anticipated at the start of the project that CT may yield the highest resolution images that 
were the most suitable for segmentation and use in protocol 4. Unfortunately, due to heavy 
calcification in some valves, suitable images were only obtained for five out of eleven patients that 
underwent CT. CT was used in one patient that had inadequate 3D transthoracic imaging and was 
unable to complete the MRI scan due to claustrophobia. These LV volumes were used as inputs to 
the model for protocols 1-3; this patient was excluded from protocol 4 due to poor imaging of the 
valve. This could have introduced some variability in the results, but LV volumetric data from CT is 
comparable to that obtained by both 3D echocardiography and CMR imaging[218], [224]. Another 
issue is that most cardiac CTs are prospectively gated to reduce the amount of radiation to which the 
patient is exposed. In some protocols for aortic assessment for TAVI only 40-80% of the R-R interval 
is obtained; this would often exclude images at mid-systole when the valve was fully open, and these 
are the exact images required for the segmentation and modelling process in protocol 4. In routine 
clinical scans the valve and aorta are often assessed during diastole, when there is less motion of the 
heart, but as the heart contracts the size of the aortic root changes. Therefore, measurement of the 
size in mid- systole when the valve is fully open is helpful. In this cohort, 20-40% of the cardiac cycle 
was also imaged. Due the balance of data collection, storage and analysis time, it was decided that 
data would be stored only at 10% intervals. It is likely that mid-systole did not occur at exactly 30% 
of the R-R interval; it could have occurred at 25%, 28%, 32% etc, potentially missing the valve at its 
maximally open point and affecting the results. It was judged that this is unlikely to have affected 
the results as the valve opens quickly even in AS to its maximum (within approximately 130ms[214]) 
and stays relatively open until the end of systole, so examining at 20% and 30% of the cardiac cycle 
should be representative. In low flow, low gradient AS, when the stroke volume is less than 35ml, 
this is more likely to be a problem (only one case in this study). Missing the point of the valve 
maximally open is less likely to happen if retrospective gating is used, when data is acquired across 
the entire cardiac cycle. Although this technique requires more radiation, it is useful in patients with 




arrhythmias; and a high proportion of patients with AS have atrial fibrillation. If the use of the tools 
and concepts developed in this thesis could be further validated and a clear benefit to patients 
shown, then the benefit may outweigh the small risk of increased radiation dose. 
 
Use of a static image and not capturing the dynamic motion of the aortic valve is also a limitation. 
The mean aortic gradient is best to determine the severity of the stenosis, and this is calculated 
across the systolic period. However, due to the complexity of modelling flows through the moving 
structure, it was not performed in this project. Assessing the flow through the outflow tract and 
valve could be performed using 4D flow CMR imaging and used as boundary conditions to the 




4.2.4. Magnetic Resonance Imaging 
 
Volumes for the model processing were acquired using this method for the majority of patients (20 
out of 22) as, whilst comparable to 3D echocardiography and CT, it is thought by many to be the 
‘gold standard’ test due to its accuracy and reproducibility[218]. The results showed that there was 
no real change in volumes or significant change in ejection fraction following intervention, but this 
may be because only eight patients had evidence of LV systolic dysfunction prior to intervention. The 
majority had mild impairment, so in this cohort it may be difficult to appreciate a significant 
difference overall. However, even in a sub-group analysis of the patients with LV systolic 
impairment, although there was a trend of increasing ejection fraction, this was not significant, and 
the majority of these patients still had systolic impairment following intervention. As mentioned in 
section 1.11.8, there is an issue with the use of ejection fraction as a measure of cardiac function. 
Ejection fraction should be seen really as a measure of performance rather than function, as the 
function depends upon the loading conditions of the ventricle. For instance, a normal ejection 
fraction in severe mitral regurgitation suggests that the left ventricle is failing, because a higher than 




normal ejection fraction should be expected. Similarly, in AS, although the ejection fraction is 
normal, the heart may be failing. This is illustrated in section 3.9.3, where elastance may be a better 
assessment of the true function of the left ventricle. 
 
Following intervention, and reduction of the load on the ventricle, as evidenced by the reduction in 
pressure gradient, there was a significant reduction of LV mass. There is evidence that hypertrophy 
is associated with excess cardiac mortality and morbidity in those undergoing aortic valve 
replacement[225] [226]. It is therefore important to know the likelihood of positive 
remodelling[227] which was associated with a number results from the modelling process. 
Favourable or adverse left ventricular remodelling is affected by several factors including age, 
gender, haemodynamics, patient prosthesis mismatch, type of valve replacement, blood pressure 
control and ethnicity. Myocardial metabolism and coronary artery circulation are also involved in the 
changes occurring after aortic valve replacement[228]. In a further study older age, advanced NYHA 
class, reduced left ventricle ejection fraction, hypertension, and high pre-operative left ventricular 
mass index were associated with reduced survival. Early myocardial regression as seen in this study 
was weakly associated with mid-term outcome[229]. 
 
 
4.3.  Measured pressure volume loop 
 
From the measured loops it was possible to calculate stroke work, wasted work and total myocardial 
work and to estimate peak power, stroke power and wasted power; the mathematical formulae are 
described in section 2.4.1.2. These were used as one of the comparators for data obtained in the 
modelling process. Data were obtained in patients undergoing TAVI only to help validate the results 
of the modelling; but there were a number of issues that could affect accuracy of these results. 
However, the LV pressure data obtained were consistent with data obtained by other imaging 
modalities and generated by the modelling process. The mean measured LVEDP of 23 ± 12mmHg 




was consistent with the LVEDP calculated by the Nagueh formula and TTE Doppler data 23mmHg ± 
9mmHg.  
 
This work is the first attempt at creating a PV loop using invasive pressure data coupled with MRI 
derived LV volumes. The advantage of this technique is that the MRI derived LV volumes are more 
accurate than volumes usually derived from conductance catheters[230]. However, the pressures 
and flows were not measured simultaneously; some MRIs were performed up to 3 weeks prior to 
the procedure where the invasive pressure measurements were obtained. However, during this 
period there were no changes in medications and the degree of stenosis will not have changed 
significantly, but the loading conditions due to fluid intake and the timing of the procedures, e.g. 
occurring first thing in the morning after medications, may have affected the data. Also, as the data 
were not acquired simultaneously, there were differences in cardiac cycle length that had to be 
taken into account. To minimise this issue, care was taken to select the pressure traces that were a 
similar cycle length, and the pressure data was re-scaled temporally to the same cardiac period as 
that for MRI volume data. A further disadvantage was that the pressure was obtained using a 7 
French catheter which crossed the aortic valve. This will have introduced some aortic regurgitation 
and although this was not evident on a number of tracings, it could be seen in some of the PV loops, 
suggesting significant aortic regurgitation which may also have affected the results. A similar if not 
larger size catheter is used in the conductance catheter method.  
 
Data suggest the average stroke work is approximately 1.21 joules/beat [231]. The average age of 
this literature cohort was younger at 60, and 50% were hypertensive although the systolic and 
diastolic blood pressures were not stated. As expected, the patients in the current study had higher 
stroke work, averaging 1.34 Joules/beat. 
 




As seen in section 3.8 the modelled and measured data produce a similar smooth curve of LV power 
over the cardiac cycle suggesting that that the measured data produces a reasonable estimate of 
cardiac power. This is the first study that illustrates that the peak LV power occurs in early systole 
just after the valve opens giving insight into cardiac haemodynamics. 
 
4.4.  Outcome measures 
 
NYHA class assessed by the clinician and the Borg scale of effort during the 6MWT were the only 
markers to suggest there was an improvement in functional capacity following intervention in this 
study. The NYHA class assessment has a number of deficiencies, including the fact that it is 
subjective, is made by the clinician who would like the patient to improve following a treatment 
(which may introduce some bias) and that it is an assessment made at a single point of time from 
the patient’s description of their symptoms. Again, the Borg scale is the patient’s subjective 
assessment at the time of the activity, so perhaps may be more accurate; but again, this may be 
subject to bias and the placebo effect.  
 
The use of wearable technology to examine the patient’s activity prior to intervention, during the 
recovery period and subsequently is feasible and initial results seem to correlate with both patients 
reported outcomes and the results of the 6MWT. This is the first research using wearable devices in 
the context of aortic valve disease that gives us an insight not just into patients’ overall exercise 
capacity but their daily lives. Using both wearable technologies the trend of decline at discharge and 
significant recovery at 3-4 months was clearly seen. The trend of improvement and increased activity 
continued into the extended follow up periods when a number of parameters from the Sphere kit 
and Philips health watch were examined (see sections 3.4.1.2 and 3.4.1.3). There are large standard 
deviations in this data suggesting some patients did very well and some very poorly. Due to the 
limited numbers in this group it would be difficult to identify reasons for this. In a larger cohort a 




multivariate analysis may identify patient or procedural factors that contribute to the difference in 
recovery. 
 
The objective measures from the wearable devices (Sphere kit and Philips watch) were consistent 
with each other and with the six-minute walk test results at early follow-up, and the patient 
reported measures of physical activity from the MLHFQ and the WHO BREF questionnaire. These 
indicate that overall, there was no significant improvement in physical activity pre and post 
intervention at 3-4 months. This mutual correlation of data from alternative modalities might give 
some confidence in this novel approach using wearable devices to assess quantitatively the changes 
in patient’s activity following aortic valve intervention. From a clinical perspective, it is disappointing 
to see such minimal change following the intervention in this cohort. 
 
The time of day when patients undertake certain activities, and where they perform these activities, 
could be identified. This could be helpful clinically, for instance identifying when patients are 
sleeping in a chair in the living room because of heart failure which may prompt medical contact. It 
could also be used to counsel patients about how much exercise to take and inform a structured 
rehabilitation programme which is known to be beneficial to patients following valve 
replacement[232]. Identifying patients who are performing well post intervention can help plan 
follow-up and reduce the need for clinic visits. Conversely, if a patient’s activity levels are declining 
following intervention then close follow up or further treatments could be instigated.  
There is a lack of consistency in reports of change of activity following TAVI. Some suggest 
improvement, whilst others reflect the results of the current study. A meta-analysis[233] suggests 
there is an overall improvement in the activity in patients who underwent TAVI but the majority of 
patients included in the analysis were followed up at 12 months, with the minimum follow-up period 
of 6 months. This makes , it difficult to make comparisons with the data presented in this thesis and 
may explain the differences. Hiltrop et al also showed a significant increase in walk test difference at 




one, six and twelve months of 8.2, 8.1 and 8.8 meters respectively when 147 patients were followed 
up over a four-year period. However, it could be argued that an improvement of up to 9m during a 
six-minute walk test is unlikely to translate to a functional benefit in day-to-day living. Other studies 
that have looked at change in physical activity following TAVI showed similar results[200]. Green et 
al[234], in patients undergoing TAVI, showed that post intervention 6MWT distance was dependent 
upon distance walked pre-intervention. Generally, for people who could walk reasonably well prior 
to TAVI, their walk distance reduced up to 12 months after the procedure; however, the people who 
were slow walkers or unable to walk pre-intervention significantly improved following intervention. 
Again, there were wide standard deviations, with some people doing considerably better and some 
considerably worse than others. A further more recent study shows that a third of patients that 
undergo TAVI do not improve their exercise capacity following intervention[235]. There is a paucity 
of literature describing the change in functional capacity following aortic valve surgery, particularly 
with objective measures. In a study by Kim et al, patients undergoing SAVR, who were relatively 
healthier and had higher baseline function compared with TAVI patients, experienced a subjective 
NYHA class functional status improvement in three quarters of cases, remained stable in 
approximately one fifth, and declined in very few[236]. 
 
In this study, it was envisaged that patients would be able to set up equipment and calibrate the 
equipment for activity monitoring themselves. It was designed to be as simple as possible with 
detailed written instructions and demonstrations given by the author. However, with the older 
demographic that presents with AS, this proved difficult. The author had to make numerous home 
visits to set up and retrieve the equipment. This would have to be taken into account in future 
studies or if such technologies were to be used in clinical practice. Rather than dichotomising end 
points of function or disease specific decline in patients undergoing treatment with SAVR or TAVI, 
preoperative assessment of their functional status using wearable devices may offer clinicians and 
patients important information beyond the risk score about their expected trajectory following 




intervention. This has already been shown using the six-minute walk test. Further research is needed 
to see if these data could be used to guide patient selection.  
 
It could be argued that most people would want to have increased physical capacity following their 
procedure or find the activities that they could do before the intervention easier. The data suggests 
that although trends were seen there was no significant increase in the amount of activity the 
patient performed following intervention in this cohort which suggest they were not limited by the 
disease prior to intervention, they had not fully recovered, or that the intervention had no benefit. 
The improvement in the reported Borg score at the 6MWT and the reduction in NYHA class suggests 
that the first is more likely; and that, although patients could still perform tasks, they found them 
easier following intervention. 
 
4.5.   4D flow CMR  
 
4.5.1. Peak gradient and effective orifice area assessment 
 
This is the first research to validate peak pressure gradient across the aortic valve by 4D flow CMR 
against a reference invasive method. In addition, a novel 4D flow derived method for EOA in pre-
post-aortic valve intervention is described and validated against Doppler TTE. Importantly, 4D flow 
derived pressure gradient and EOA demonstrated an association with the 6MWT. The 4D flow-
derived peak pressure gradient also demonstrated association to LV mass regression at three-
months.  
 
Previous studies have demonstrated that there is discordance between the invasive and Doppler TTE 
peak pressure gradient assessment. It is established that Doppler methods overestimate the peak 
pressure drop[237], [238]. Many reasons for this over-estimation have been proposed. First, due to 




the inherent differences between Doppler pressure gradient method, which provides a maximum 
instantaneous pressure gradient at one time point versus the invasive method that provides the 
peak-to-peak gradient which occurs at two different time points can lead to this over-
estimation[239]. Second, if the gain setting on the Doppler scale is set high, it can lead to over-
estimation of peak velocity. Other reasons include human errors associated with the Doppler 
methods[240] and pressure recovery in the distal vessel[38]. Although the 4D flow methods 
described in this thesis share some of these flaws, there was no overestimation as a result. In fact, 
for defining severe AS, 4D flow derived pressure gradient was more consistent with invasive method. 
Reduction in over-estimation could be because the peak velocity plane was spatially identified by 
velocity vector visualization. This technique is not routinely applied in Doppler TTE, as peak velocity 
assessment is made by continuous wave Doppler which sums all velocities in one direction.  
EOA assessment can offer complementary information when making comprehensive assessment of 
AS. EOA is relatively pre-load independent when compared to peak velocity assessment. In addition, 
the novel EOA derived by 4D flow described in this thesis is not subject to the geometric 
assumptions made using transthoracic echocardiography. As this method is the gradient of the linear 
regression line between flow and velocity through the aortic valve, it may remain relevant in slow 
flow, low gradient AS but larger studies are needed to evaluate our proposed methods in these 
challenging cases of AS.  
 
One of the most important clinical criteria to determine the timing of aortic valve intervention is 
symptoms onset. Studies have demonstrated that the 6MWT predicts clinical outcomes and, in some 
centres, a 6MWT is part of the routine assessment for patients referred for TAVI[118]. It was 
noteworthy that, compared with measures from transthoracic echocardiography, it was only 4D flow 
derived pressure gradient and EOA which were associated with both NYHA functional class and, 
more importantly, with the 6MWT distance; this may help with prognostication.  
 




As discussed above, LV mass regresses with decrease in afterload. LV mass regression is 
independently associated with improved long-term survival[226] . It is plausible to expect a 
proportional decrease in afterload, or the pressure gradient across the aortic valve and LV mass post 
aortic valve replacement. In this study, LV mass regression demonstrated correlation to only 4D 
flow-derived pressure gradient change; once again suggesting its superiority over the standard 
methods of assessment.  
 
Limited as it is by the small number of patients studied, this study offers hypothesis-generating data 
for future larger studies. However, it is still plausible to suggest that 4D flow CMR offers an 
alternative non-invasive method to quantify AS and its severity. Another limitation in the CMR 
methodology included omission of respiratory navigation, which may have had an impact on the 
accuracy of derived velocity parameters. However, studies that carried out a head-to-head 
comparison of whole-heart 4D flow have demonstrated that for quantification of intra-cardiac KE, 
both respiratory , and non-respiratory navigated, 4D flow acquisitions are comparable[241]. Other 
limitations were a low temporal resolution (40ms), and variation in the heart rate and physiological 
condition between the two acquisitions.  
 
 
4.5.2. Left ventricular intra-cavity blood flow kinetic energy assessment  
 
This is the first research into the LV blood flow KE in patients with AS, both pre- and post- valvular 
intervention. It gives mechanistic insight into changes associated with AS by the assessment of KE of 
the blood flow component. The main findings were that the average KE of the blood flow through 
the left ventricle does not change significantly after valve intervention. However, the time delay, 
direct flow and delayed flow were significantly modified after intervention indicating valve 
replacement alters how blood is ejected from the heart, making the process more energy efficient 
and suggesting an improvement in diastolic function. LV blood flow KE metrics demonstrated an 
association with the 6MWT and LV remodelling at three-months was associated with the delayed 




flow component of left ventricular flow. Different components of blood flow KE demonstrated 
changes pre vs post valve intervention. Both direct and delayed flow components KE were 
significantly reduced post valvular intervention. The rise in direct and delayed flow components in 
severe AS patients was mainly observed in the late diastolic filling phase but further research is 
warranted to explain this phenomenon.  
 
LV blood flow KE demonstrated an inverse correlation to the 6MWT distance achieved. This was not 
seen for standard CMR derived functional and volumetric assessment. An increase in the LV blood 
flow KE may provide a novel haemodynamic biomarker of physical endurance that could be a useful 
early parameter in the assessment of function, morbidity and perhaps prognosis in patients with AS. 
Future studies should evaluate clinical cut-offs which predict outcomes in AS.  
 
Normally, blood flows rapidly into the LV cavity from the base to the apex of the heart. The time 
delay of this has been described previously as a marker of LV compliance and diastolic function 
[242], [243]. In this cohort there was a significant reduction in time delay, reflecting an improvement 
in restrictive LV filling after the valve intervention. This was not seen with diastolic assessment using 
echocardiography so perhaps this is a more sensitive marker. In this, the time delay is derived 
automatically using 3D flow quantified data versus echocardiographic methods which very 
susceptible to operator and variability. Averaged LV blood flow KEiEDV for the complete cardiac 
cycle demonstrated an association with LV remodelling post intervention. Peak E wave KEiEDV 
showed a trend towards association with LV remodelling.  
 
Although healthy controls were not recruited in this research, patients with AS appear to have 
higher LV KE when compared to similar age group patients in previous studies (12.0±3.4μJ/ml versus 
8±1.3μJ/ml) [244]. This is plausibly explained by the increased outflow tract velocity in this cohort. 
Also, the diastolic and peak E-wave KE were higher in this study when compared to Crandon et al’s 




work and may reflect a higher degree of deterioration of LV compliance in AS patients than 
previously studied healthy controls.  
 
4.6.  Computational modelling  
 
Computational models of the circulation including the effect of AS have been previously proposed by 
Li et al [159] et al and Smith et al[226]. However, in these models, AS was represented by the valve 
resistance as defined by Ohm's law as the ratio of the pressure gradient to flow. Others [227]–[229] 
have demonstrated that this resistance does not completely describe the LV burden imposed by the 
stenotic valve. Garcia et al[161] created a mathematical model of AS based upon the energy loss 
concept rather than direct measurements. In the present work either the Doppler measured 
transvalvular gradient or the gradient derived from CFD was incorporated, making the model more 
clinically applicable than the initial descriptive models. The main advantage of the personalised 
model is that it may explicitly and accurately describe the pressure volume relationship if a few (six) 
cardiovascular parameters are known. Other studies either require measurements that are not 
practical to obtain or extensive estimation of parameters, using population averages or 
mathematical solutions that make the process less personalise. For example, adding additional 
elements such as the four-element model described by Stergiopulos [184] would have required 
additional input data, which may not be available in routine practice and this results in a coupling 
model that is difficult to apply in the clinical situation. 
 
As described in section 1.3, AS is probably not a disease solely limited to the valve in the majority of 
patients. 41% of the patients concomitantly have low systemic arterial compliance[245] and 
systemic hypertension is present in 30–40% of patients [246], [247]. Abnormal vascular properties 
are not taken into account in current clinical guidelines for diagnosis and management. In such 
patients, a systems model may be useful to assess better the respective contributions of the valve 




disease and the systemic arterial system to the LV workload. This could help determine whether the 
treatment should be targeted to the reduction of the arterial load with medication, the reduction of 
the valvular load by aortic valve replacement, or indeed both facets of the disease. In this context, 
the proposed methods may be superior to existing methods (pressure gradient and systolic arterial 
pressure) for characterising these two components of the left ventricular load. Both of these 
methods are highly flow-dependent and are subject to pseudo-normalisation in patients with 
reduced cardiac output[245] underestimating the impact of the aortic valve and/or systemic arterial 
system upon the LV workload. Also, when these parameters are analysed separately, it is difficult to 
estimate what is the contribution of each parameter to the overall LV workload. Multivariate 
regression could be performed to overcome this and determine the contributions of each 
parameter, but this assumes that there is a linear relationship between the different parameters, 
which is obviously not the case in the ventricular-valvular-vascular coupled system. The potential 
clinical usefulness of this coupled system, however, remains to be confirmed in a larger cohort of 
patients.  
 
4.6.1. Elastance model 
 
There are several options for the representation of the performance of the heart chambers and of 
the valves and, indeed, of the systemic circulation. In this body of work, the variable elastance 
description of the heart chambers’ contraction was used, but other representations, including the 
single fibre model, could have been utilised [248]. Section 3.6.1 illustrates the elastance curves that 
were produced using four alternative options for the variable elastance model, namely a Shi double-
cosine model and double Hill models with Mynard, Seemann and personalised constants. All options 
were investigated for a number of patients and it was determined that the double Hill models 
produced the curves that were both most physiologically plausible, with a fast rise followed by a 
wide plateau, and most consistent with the measured data. This confirms suggestions in the 




literature that the double-Hill model is the most accurate representation[173], [189]. For this cohort 
the Mynard constants fitted the measured data better than the Seemann constants. A standard 
process for model personalisation was followed for all patients in each of protocols 2-4, and this 
included personalisation of the maximum and minimum elastance in the double Hill model with the 
Mynard constants for the Hill functions. The option of personalising the Hill constants was also 
explored but no consistent protocol was found that produced best results for all patients. The 
primary issue was that the optimisation process tended to become unstable or to converge to 
combinations that did not produce low residuals in the target parameters when starting from a 
reference set and attempting to optimise all parameters simultaneously. Although, as indicated in 
figure 2.13, it was possible to produce more optimised fits to the measured time-series data by 
improving the estimate iteratively, operating on a subset of the model parameters at each iteration 
and including the double Hill parameters, the final result was to some degree dependent on the 
order of operations. This, combined with the much higher processing time, led to the decision to fix 
the double Hill constants for the purposes of the current study, leaving their personalisation as a 
subject of further work. 
 
As described in sections 3.9.2 - 3.9.4, ELVmin and ELVmax may be useful diagnostic and prognostic 
parameters, but there are issues in estimating these in standard clinical workflows without 
simultaneous measurement of LV volume and pressure. Even in the current research study the 
measurements were not simultaneous. The standard method for estimating maximum elastance is 
that it occurs at end systole, just before the isovolumetric relaxation phase. Inspection of the typical 
LV PV loop, figure 1.18 (point C), confirms that this is where the maximum ratio of pressure to 
volume might be expected, but for patients with a high dome in the systolic phase (including those 
with aortic valve disease) this might not be the case. There has been debate in the literature as to 
whether the end-systole pressure-volume relationship is linear and load independent as it had 
originally been described[169]. Much of the debate focused on what can be deemed an appropriate 




approximation within the physiological range and the context of the model in question[249], [250] . 
Generally, it is acknowledged that the relationship is linear and load-independent within normal 
physiological ranges[251]–[253]. The consistent results of the model processing, using the time-
varying elastance model integrated into systems 0D method, especially when compared with the 
measured data, suggest that that the time-varying elastance model is a suitable model in this cohort, 
even when the afterload is high. Further, larger studies in patients with AS are needed to assess the 
inter-individual variability of elastance in this cohort. It should be noted that the model used in this 
study does not include an inertial element in the afterload, which might change the temporal 
distribution of pressure in the acceleration and deceleration phases.  
 
4.6.2. Model protocols 
 
The results show that all the documented processes for each protocol are feasible in a workflow and 
give plausible results. Results can be produced in near real-time, making this clinically applicable. 
The pilot data resulting from the computational model are encouraging and suggest that the 
concepts and techniques developed in this thesis could be applied for both prognostication and 
diagnosis. The PV loops are similar to those found in the literature[254][168] and the shapes of the 
post intervention curves are as expected. As in all computer model simulations, the results are only 
as good as the input data. As we have seen with the segmented medical images and the clinical 
measurements of both volume and pressure, an uncertainty estimation should be quoted with the 
results to aid the clinician’s interpretation. There could be debate about the level of certainty that 
would be acceptable; 10% would probably be better than most clinical measures.  
 
Understanding the resulting metrics, whichever protocol is used, is important. Terms such as 
maximum elastance, minimum elastance are common engineering terms which relate to the 
contractility and compliance of a structure. Contractility and compliance are terms familiar to 




clinicians and therefore should be used in the reporting of the modelling parameters, if such 
techniques are to be successfully translated into clinical practice. The compliance and resistance 
reported in such computer models are very consistent with the ones directly obtained from 
experimental data[168]. Further research is needed to understand what ranges of results are 
clinically relevant. For example, is there a load that a ventricle may struggle to cope with and would 
cause it to fail within a certain time period? These techniques would need to be applied to a much 
larger cohort and patients studied longitudinally to help answer this question. Also, is there either an 
absolute reduction of work or a percentage of work reduction that is needed to lead to positive 
remodelling and improved outcomes? The author was unable to demonstrate this in this cohort but, 
this may be due to the short follow up with lack of hard end points. 
 
Stroke work refers to the work done by the ventricle to eject the stroke volume. The force applied to 
the blood is the intraventricular pressure. Stroke work could be estimated as the product of mean 
systolic pressure during the ejection period and the stroke volume. In a normal heart, the LV 
pressure can be approximated by the mean aortic systolic pressure or the mean arterial pressure, 
although using the MAP will underestimate the stroke work. When aortic pressure or MAP are used 
instead of intraventricular pressure, it is assumed that kinetic energy is negligible, which although 
generally true at rest, is not always the case. In AS this is complicated further, and the pressure drop 
across the valve must be taken into account.  
 
This is the first piece of work to describe a purely mathematical model that can produce a PV loop 
from non-invasive blood pressure measurements and imaging data in AS. The difficulty of this 
method was in describing the PV curve during ejection. Four mathematical models were trialled (see 
figure4.1). 





Figure 4.1 Mathematically derived curves during ejection illustrating the aortic pressure, LV pressure, 
LV volume using a quadratic fit (yellow, grey and orange lines respectively). The LV pressure is also 
assumed to be cubic (blue), quadratic with no timing to fit to (purple) and when the timing of the 
peak pressure gradient is known (green). 
 
 
It is assumed that the pressures at the start and at the end of ejection are the same as the aortic 
pressures at those timing points (that is, the pressures when the valve opens and when it closes, 
neglecting any inertial effects). The most comprehensive measurement data would include the 
maximum aortic valve pressure difference and its timing and the maximum left ventricular pressure 
and its timing. Each of these yields two independent constraints (a maximum LV pressure and a peak 
gradient). Together with the start and end data there are six constraints, and if a polynomial is 
chosen for the representation this would support the unique identification of the coefficients. 
However, experimentation with any polynomial of higher order than two has shown that, depending 
upon the measurement values, the polynomial can exhibit points of inflection that are 
physiologically implausible. In figure 4.1, the cubic representation is very similar to the quadratic 
one, but this is not always so. The simple quadratic uses minimal information but tends to produce a 
peak that occurs later than that measured in practice. Using timing data in a piecewise quadratic 
formula produces a more realistic temporal distribution of left ventricular pressure over the ejection 




period, and therefore more plausible LV PV loops. This is why this method was selected for 
processing cases through protocol one. 
 
The results from protocol 1 are encouraging. There were no significant differences in the key 
parameters of stroke work, wasted work, peak LV power and maximum elastance and minimum 
elastance compared with the measured data. Due to the low numbers of patients and the wide 
standard deviations, the study may have been underpowered to detect a statistical significance but, 
as pilot data, this is interesting and warrants further study.  
 
This protocol runs without modelling or simulations and therefore may not be able to predict the 
haemodynamic changes following an intervention accurately and cannot be used to model a patient 
in the exercise state. Therefore, this was not performed in the current study. However, changing the 
peak gradient to 10-20mmg, a plausible post intervention gradient and keeping the other variables 
the same, could give an initial first estimate. The calculated parameters in protocol 1 require very 
little computing power and can be performed in an Excel® (Microsoft, CA, USA) spreadsheet 
almost instantaneously and with very little cost. This would be an advantage as the clinician would 
be able to assess the data with the patient in front of them during a clinical consultation. This would 
give the clinician an idea of the global burden on the LV. 
 
Protocols 2 and 3 yielded very similar results for many of the calculated parameters; this was 
unexpected. The author believed that incorporating LV time series data to enable personalisation of 
the double-Hill model would lead to improved accuracy. Although this may be the case, it did not 
result in significant difference when assessing stroke work, stroke power, maximum and minimum 
elastance. It is assumed that, where there was a difference in results, protocol 3 was more accurate 
due to the increased information provided to the model. For assessing wasted work, wasted power 
and total myocardial power, protocol 3 should ideally be used. 




Protocol 4 was the most sophisticated, incorporating medical imaging data in a 3D model coupled to 
the OD model and using information from wearable devices to run predictive simulations. The step 
that is prone to the most error was segmentation. It is difficult to quantify the accuracy of 
segmentation, especially as there is no gold standard against which to compare. Inaccurate 
segmentation would lead to incorrect haemodynamic parameters, because the model was sensitive 
to this input parameter. This was why, after careful analysis of the medical images and segmented 
models, only 11 cases were fully analysed. Analysis of these cases showed a good correlation with 
the measured peak gradient, with an overestimation of the peak gradient by echocardiography as 
expected, in part validating this technique. In hindsight the difficulty in imaging a calcified diseased 
valve should have been foreseen and limits its utility in clinical practice. However, as technology 
improves, it may be possible to image these valves better with ultrasound and CT in the future, 
improving the accuracy. Although there were limited measured data for comparison, there was no 
difference in the calculated stroke work, stroke power, LV peak power and maximum and minimum 
elastance. This protocol seems superior to the other two modelling protocols when assessing LV 
peak power.  
 
The point in the cardiac cycle that peak LV power occurs in AS can be assessed using computer 
modelling, this occurs in the early ejection phase after the valve has started to open. Although 
perhaps expected, this has not previously been described. These data suggest that the sampling rate 
of the measured data was high enough to capture the gradients in the curve which may explain why 
the modelled data did not produce a higher peak power. The model does give confidence that the 
measured data may give reasonable estimates of LV power outputs and vice versa. One might have 
expected the modelled data to be more accurate than data derived from the measured data using a 
purely mathematical formula and result in higher values, as the computer model is based more on 
physiology  rather than being a simple numerical equation. 




4.6.3. Diagnostic utility 
 
One hypothesis of this study, quite independent of any mathematical modelling, was that the degree 
of activity (whether intensity or duration) that a patient undertakes in the pre-intervention state 
might be a diagnostic marker of disease severity, but this was not proven in this small cohort. There 
was a significant negative correlation between both peak and mean gradients assessed by standard 
Doppler echocardiography with the distance achieved during the 6MWT, but no association with LV 
function. As there was no association with any other activity metric or symptoms reported by the 
patient, which suggests that, although limited when asked to exercise to their maximum capacity, 
even with severely stenotic valves, their day-to-day activities were not limited by the disease. There 
was also no correlation with mass or ejection fraction, which suggests that other factors that load 
the ventricle and cause it to fail such as hypertension are important, consistent with the above 
hypothesis. 
 
Interestingly, there was no correlation between ejection fraction with either the 6MWT or step 
count. Ejection fraction, although often stated as measure of function, is more a measure of 
performance and the function depends on the loading of the ventricle. Patients often have a normal 
ejection fraction, yet the ventricle may have already started to fail. These data may provide some 
evidence for this. There was a suggestion that the higher the ejection fraction, the more energy the 
patient could expend and that, if the ejection fraction were lower, the patient may spend longer 
asleep. If there is reduction of ejection fraction, this is a relatively late stage in the disease process, 
so it is perhaps not surprising that these patients do not expend as much energy and spend more 
time asleep. 
 
Compared with the standard clinical techniques to assess the severity of the disease, the calculated 
parameters from the computer model seem to perform better with stronger and more frequent 




correlation with the activity data. ELVmin or left ventricular compliance seems to be the most 
consistent parameter in determining the effect on patient function and negative myocardial 
remodelling. It exhibited relatively strong correlations with objective measures of activity, including 
the 6MWT, as well as a number of parameters from the wearable devices. It also correlated with LV 
mass. It is likely that it is the rise in myocardial mass that results in the elevated ELVmin. This is 
consistent with what is already known. ELVmin can be considered analogous to LV strain 
assessment[255], [256] and it is likely to change prior to any changes in LV systolic function. This 
could be the consequence of fibrosis, as seen on CMR[25]. Assessing early diastolic dysfunction using 
calculated ELVMin may be more reliable and reproducible than strain and fibrosis assessment, but 
more research is needed. 
 
ELVmax had a strong correlation with ejection fraction or LV systolic performance. It reflects the 
systolic contractility of the heart but also takes into account the loading conditions, which could 
provide a reason for why this is better associated with adverse myocardial modelling and average 
daily step count than ejection fraction. The negative correlation with LV mass is interesting. It 
suggests that the LV hypertrophy that develops in an attempt to cope with the increased afterload is 
actually maladaptive, and although ejection fraction is maintained or increased, contractility is 
reduced. This can be seen in other conditions such as hypertrophic cardiomyopathy and is likely 
caused by fibrosis and infiltration that has been seen during MRI in severe AS[25]. This pathological 
process reduces the compliance of the ventricle. There was no correlation with the 6MWT, which 
was unexpected, but could be explained by the patient being in the adaptive phase with preserved 
ventricular function or in decline, with the heart starting to fail (see section 3.9.3), yet still having a 
normal ejection fraction. 
 
ELVmax has promise when a patient is followed longitudinally to detect early signs of LV failure. In 
terms of identifying patients for intervention, ELVmax may help in selecting patients before a 




reduction in ejection fraction is seen. Serial monitoring of modelled ELV max could be used (see 
figure 3.39). An increase in ELVmax , from normal (red) to supra-normal (green) shows that the LV is 
adapting to the increase in load. When the ELVmax moves from supra-normal towards the normal 
range this is likely to be a sign that the LV is starting to fail. Assessment of ELVmax might identify 
changes in cardiac function before there are apparent changes in the ejection fraction. If ELVmax 
were to be serially measured in an individual, this may help in the timing of intervention. In patients 
with reduced ejection fraction prior to intervention ELVmax may help identify the likelihood of 
recovery in ejection fraction following intervention. Further research into this notion is required in a 
larger cohort.  
 
LV work, not LV peak power, was significantly correlated with LV mass. This suggests that it is the 
work over the cardiac cycle rather than instantaneous peak power that results in LV hypertrophy. 
Whether average work over the cardiac cycle or peak LV power leads to hypertrophy has not 
previously been investigated. However, these findings make sense as the amount of time the heart is 
exposed to peak LV pressure is very short. There was a better association between peak LV power 
and activity, suggesting that it is the heart’s ability to generate a high-pressure during exercise which 
is important. 
 
It is not known whether values of peak or mean power might be the most relevant in the context of 
progression of cardiac remodelling, towards heart failure. In normal engineering materials, peak 
stresses are often critical in failure modes. Because peak power is a temporal gradient of work, it is 
particularly sensitive to inaccuracies in the measurement process, and to assumptions made in the 
interpolation process. For this reason, if the underpinning computational models of elastance are 
capturing the proper form of the contraction curve, it is likely that the 0D models more accurately 
estimate this parameter. It will be interesting to see if, in extended clinical trials, this parameter 
proves to be associated with disease progression and outcome of interventions. If it does then it 




would both increase our understanding of the underlying factors in these events and demonstrate 
the utility of a physiology-based computational model in assisting clinical decision support. Wasted 
energy correlated well with myocardial mass, which may be expected. There was no correlation with 
the patient’s symptoms or activity. 
 
It is possible that using a multi-biomarker strategy to identify LV decompensation may prove 
superior to any single biomarker. In the EVoLVeD trial[257], patients are initially screened with an 
ECG and a high sensitivity troponin I blood test. Patients in whom these tests are normal are deemed 
to have a normal heart with no further imaging required. Patients with LVH and abnormal strain 
pattern, or an elevated level of troponin, proceed to cardiac magnetic resonance imaging. Those 
found to have mid-wall fibrosis are then randomised to either early valve intervention or routine 
clinical care. It is hoped that this strategy will target valve intervention to those patients who will 
derive greatest benefit. The same could be achieved with ‘bio-markers’ resulting from the modelling 
process such as maximum elastance as illustrated in section 3.9. 
 
4.6.4. Predictive utility 
 
PV loops were produced for each patient in the rest and exercise state pre- and post- intervention. 
The loops produced were consistent with the known physiological changes and the expected 
changes previously published[191], [258], [259]. The results are physiologically plausible, suggesting 
that the model can be predictive. Further validation of the exercise PV loops is needed but this is 
difficult to do practically and, as the level of activity the patient performed was used as an input to 
the model, activity levels cannot be used as a surrogate marker for validation. The model predicts 
and quantifies the expected reductions in cardiac work and wasted energy following intervention 
(section 3.9.2) but, as discussed previously, it is as yet unclear what reduction in work or wasted 
energy is clinically significant and result in positive remodelling and a reduction of symptoms. The 




author was unable to show a relationship between either the relative or the absolute reduction in 
modelled parameters and the degree of clinical improvement or LV mass regression. If there is a 
relationship, a much larger cohort would be needed to demonstrate this. 
 
The post-intervention gradient could be predicted and measured. The determinants of the pressure 
gradient following intervention are the size of the valve implanted and the size of the patient. 
However, the model-predicted peak gradient following intervention had a better correlation with 
the measured peak than the BSA indexed EOA of the valve implanted (r2 = 0.47 and r2 =0.38, 
respectively). This suggests that simulating the patients’ haemodynamics following intervention 
improves predictive capability. For one patient, the model predicted a post-operative gradient of 
60mmHg, and the measured post-operative gradient in this patient was 51mmHg. This patient 
remained symptomatic following intervention, suggesting a patient-prosthesis mismatch. This was 
confirmed, with the estimated iEOA was calculated to be 0.6cm2[260]. Had the model been run prior 
to the planned intervention, this could have been avoided. A sutureless valve or a TAVI may have 
been the preferred option for this patient. The model’s sensitivity and sensitivity of predicting a 
successful reduction in pressure gradient (to <20mmHg) suggests that this may be a good tool to 
help clinicians with valve selection in their patients. This could be as an adjunct to BSA, which was 
not used as an input to the model. 
 
There are two main reasons to replace the diseased valve; one is to improve prognosis and the other 
is to relieve symptoms. The modelled pre-operative ELVmax may help predict a recovery in ejection 
fraction following intervention, which is known to determine outcome [261], [262]. In patients in this 
study with low ELVmax and low ejection fraction, the ejection fraction did not return to normal 
following intervention. Ejection fraction returned to normal in only one out of six patients with an 
ELVmax in the normal range prior to intervention. 




Symptoms are subjective and there are well-documented problems with self-reported symptoms 
and the NYHA assessment [263], [264]. It would be beneficial if improvement in physical capacity 
following intervention could be predicted for an individual ; this would help manage patients’ 
expectations and be helpful to clinicians when counselling a patient about a procedure. There are a 
number of patients that undergo aortic valve replacements in the late stage of the disease, when the 
heart has remodelled and become stiff, who do not get an improvement in their symptoms or 
exercise capacity following intervention. 
 
The model-predicted post-operative activity levels correlated well with measured activity post-
intervention in terms of METs calculated from the 6MWT distance. There was a systematic bias of 
the model, over-predicting activity by 0.5 METS. Thus, expected capacity following intervention 
could be predicted as the modelled exercise capacity – 0.5METS. However, post-intervention 
exercise capacity is likely to be determined, primarily, by pre-intervention capacity as shown in 
previous studies[234], [236]. 
 
4.7.  Clinical decision support system 
 
Clinical decision support systems (CDSS) are tools that incorporate clinical knowledge and patient 
information to enhance patient care. In this case it also incorporates patient-specific modelled 
information. CDSS can encompass an array of strategies supporting a variety of topics and are 
designed to assist the physician-patient encounter at multiple points from initial consultation to 
diagnosis to follow up. The expectation is that a properly equipped clinical decision support system 
will significantly benefit patient care at all levels[265]. Despite promising initial data from systems 
based around medication management[266], [267] and pathology systems[268], [269], the majority 
of CDSS’s have not provided features beyond reminders, general alerts , automated information 
retrieval and summary dashboards[270], [271]. 




The modelling and activity components of this specific clinical decision support system were well-
received by the clinicians involved, with about 80% of participants finding the information useful or 
very useful. It is interesting that, in some cases, this data has the ability to influence decisions and 
improve confidence in decisions, irrespective of the accuracy. This suggests that, once fully 
validated, these tools and techniques could impact on patient care. Larger studies are needed 
(including a randomised control trial) to investigate whether such a tool could have a positive effect 
upon outcome. What this experiment did not do was assess whether the management of the patient 
would change in terms of the method of intervention. In the cases where there was a clear and 
confident decision to intervene, would the patient have been offered a different treatment such as 
TAVI instead of SAVR or a different approach to the surgery or a different type of valve as a result of 
the information presented? 
 
The job of the clinician is to weigh up benefit and risk, to the individual patient in front of them, of 
intervening and replacing the valve or not. In the guidelines, there is a focus on risk scores such as 
the EuroScore and the STS score; indeed 89% of our participants found such scores helpful. 
Quantifying benefit for an individual appears to be much more difficult. Which of these patients will 
live a lot longer and by how much? Which will see an improvement of ventricular function and by 
how much? Which of these patients will see a reduction of symptoms and how much more will they 
be able to do? This pilot study suggests that computational modelling may go some way to 
addressing some of these questions. In our cohort, 96% of clinicians certainly suggested that a 









4.8.  Key limitations 
 
Although some limitations are discussed in the relevant sections above, Table 4.1 summarises the 
main limitations of this work, the reasons for these, the steps taken to mitigate any effects and 
changes suggested for future study. 
Feature/Concept Issue Limitation Reason/ Mitigation Future Direction/ 
change needed 
Study design Small sample 
size 
 






extended follow up. 
 3-4 month follow-up 
likely too soon to assess 
full recovery. 
Pilot study, designed for 
hypothesis generation.  
Similar size to other 
studies[156], [168]. 
 
Literature suggests 3-4 




Randomised trial to 
assess CDSS. 
Extended follow up 
to 2 years at 2 
monthly intervals. 
Hard end points (e.g. 
death) to be used.  










generalisable to wider 
diverse population 
Patients without CAD 
and TAVI cases were 
sought. CAD more 
common in men and as 
their life-expectancy is 
shorter, many may die 




trial or propensity 





more diverse cohort 
to be studied. 
Study design Missing data  Biased results (although 
random data missing) 
 
Limits analysis therefore 
not able to identify 
significant differences. 
 
4D flow data acquisition 
was inadequate in 
some. This may limit the 
application in clinical 
practice 
Occurs in real life, 
routine data used to 
make process applicable 
in clinical practice. 
 
Either data omitted or 




























Model very sensitive to 
six input parameters. 
Mean error in blood 
pressure assessment is 
likely to be around +/- 
8mmHg[273] and the 
error in the LV 
volumetric 10% [274]. 




measurements taken by 
the author. 
 
Pressure and volume 
temporal profiles 






catheter at time of 
TAVI preferable for 
validation. 
Performing MRI 
same day as 
procedure if 
possible. 






Pressures and volumes 
affected by different 
loading conditions. 
Clinical measures 
repeated and averaged. 
 
4D MRI flow fields 











Does not account for 
dynamic valve 
movement. Unable to 
model challenging cases 





inaccurate which limits 
clinical application. 
Different imaging 
modalities used for 
segmentation which 
allowed processing of 

















True effects of replacing 
valve not assessed. 
Other factors affecting 
recovery time and 
myocardial function e.g. 
CAB not assessed. 
These are important 
factors that influence 
outcome. 
Would increase 
complexity of modelling 
process. Out of scope 
for this project. 
 







Modelling the short- 
and long-term 




performed by Kroon 
et al[275] and a 
similar approach 
could be taken. 
Computational 
modelling 
Modelled AS in 
isolation 
Not applicable to other 
valvular pathologies. 




complexity of modelling 
process. Out of scope 
for this project. 
MATLAB script 
created to be flexible 
and can account for 
aortic regurgitation, 
mitral regurgitation, 








Elderly patients needed 
help and support with 
the technology. Makes 
it less clinically 
applicable due to cost 
and time taken 
Devices used were as 
simple as possible to 
obtain this data. 
Use of simple 
techniques or reduce 
need for 
charging[276]. A 





Table 4.1 Key limitations of the study 
 






5.  Conclusion and further work 
 
5.1.   Conclusion 
 
AS is an important entity that is associated with significant morbidity and mortality. There are 
several limitations with the current diagnostic approach. This work demonstrates that the physiology 
of patients with AS can be characterised using computational models. A number of processing 
protocols have been developed that show it is possible to ‘measure’ cardiac work and run 
simulations that predict haemodynamic changes under exercise and following valve replacement, 
achieving the first aim of this project; however, further validation is necessary in a larger cohort. The 
accuracy of the model will be affected by the clinical data available and it is a case of balancing this 
with practical and patient constraints. Linking the reduction of cardiac work or indeed the prediction 
of reduced work with activity and outcome will be the next goal. This work takes the first steps 
towards this, showing how this may be done in this patient cohort and that wearable devices can be 
used to measure outcome. However, although trends were seen, this study failed to show a 
significant, measurable, improvement in functional capacity following intervention. 
MRI 4D flow for the assessment and grading of AS appears promising. The assessment of aortic valve 
gradient and effective orifice area using these techniques are comparable to invasive and 
transthoracic echocardiographic assessment and provide a viable alternative. In addition, 4D flow-
derived valve metrics have minimal bias and superior association to prognostically relevant 6MWT 
and LV mass regression. Discordance between EOA and the pressure gradient to grade the severity 
of AS frequently occurs and can lead to confusion. It is clinically desirable to have more non-invasive 
tools to reduce the clinical dilemma and make an affirmative diagnosis and grading of AS. The 
accuracy of 4D flow pressure gradient assessment was slightly inferior to Doppler TTE when 
compared against the reference invasive methods. However, the precision was much better with 4D 




flow pressure gradient. Hence, in patients where Doppler TTE is inconsistent with symptoms and has 
discordant results, 4D flow CMR could help in clinical decision making for deciding on aortic valve 
intervention. 
 
Assessment of the kinetic energy of the blood pool of the left ventricle gives an insight to the 
haemodynamics and may provide a further diagnostic tool. The results of these techniques 
correlated better with the symptoms, functional capacity and LV remodelling than routine 
echocardiographic assessment. Although 4D flow assessment may add incremental value to the 
assessment and prognostication of patients with severe AS, it does not provide the same 
haemodynamic information as the modelling process and different scenarios cannot be simulated 
with this method. Therefore, 4D flow assessment, although adding to our understanding, does not 
negate the need for modelling. In fact, the two techniques could work synergistically with MRI, 
producing flow fields that could be used as boundary conditions for the model. 
 
Wearable devices are well-tolerated by patients and provide insight to both their recovery and daily 
life patterns, which could in turn provide valuable information for clinicians and help determine 
timing of intervention, treatment type and follow up required. This small study failed to show a 
significant increase in exercise capacity, but it does perhaps suggest that patients found it easier to 
do the same level of activity following intervention. It suggests that patients in this cohort may have 
not been limited by the disease with other factors contributing to the poor exercise capacity or that 
the valve intervention offered no significant benefit in terms of activity for the majority of people. 
The other possibility is that the study was not powered to detect the difference. The objective 
measures may be better than standard NYHA assessment. The NYHA assessment suggested 
significant improvement in symptoms following intervention but this was not borne out in the any of 
the objective measures or the patient reported outcomes in the questionnaires completed and 
suggests its subjective assessment is not accurate. 





The clinical decision support system which was able to provide an overview of the whole patient and 
summarise both risks and potential benefit for a patient was well-received by the clinicians that 
trialled the platform. It would appear that once validated, the modelling and activity data could 
influence the care of patients particularly in borderline cases. Being able to simulate different 
scenarios in a ‘virtual’ safe environment was a feature incorporated into the clinical decision support 
system and may help predict outcome. With more understanding of the information, this may be a 
useful tool in clinical practice and/or as an educational tool. For patients with hypertension and AS, 
treating the hypertension first to see if there is an improvement in symptoms, may delay the need 
for an operation. This may not be a revelation, but this model can potentially assess individual 
factors affecting the load on the left ventricle and suggest whether a reduction in BP or intervention 
or both is necessary in such a patient. This pilot study has identified several areas that need further 
research and validation in a large cohort. The processes and techniques developed, once validated, 
need assessment in a randomised control trial to see if they can have a positive impact on the 
outcomes of patients with severe AS. 
 














Hypothesis/ aim Achievement Upheld/ met 
Computational modelling can aid the 
diagnosis and management of AS by 
producing non-invasive pressure volume loops 
to study LV haemodynamics 
The pilot data suggests that 
modelling can create non-invasive 
could have diagnostic utility (section 
3.9) and prognostic utility (sections 
3.9.3 and 3.9.4). 
Hypothesis upheld 
Can a simple, personalised, mathematical 
model of patient with AS ‘measure’ cardiac 
work and power parameters that provide an 
effective characterisation of the demand on 
the heart in both rest and exercise conditions 
and predict the changes of these parameters 
following a prospective intervention? 
PV loops can be modelled using 4 
different protocols of varying 
complexity (section 2.4.3) 
Protocols 2-4 can be used for 
predictive simulation. 
Met 
Can 4D flow MRI data provide novel diagnostic 
methods of AS and add to the of 
haemodynamic assessment, negating the 
need for computational modelling? 
Parameters derived from 4D flow 
MRI data (PG, EOA and LV blood flow 
KE) may have a role in diagnosis and 





that of the model. 
Could be used as 
an input to the 
model in future 
work (section 
5.2.1). 
Does computational modelling have an 
advantage over and above current clinical 
assessment of AS? 
Data suggest that modelling data is 
better associated with 
symptoms/activity and may provide 






Do pervasive wearable monitors give a better 
insight into how AS affects a patient’s activity 
and how this changes following intervention? 
Wearable monitors were successful 
in describing activity pre and post 
intervention. (Sections 3.4.1.2 and 
3.4.1.3). They give an insight into 
patients’ lives that has previously 
been unavailable to clinicians. 
The data was consistent both with 
the validated 6MWT and patient 
reported measures from 
questionnaires. 
Met 
Can a decision support tool be created, using 
data generated in this study, that can be 
utilised in clinical practice? 
A CDSS was created (section 2.7), it 
can produce results in near time real 
time and if validated further could 
have an impact of decisions 




and an RCT is 
needed before 
regulatory approval 
for use in clinical 
practice. 
Table 5.1 Identifies what this study achieved against originally stated hypothesis and aims and 
whether these were met. 




5.2.   Further work 
 
A larger cohort study with a longer follow-up to further validate and extend the work in this thesis is 
required. If successful, the techniques developed should be trialled in clinical practice to see if the 
outcomes of patients with AS can be improved using the data that the techniques in this thesis 
provide. A number of questions and further research opportunities have arisen from the work 
carried out. 
 
5.2.1.  Model personalisation 
 
Further model personalisation could be achieved utilising more data from medical images. The 
model could be tuned to both aortic and mitral flows, which could be obtained from cardiac MRI 
imaging, either using 2D phase contrast or 4D flow studies. Echocardiography can measure the 
velocity profile through the valves, and this could also be used to help tune the shape of the flow 
profiles in the model. Figure 5.1 shows the modelled aortic flow and measured aortic flow for one 
patient in the study. Figure 5.2 shows the modelled flow through the mitral valve and the velocity 
profile through the mitral valve obtained from echocardiography. 
 
 





Figure 5.1. Illustrating the modelled flow through the aortic valve and measured flow in the aorta 
obtained from MRI 2D phase contrast imaging in one study participant. 
 
 
Figure 5.2 Modelled flow through the mitral valve (a) and the velocity profile through the mitral valve 
measured with pulse wave Doppler during echocardiography (b). 
 
 
These profiles could be used to further validate the model as carried out in previous studies[277] but 
the model could also be tuned to fit the measured profiles, increasing the personalisation and 
accuracy of the modelling process. Figure 5.1 shows a similar flow profile in through the aortic valve 
and in the aorta from the modelled and measured data, giving confidence in the result. As can be 
seen from figure 5.2, the velocity and flow profiles through the mitral valve are quite different and 
tuning the model to the measured data in this patient may improve the accuracy of the model. 
CFD simulation can be run using 4D flow fields at the inlet boundary conditions to the 0D model not 
the variable elastance model, this may improve accuracy and may prove more patient specific. A 
b a 




previous study has shown that it is possible to use 2D flow data from MRI for this purpose, in order 
to provide a non-invasive haemodynamic assessment in range of aortic valve pathologies[278]. Using 
flow data before and after the stenosed valve, it should be possible to accurately assess the pressure 
gradient, and this may help to validate the results from the 0D model. 
 
5.2.2.  Improved estimation of input parameters 
 
 
Cuff blood pressure was used as a surrogate for aortic pressure to enable the process to be non-
invasive; however, this will have led to some inaccuracies. A future protocol could use a transfer 
function to derive a potentially more accurate representation of aortic pressure from the non-
invasive blood pressure measurements. 
 
Machine learning uses statistical techniques to give computer systems the ability to learn from data 
and make predictions where clinical data cannot be obtained or measured directly, and this could be 
used for estimating input parameters instead of having to resort to population averages. For 
example, it could be used for parameters such as stressed blood volume and atrial elastance. The 
data could then be estimated for a specific patient based on other characteristics that can be 
recognised or measured in a form of pattern recognition, improving personalisation. Measured 
values would continue to be used, where available, to improve the accuracy and personalisation of 
the model. Therefore, in the future it is anticipated that some of these values will be personalised 
based on machine learning against broader clinical observations or patient characteristics 
 
5.2.3.  Normalisation of modelled parameters 
 
Early proposals for indexing myocardial properties included normalising for muscle mass [279]. 
However, limitations of this approach are recognised, particularly when relative wall thickness 
deviates from normal, as in the case of AS. Instead, parameters derived from estimated end-systolic 




myocardial stress-strain relations are suggested[280]. The slope of the end-systolic myocardial 
stress-strain relationship has been shown to be load independent [281] and sensitive to changes in 
myocardial contractility when geometry is also changing[282]. Other authors have normalised stroke 
work to stroke volume[283]; the rationale for this is unclear but it is suggested this may have a role 
in low flow low gradient AS. In this study, when following these patients longitudinally and trying to 
associate outcome with predicted changes of work, no normalisation was required. However, when 
using parameters such as stroke work and maximum elastance as diagnostic measures linked to 
functional capacity, normalising these values to the size of the heart seems logical.  
 
The best approach for normalising myocardial mechanical properties for chamber size and geometry 
is uncertain. It is likely that myocardial contractility is assessed most appropriately using the 
myocardial stress-strain relationship. In the next phase of investigation it is therefore suggested that 
this method is adopted, following concepts proposed by Burkhoff et al[280].  
 
 
5.2.4.  Wearable devices for activity assessment 
 
Data for both the Philips Health Watch and the Bristol device are encoded with time stamps; 
although the time reference points are different, this enables the data to be combined within an 
accuracy of a few seconds. The feasibility of combining activity data was demonstrated in one case 
within the study (see figure 3.19). The data could be used to measure HR accurately for a given 
activity such as climbing a flight of stairs. This, then, could be compared pre- and post-intervention. 
This may give an indication of myocardial efficiency but could be significantly affected by changes in 
medication such as beta blockers following intervention. There has been research into the effect of 
resting heart rate on outcome and mortality [284], [285]. The effect could be studied accurately in 
this patient cohort using the Philips Healthwatch. The follow-up was too short to assess this in this 
study. There was an indication that resting heart rate may be important as it was found to correlate 




to LV mass (r=-0.684P=0.007) and total energy expenditure of the patient r=-0.525 p=0.04, but more 
research is needed. O’sullivan et al attempted to show a correlation with resting heart rate and 
outcome; the study concluded that the baseline and discharge resting heart rates were not 
associated with adverse outcomes after TAVI[284].However, this study had a number of limitations 
including that the resting heart rate was measured using 12 lead ECG which may not represent the 
true resting heart rate and that the heart rates of patients were dichotomised to low (<77bpm) and 
high (≥77bpm). There may be a link between the resting heart rate before and after aortic valve 
intervention in terms of physical activity and patient reported outcomes. It is also thought that heart 
rate variability may also play a role [286] in outcome and this also could be studied. Using wearable 
activity monitors to assess outcomes, in future larger cardiovascular trials to assess outcomes seems 
a feasible next step. 
 
5.3.  Clinical decision support system 
 
Further validation is needed and a randomised control trial to see if such a platform could influence 
clinical care as mentioned above. Future work that may make the system more useful for clinicians is 
the development of a benefit score and summary of the benefits and risk, indicating what course of 
action may be of benefit to the patient. This would require a large database and a retrospective 
analysis of outcome. 
Once the database is populated with cases, a multi-regression analysis could be performed to create 
the weightings for the benefit score, much in the way that risk scores are developed. An example of 
how this data could be presented is given in figure 5.3. 





Figure 5.3 Illustrating a mock-up used to present the concept during the CDSS evaluation. A 
hypothetical case is used where risk and benefit scores are summarised. The funnel plot (1.0 
representing a perfect score) indicates that for this patient the scores would favour surveillance with 




5.4.  Other clinically important applications  
 
5.4.1.  Low flow low gradient AS 
 
Currently protocol 4 represents the patient’s valve as a single fixed orifice. Obviously this is not true 
and there is flow through the valve as it opens throughout systole. In future studies this would be 
represented by a dynamic CFD model such as the 3D fluid-structure interaction model of the aortic 
valve[287]. This may have a role in the diagnosis and prognostication of low flow low gradient as 
that still remains a challenge[39]. As alluded to in section 4.5.1, MRI 4D flow assessment of the 
effective orifice area could also play a role in the diagnosis of low flow low gradient AS but further 
investigation into this specific subgroup is needed, with a comparison with low dose dobutamine 
stress or exercise echocardiography to evaluate its efficacy. 
 




5.4.2.  Asymptomatic severe AS 
 
Modelling in this cohort may help with the timing of intervention. This study suggests that markers 
such as ELVmax may be used to monitor a patient so that intervention can be performed before the 
left ventricle is irreparably damaged. Longitudinal studies of patients who are deemed to have 
asymptomatic AS are needed to test this hypothesis. A retrospective study could also be performed 
looking at the outcome of patients who were previously observed could also be performed. 
 
5.4.3.  Other valvular pathologies 
 
The 0D model utilised in this work describes the left heart which includes the aortic and the mitral 
valves. Pathologies affecting both these valves could potentially be modelled. The MATLAB script 
was written to be flexible; if the gradient through or orifice of the mitral valve in mid-diastole can be 
a measured, the model could be used to assess mitral stenosis this could be inputted into the model 
and mitral stenosis assessed. Similarly, if the regurgitant orifice in mid-systole can be measured, the 
effect of mitral regurgitation could be assessed. Image-based geometries would potentially be more 
accurate as it is difficult to quantify the degree if mitral regurgitation or stenosis using current 
diagnostic techniques[288]–[290]. However, this would involve imaging small orifice areas which, 
again, may be difficult in a diseased valve, especially with a complex structure like the mitral valve. 
The effect of aortic regurgitation could also be assessed using the same rationale and technique if 









5.5.  Educational tool 
 
Finally, one of the great advantages of using computational modelling is to be able to run 
simulations in a safe environment. This can help us understand the impact of changing certain 
conditions on the global haemodynamics of the patient. For example, the effects of given 
medications such as vasodilators, beta blockers diuretics and inotropes can be studied by altering 
the systemic vascular resistance, heart rate, stressed blood volume and ELVMax respectively in the 
model. This could be exploited as an educational tool in the undergraduate or clinical setting. 
Computational models have already been used in e-learning platforms for conditions affecting the 
cardiovascular system[291]. The effect of using this model for educational purposes could be studied 
in a similar way. For instance, in AS assessment with echocardiography we do not normalise the 
gradient for heart rate, perhaps we should do as it is likely to have a significant effect on the 
gradient. Understanding the effect of heart rate on gradient may influence how scans are reported.  
 
5.6.  Final conclusion 
 
Understanding the global haemodynamic burden of AS and how this affects an individual patient has 
clear benefits. This body of work begins to explore how computational modelling can provide new 
insights, making use of routine, non-invasive, measurements. Data obtained can be used in 
conjunction with other information from complementary techniques such as pervasive monitoring 
from wearable devices and 4D flow MRI, allowing an assessment of functional status and other 
haemodynamic parameters. This can help describe the likely physiological envelope for an 
individual. These preliminary findings show that the concepts and processes are feasible and could 
realistically be translated into a clinical workflow once the essential validation step has been 
successfully completed. Further research is needed to examine if these data can help in improve 
patient experience and outcome. 
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7.  Appendices 
 
i. cMR protocol 
  
3T EurValve STUDY 
Cardiac 
Investigator:  Dr Gareth Archer     Protocol:  EurValve      
Research Flag: 3T EurValve 
Study Information 
• Recruited patients will be scanned twice - Pre and Post Aortic Valve Replacement 
SAFETY 
The patients recruited for this study will have all had heart valves inserted prior to their 2nd scan. The 
investigator will provide the make and model for safety to be clarified and appropriate steps taken to ensure 
compliance. 
 
Registering Patient on Scanner 
Name & Register: Subject id number 
Date of Birth = 01 + Patient’s month & year 
Exam Name: EurValve Visit no 
Accession Number: MRI no 
Referring Physician: NPB 
Study Comments: EurValve Visit no 
 
Patient Positioning 
• Use body phased array coil  





1) Survey NON BREATH-HOLD 
2) B1_CALIBRATION  
3) SSH_BTFE_M2D AXIAL TROUGH HEART AND CHEST FOR PLANNING 2 X BREATH HOLD 
4) Cine LVLA LVLA CINE SINGLE BREATH-HOLD 
5) Cine pSA SA CINE SINGLE BREATH-HOLD 
6) Cine 4CH 4CH CINE SINGLE BREATH-HOLD 
7) SA STACK SA STACK TO COVER WHOLE OF VENTRICLES – MULTIPLE BREATH-HOLDS 
8) 4CH STACK 4CH STACK TO COVER WHOLE HEART – MULTIPLE BREATH-HOLDS 
9) GRID_SA_MID TAGGING SEQ IN SHORT AXIS PLANE. 1 SL MID LT VENTRICLE SINGLE BREATH-HOLD 
10) GRID_SA_BASAL AS ABOVE BUT POSITION AT SLICE AT LT VENTRICULAR BASE  
11) GRID_SA_APICAL AS ABOVE BUT POSITION AT SLICE AT LT VENTRICULAR APEX 
12) GRID_LVLA TAGGING SEQ IN LVLA PLANE 
13) GRID_4CH TAGGING SEQ IN 4CH PLANE 
GIVE GADOLINIUM 
14) CINE AORTIC ARCH PLAN ON AXIAL, SAG OBLIQUE THROUGH ARCH- SINGLE BREATH-HOLD 
15) CINE AXIAL AORTA AXIAL CINE AT LEVEL OF PULMONARY ARTERY BIFURCATION, PERPENDICULAR TO ASCENDING AORTA, SINGLE BREATH-
HOLD 
16) CINE LIFOF LIFOF FOR PLANNING, PLAN ON APICAL SLICE OF SA STACK, SINGLE BREATH-HOLD 
17) AA QFLOW PLAN PERPENDICULAR TO LIFOF, FOR PLANNING, SINGLE BREATH-HOLD 
18) AA QFLOW THROUGH AND PERPENDICULAR TO ASCENDING AORTA AT LEVEL OF PULMONARY ARTERY, SINGLE BREATH-HOLD 
19) LOOK LOCKER MORE THAN 8 MINS POST GAD - SA SINGLE SLICE WITH MULTIPLE TI. PLAN ON LVLA AND 4CH. LOAD RESULTANT IMAGES 
INTO VIEWER AND SELECT THE IMAGE WITH THE BEST SUPPRESSION OF VIABLE MYOCARDIUM. NOTE THE TD OF THIS 
IMAGE. 
20) IR_TFE_BH_2BEATS SA STACK, COVERAGE FROM BASE TO APEX. MULTIPLE BREATH HOLDS. SELECT CONTRAST TAB, SCROLL DOWN TO TFE 
DELAY TIME AND TYPE IN THE NUMBER YOU NOTED FROM THE LOOK LOCKER + 20MS. NB SPEED IS NOW OF THE 
ESSENCE BEFORE THE TI DRIFTS OFF! 
21) IR_TFE_BH_2BEATS LVLA SINGLE SLICE BREATH-HOLD. POSITION COPIES FROM LVLA GRID. ALTER THE TFE DELAY TIME AS ABOVE + 
ANOTHER 20MS TO TAKE ACCOUNT OF THE FURTHER TIME DELAY. SINGLE BREATH HOLD (PLUS SENSE REF BREATH-




• Place ECG stickers around the heart on the left back. The leads are colour coded for LA 
(left arm), RA (right arm), LL (left leg), RL (right leg). 
• Patient supine, headfirst 
• Use respiratory gating 
• Centre on heart 
• NB All scans are in expiration 
 
Contrast 
Administer 0.2mmol/kg of Gadovist (i.e.1ml/kg)  












22) IR_TFE_BH_2BEATS LIFOF SINGLE SLICE BREATH-HOLD. POSITION COPIES FROM LIFOF CINE. ADD A FURTHER 20MS TO THE TFE DELAY 
TIME. SINGLE BREATH HOLD (PLUS SENSE REF BREATH HOLD). 
23) IR_TFE_BH_2BEATS 4 CH SINGLE SLICE BREATH HOLD. POSITION COPIES FROM 4 CH. ADD A FURTHER 20MS TO THE TFE DELAY TIME. 
SINGLE BREATH-HOLD (PLUS SENSE REF BREATH HOLD). 
24) 4DFWHOLEHEART+AORTA POSITION AS FOR A 4 CHAMBER TO COVER THE WHOLE HEART. FREE BREATH. 
25) AV XCUT CINE THROUGH AORTIC VALVE. PLAN ON LIFOF AND AA QFLOW PLAN 




ii. Sphere kit instructions developed for participants 
 
Activity Monitoring ‘5 Step’ Instructions 
1. Setup the Router 
Connect to the power supply and position in an area that has 3G or 4G signal - this is indicated on 
the front of the router. The router is already switched on and after a minute the signal strength will 
be displayed as bars like on a mobile phone, see Figure 1 and Figure 2. 
 
 
Figure 1: The Router 
 
Figure 2: The Router’s Signal Strength 
 
2. Setup and Position White Gateway Boxes 
There are four white gateway boxes provided that need to be placed in different rooms and 
powered. Each box has the house number and GW number labelled on the side. To power, connect 
the box to the USB cable and USB adaptor/ Plug as in the figures below. Place each box in the room 
labelled (Living Room, Kitchen and Bedroom). The Forth box (GW4) can go in any other 
room/Hallway that is commonly use. 
 
 
Figure 3: The Kitchen Gateway Box 
 
Figure 4: The Bedroom Gateway Box 
 
 
The idea is to achieve maximal separation between the boxes so please do not place either side of a 
dividing wall (see the example floor plan in Figure 6). 




Note you can continue to use this as a socket as usual but please ensure it remains turned on during 
the monitoring period. 
Please use Velcro provided to ensure that the boxes go in the exact same position and orientation 
for pre and post surgery. 
 
3. Plug in the charger and ensure watch fully charged 
The USB charger can be plugged into spare USB socket on the top of the plugs or can be plugged into 
any of the USB ports in the front of the white boxes wherever is most convenient. 
The charger has a red light on when it has power. To charge the watch place strap facing down on 
the charge, as shown in Figure 5. 
 
Figure 5: The Wristband properly charging 
 
A green light will also appear on the charger when the watch is charging. The watch will take 
approximately 40 minutes to fully charge. 
When fully charged the device should last 2 weeks. Please only top up the charge when you are 
bathing/ Showering for 15-30 minutes. This will also indicate to us you are doing this activity which is 
a useful marker.  
 
 
4. Complete Questionnaire and sketch floor plan 
Complete the questionnaire entitled ‘APPENDIX F:SPHERE EurValve Questionnaire’. In part B, 
please sketch a rough floor plan of each floor in your house showing where the white gateway boxes 
and the router are positioned. Use Figure 6 as a guide for the floor plan (room dimensions are not 
necessary). 
 





Figure 6 Example Floor plan 
 
5.  Calibrate the system 
Please complete steps 1-4 (the router and gateways should be on) before 
performing this important step. 
1. Place your wrist with the wristband as close to the white ‘gateway’ 
in your living room as possible for around ten seconds. 
2. Next, in the living room, please sit on your sofa / chair as naturally 
as possible (i.e. like you normally do) for around two minutes. Then 
go to the kitchen. 
3. Place your wrist with the wristband as close to the white ‘gateway’ 
in your kitchen as possible for around ten seconds. 
4. Next, in the kitchen, please walk around as naturally as possible for 
around two minutes. Then go to the bedroom. 
5. Place your wrist with the wristband as close to the white ‘gateway’ 
in your bedroom as possible for around ten seconds. 
6. Next, in the bedroom, please lie on your bed as you normally do 
(for e.g. when sleeping) for around two minutes. Now go to the 
fourth white ‘gateway’ in the other room. 
7. Place your wrist with the wristband as close to the white ‘gateway’ 
in your fourth location as possible for around ten seconds 




8. In the fourth location, please do whatever activity you normally 
do in this room for around two minutes. 
Date and Time of Calibration  
____________________________________________________________
_ 
Person who performed the Calibration  
____________________________________________________________
_ 
What activity did you do in the fourth room?  
____________________________________________________________
_ 
Please wear the Wristband as much as you can. You should wear the Wristband on the hand 
you use most (i.e. your dominant hand). If possible wear it at night too, since sleep is an 
important part of health. The Wristband battery will last for a couple of weeks so you will 





iii. Derivation of equations used in protocol 1. 
 
Aortic Pressure 
Assume that during the period of forward flow the aortic pressure has a parabolic distribution 
with its peak at the end, when the aortic valve closes: 
𝑝𝑎𝑜𝑟𝑡𝑎 = 𝑎0 + 𝑎1𝑡 + 𝑎2𝑡
2 
 where t is normalised to the period of forward flow, 0 at start and 1 at end. 
𝑑𝑝𝑎𝑜𝑟𝑡𝑎
𝑑𝑡
= 𝑎1 + 2𝑎2𝑡 
Then: 
𝑎0 = 𝑝𝑠𝑡𝑎𝑟𝑡 ;  𝑎1 = 2(𝑝𝑒𝑛𝑑 − 𝑝𝑠𝑡𝑎𝑟𝑡) ; 𝑎2 = −(𝑝𝑒𝑛𝑑 − 𝑝𝑠𝑡𝑎𝑟𝑡) 
 
 
Left Ventricular Volume 
 
Assume that during systole the left ventricular volume has a parabolic distribution with its minimum 
at end systole: 
𝑉𝐿𝑉 = 𝑐0 + 𝑐1𝑡 + 𝑐2𝑡
2 
 where t is normalised to the period of systole, 0 at start and 1 at end. 
𝑑𝑉𝐿𝑉
𝑑𝑡
= 𝑐1 + 2𝑐2𝑡 










Left Ventricular Pressure 
It is assumed that the pressures at the start and at the end of ejection are the same as the 
aortic pressures at those timing points (the pressures when the valve opens and when it 
closes, neglecting any inertial effects). 
The most comprehensive measurement data would include the maximum aortic valve 
pressure difference and its timing and the maximum left ventricular pressure and its timing. 
Each of these yields two independent constraints (a pressure constraint and a gradient 
constraint at each of the maxima. Together with the start and end data there are six 
constraints, and if a polynomial is chosen for the representation this would support the 
unique identification of the coefficients of a quantic equation. However, experimentation with 
any polynomial of higher order than two has shown that, depending on the measurement 
values, the polynomial can exhibit local minima or points of inflection that are physiologically 
implausible. In practice we are interested in the construction of the LV PV loop from non-
invasive data, and the simplest is when only the peak aortic valve pressure drop has been 
measured by Doppler ultrasound. 
 
Below is the derivation of the coefficients of two piecewise continuous quadratic representations of 
left ventricular pressure, one from the start of ejection to the time of peak LV pressure and one from 
the time of peak LV pressure to the end of ejection given:  
• LV pressure at start of ejection phase 
• LV pressure at end of ejection phase 
• Maximum aortic valve pressure drop, assuming that the aortic valve 
pressure is represented by a quadratic with peak pressure at the end of 
the ejection phase (see above) 
• Timing of the maximum aortic valve pressure drop 
 
Derivation 
Given 𝑝𝑠𝑡𝑎𝑟𝑡 , 𝑝𝑒𝑛𝑑 and 𝑑𝑝𝐴𝑉𝑚𝑎𝑥  , and the coefficients of the quadratic representation of aortic 
pressure plus the timing of the peak aortic valve pressure drop, 𝑡𝑑𝑝𝐴𝑉𝑚𝑎𝑥 . 
Then: 
𝑝𝐿𝑉 = 𝑏01 + 𝑏11𝑡 + 𝑏21𝑡
2 ∶  0 ≤ 𝑡 ≤ 𝑡𝐿𝑉𝑚𝑎𝑥  
𝑝𝐿𝑉 = 𝑏02 + 𝑏12𝑡 + 𝑏22𝑡
2 ∶  𝑡𝐿𝑉𝑚𝑎𝑥 < 𝑡 ≤ 1 
 Assume that the maximum left ventricular pressure occurs later than the maximum aortic 
valve pressure drop (this will generally be true) then a number of relationships between the 
coefficients in the first segment can be determined. 
  The start point immediately fixes the constant term: 
𝑏01 = 𝑝𝑠𝑡𝑎𝑟𝑡 




 The pressure drop across the aortic valve is: 
𝑑𝑝𝐴𝑉 = (𝑏01 − 𝑎0) + (𝑏11 − 𝑎1)𝑡 + (𝑏01 − 𝑎0)𝑡
2 
and, since the constant coefficients are the same: 
𝑑𝑝𝐴𝑉 = (𝑏11 − 𝑎1)𝑡 + (𝑏21 − 𝑎2)𝑡
2 
 The peak pressure drop and its timing are known: 
𝑑𝑝𝐴𝑉𝑚𝑎𝑥 = (𝑏11 − 𝑎1)𝑡𝑑𝑝𝐴𝑉𝑚𝑎𝑥 + (𝑏21 − 𝑎2)𝑡𝑑𝑝𝐴𝑉𝑚𝑎𝑥
2 




= (𝑏11 − 𝑎1) + 2(𝑏21 − 𝑎2)𝑡 
and since this is zero when the gradient is a peak: 
0 = (𝑏11 − 𝑎1) + 2(𝑏21 − 𝑎2)𝑡𝑑𝑝𝐴𝑉𝑚𝑎𝑥  
From these two equations: 
𝑑𝑝𝐴𝑉𝑚𝑎𝑥 = −(𝑏21 − 𝑎2)𝑡𝑑𝑝𝐴𝑉𝑚𝑎𝑥
2 














 Hence the coefficients of the first quadratic segment are fully defined from the two 
points and the known temporal gradient. 
 The temporal gradient of the LV pressure is: 
𝑑𝑝𝐿𝑉
𝑑𝑡
= 𝑏11 + 2𝑏21𝑡 



























 The maximum LV pressure, 𝑝𝐿𝑉𝑚𝑎𝑥  , can be derived by substituting this value of time 
into the quadratic equation for the first segment. 
 
Now consider the second quadratic segment: 
𝑝𝐿𝑉 = 𝑏02 + 𝑏12𝑡 + 𝑏22𝑡
2 ∶  𝑡𝐿𝑉𝑚𝑎𝑥 < 𝑡 ≤ 1 
At the end of the ejection period: 
𝑝𝑒𝑛𝑑 = 𝑏02 + 𝑏12 + 𝑏22  
 At 𝑡𝐿𝑉𝑚𝑎𝑥  the pressure is: 
𝑝𝐿𝑉𝑚𝑎𝑥 = 𝑏02 + 𝑏12𝑡𝐿𝑉𝑚𝑎𝑥 + 𝑏22𝑡𝐿𝑉𝑚𝑎𝑥
2 
  and the temporal gradient is: 
0 = 𝑏12 + 2𝑏22𝑡𝐿𝑉𝑚𝑎𝑥  
 Eliminating 𝑏02  from the first two equations: 




𝑝𝐿𝑉𝑚𝑎𝑥 − 𝑝𝑒𝑛𝑑 = 𝑏12(𝑡𝐿𝑉𝑚𝑎𝑥 − 1) + 𝑏22(𝑡𝐿𝑉𝑚𝑎𝑥
2 − 1) 
 And substituting from the third equation: 
𝑝𝐿𝑉𝑚𝑎𝑥 − 𝑝𝑒𝑛𝑑 = −2𝑏22𝑡𝐿𝑉𝑚𝑎𝑥(𝑡𝐿𝑉𝑚𝑎𝑥 − 1) + 𝑏22(𝑡𝐿𝑉𝑚𝑎𝑥
2 − 1) 
𝑝𝐿𝑉𝑚𝑎𝑥 − 𝑝𝑒𝑛𝑑 = 𝑏22(−𝑡𝐿𝑉𝑚𝑎𝑥




2   
𝑏12 = −2𝑏22𝑡𝐿𝑉𝑚𝑎𝑥   
𝑏02 = 𝑝𝑒𝑛𝑑 − 𝑏12 − 𝑏22  
 
iv. Modelling the exercise state 
 
Chantler et al [190] published a detailed study of the effects of exercise on a cohort of 203 
normotensive patients (111 male, 92 female) and 79 (52 male, 27 female) hypertensive patients, 
reporting the changes of several parameters including heart rate, left ventricular end systolic 
elastance, arterial elastance and systemic resistance. Measurements were made at rest, under 
exercise conditions at 25W and 50W and at 50% and 100% of personal maximum power. Figure 7.7 
shows the fitting of trendlines to data derived from this work for the normotensive cohort. The 
trendlines are based on the combined data from males and females, and the data points for both are 
presented in the figure. The R2 value for all fits is better than 0.96. The data are presented in terms 
of the fractional changes of the measured parameters from the rest state at each power-to-weight 
ratio (PWR). The raw data was not available to compute PWR or maximum power for each 
individual, so these were derived using the respective reported cohort averages for male and female 
participants. The effective arterial elastance is defined as the peak systolic pressure divided by the 
stroke volume, a combined measure of capacitance and resistance. 
 




Figure 7.7: Fractional changes of cardiac and arterial parameters under exercise conditions for normotensive cohort. Data 
processed from the information presented in Chantler, Melenovsky et al (2008) 
Thus, the equations for the parameters under exercise conditions, derived from these data, are: 
𝐻𝑒𝑎𝑟𝑡 𝑅𝑎𝑡𝑒𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒  = (0.7464 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒 + 1) ∙ 𝐻𝑒𝑎𝑟𝑡 𝑅𝑎𝑡𝑒𝑟𝑒𝑠𝑡 
ELVmax 𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
 = (1.2641 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒 + 1) ∙ ELVmax 𝑟𝑒𝑠𝑡
 
𝑆𝑉𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒  = (0.2848 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
4 − 1.2158 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
3 + 1.8852 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
2
− 1.3692 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒 + 1) ∙ 𝑆𝑉𝑅𝑟𝑒𝑠𝑡 
𝐴𝑟𝑡. 𝐸𝑙𝑎𝑠𝑡𝑎𝑛𝑐𝑒𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒  = (0.075 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
2 + 0.0751 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒 + 1) ∙ 𝐴𝑟𝑡. 𝐸𝑙𝑎𝑠𝑡𝑎𝑛𝑐𝑒𝑟𝑒𝑠𝑡 
The effective arterial elastance is defined as the peak systolic pressure divided by the stroke volume. 
An estimate of the arterial capacitance in the zero-dimensional model can be made by consideration 








 Data includes information on the systolic pressure, the heart period and the systemic vascular 
resistance index. There is no information on venous pressure, and for the purposes of this 
calculation it is assumed to be zero. In the absence of other information, it is further assumed that 
the period of diastole scales with the heart period and that the diastolic pressure in normotensives 
does not change under exercise conditions. Under these assumptions, and using the index data 










To be consistent with the index definitions, a capacitance index would be defined by dividing the 
capacitance by the body surface area (since the volume term is on the top line). 
C Index =
60 ∙ t_diasfraction





Figure 7.8 illustrates the fractional change of the capacitance, or capacitance index, derived from the 
Chantler data using this calculation. 






Figure 7.8: Fractional changes of cardiac and arterial parameters under exercise conditions for normotensive cohort. Data 
computed from derived capacitance index equation using data from the information presented in Chantler, Melenovsky et 
al (2008). 
The formula for adjustment of arterial capacitance based on this fit is: 
C𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒  = (0.3587 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
4 − 1.4963 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
3 + 2.2547 ∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
2 − 1.6487
∙ 𝑃𝑊𝑅𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒 + 1) ∙ C𝑟𝑒𝑠𝑡 
Measured activity data on the EurValve aortic valve disease cohort suggests that the level of activity 
is restricted, with rare excursions into moderate activity and none into high activity. A reasonable 
level of PWR for this cohort pre-intervention is 0.8 W/kg. Using the expressions derived from the 
Chantler data this would invoke an increase of heart rate of 60%, an increase of maximum left 
ventricular elastance of 101%, a reduction of systemic vascular resistance of 39%, an increase of 
effective arterial elastance of 10% and a 50% reduction in capacitance. 
Similar processing has been performed on the hypertensive cohort in the Chantler data. The results 
are illustrated in Figure 7.9, in which the normotensive results are also reproduced for easy 
comparison. The R2 values for the hypertensive cohort are lower than those for the normotensive, 
but generally the trends and ranges are similar. The largest difference for the four parameters 




investigated is for the effective arterial elastance, with smaller increases from the rest state during 
exercise for the hypertensive cohort. 
 
 
Figure 7.9: Fractional changes of cardiac and arterial parameters under exercise conditions for normotensive and 
hypertensive cohorts. Data processed from the information presented in Chantler, Melenovsky et al (2008). 
Bombardini et al[191] reported rest and peak exercise data (defined as exercise at 85% of the age-
predicted maximal heart rate) on a cohort of 891 individuals (593 male), including 91 normals. They 
reported that the end systolic elastance index approximately doubled at peak stress in normal 
subjects, from 7.1 +/- 2.4 mmHg.ml-1.m2 to 15 +/- 6.6 mmHg.ml-1.m2, but increased by less in 
patients, from 4.6 +/- 3.4 mmHg.ml-1.m2 to 6.6 +/- 5.7 mmHg.ml-1.m2. They noted that the response 
was heterogeneous at the individual level. The proportional increases are somewhat lower than 
those reported by Chantler. The effective arterial elastance index increased by approximately 25% at 
peak stress in normal subjects, from 4.5 +/- 1.3 mmHg.ml-1.m2, whilst there was a mild decrease of 
approximately 5% in patients. The relatively small effect on effective arterial elastance, especially for 
the patient group, is similar to those reported by Chantler. 
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